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1 Introduction 
1.1 Novel approaches for cancer treatment 
Cancer is a heterogeneous disease which is caused by genetic errors in the cell’s 
genome due to alterations, loss or multiplication of certain genes. The incidence of 
cancer is still rising and malignant diseases are one of the most prevalent causes of 
death. Standard treatment for solid cancer is still surgery, followed by radiation and/or 
chemotherapy. However, these regimes are not always successfully applicable, 
either due to the tumor being unresectable or already metastasized. Another 
hindrance for successful treatment of cancer by classical radiation or chemotherapy 
is the occurrence of resistance towards treatment regimes. Therefore it is important 
to develop new strategies in tumor therapy, especially for progressed tumors that are 
withdrawn from classical treatment regimes. 
1.1.1 Antiangiogenic therapy 
Vasculogenesis and angiogenesis are the fundamental processes by which new 
blood vessels are formed (1). The growth of new blood vessels, angiogenesis, is a 
critical step in developing clinical relevant cancer (FIG 2-1). 
 
 
Fig.: 1-1 Stages in tumor development leading to vascularisation: After the angiogenic switch, induced 
by certain growth factors, initially dormant tumors become angiogenic, blood supply is established and 
tumors begin to grow. 
 
The hypothesis that tumor growth and also tumor spreading is angiogenesis 
dependent was first proposed in 1971 (2). Meanwhile this hypothesis has been 
proven by several experiments and is now widely accepted. In the absence of blood 
supply, tumor growth is restricted to a microscopic size and the tumor is not able to 
spread via the vascular system to form haematogenic metastases because tumor 
angiogenic 
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neoangiogenesis tumor 
neovascularisation 
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growth 
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cells are not shed into circulation (3). In these non-angiogenic tumors cell 
proliferation and apoptosis are balanced (4). 
The angiogenic switch could be driven by several factors; e.g. angiogenic 
oncogenes, upregulation of proangiogenic factors, produced by tumor cells and/or 
the tumor stroma or down regulation of antiangiogenic factors. With the access to 
blood supply, oxygen, nutrients and growth factors are not a limiting factor for tumor 
growth anymore and exponential proliferation of the tumor mass occurs (5). Clinical 
studies have shown a direct correlation between the density of tumor vessels and an 
adverse prognosis in patients with various solid tumors regarding tumor growth and 
metastatic potential (6). 
As tumor growth critically depends on a functional blood vessel network and a large 
number of neoplastic cells depend on the supply of a relatively small number of 
endothelial cells, tumor vessels are an attractive target in fighting against cancer (7). 
1.1.1.1 The angiogenic process and antiangiogenic approaches 
The physiological formation of new blood vessels in humans mainly takes place at 
wound healing and in the course of female menstruation cycle. Angiogenesis exhibits 
a central role in different pathological processes including malignant diseases (8). 
Therefore new therapeutic strategies for cancer treatment involve antiangiogenic 
approaches. The possible starting points are multifaceted and result from the 
complex process of tumor angiogenesis. 
Malignant cells can be present over years in a dormant status (tumor dormancy); 
oxygen and nutrients are obtained form the established blood vessel network of the 
healthy tissue and reaches the tumor by diffusion (2). The reason for switching to an 
angiogenic, active stadium is currently not clarified secludingly. The activation of 
endothelial cells, however, is the crucial step in switching to an angiogenic tumor 
stadium (5). 
The activated endothelial cells change their gene expression pattern. The secretion 
of proteolytic enzymes like metalloproteases (MMP-2) aerates the surrounding matrix 
and enables migration (9). Further on, activated endothelial cells enter the cell cycle 
and start to proliferate (2). Expression of cell surface aminopeptidases further 
enhance the process of matrix remodeling (10). Adhesion molecules like integrins 
enable migration of endothelial cells (11) and modulate survival (12) and cell cycle 
(13). Immature endothelial cells migrate in the direction of the angiogenic stimulus by 
forming sprouts. In the course of further differentiation these sprouts form lumen and 
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a new basal lamina is established (14). This results in the forming of a three 
dimensional blood vessel network supplying the tumor with oxygen and nutrients. 
The complex process of tumor angiogenesis offers multiple options in interfering in 
terms of antiangiogenic therapy. Current approaches are based on the inhibition of 
one or more of the crucial steps in the angiogenic process (15). Recently, an 
antagonist of the angiogenic growth factor VEGF (AvastinR) was approved by the 
EMEA (European Medicines Agency) for progressed colon carcinoma (16). Several 
other drugs are in clinical trials.  
 
Fig.: 1-2 The complex process of angiogenesis offers several potential points of attacking the tumor 
driven establishing of a functional blood vessel network. Interference with the angiogenic process can 
be based on disturbance regarding to cytokine signaling or direct interaction with endothelial cells. The 
relevant key steps are suitable for analyzing antiangiogenic activity of drugs to evaluate their potential 
in disrupting the angiogenic process. 
1.1.1.2 Metronomically scheduled chemotherapy 
Conventional chemotherapeutics affect not only proliferating tumor cells and various 
types of healthy cells e.g. bone marrow cells, they also interfere with the endothelium 
of growing tumor vessels (17). This results in an antiangiogenic effect, when 
conventional chemotherapeutics are optimized in terms of dose and frequency of 
application. Usually anticancer drugs are scheduled at low doses and continuous 
application (metronomic schedule) in order to target preferential angiogenic active 
blood vessels (18), whereas bolus high dose chemotherapy is directed predominately 
against fast dividing tumor cells. 
For example, CPA (cyclophosphamide) was shown to exhibit potent anticancer 
activity when it was applied in a low dose antiangiogenic schedule. Metronomically 
scheduled CPA therapy led to decreased angiogenesis in matrigel plug studies (19) 
migration 
proliferation 
differentiation 
angiogenic stimulus 
Introduction   9
and increased apoptosis of proliferating endothelial cells in the tumor bed. Further in 
vitro evaluation showed decreased proliferation and migration capability of cultured 
endothelial cells in the presence of activated CPA (20). Recent studies implied an 
additional effect beside direct affection of tumor vessel endothelium. Changes in the 
expression of antiangiogenic cytokines were observed. Thrombospondin-1 was 
identified as a potential mediator of the effects of metronomic scheduled CPA (21). 
Low dosed CPA treatment of cultured endothelial cells caused marked increase of 
thrombospondin-1 mRNA and thrombospondin-1 upregulation was detected in CPA 
treated experimental tumors (22). 
However, despite intensive investigation of metronomic CPA therapy the role of 
single CPA metabolites, which may mediate antiangiogenic effects, has not been 
clarified. 
Due to the fact that antiangiogenic strategies target preferentially genetically stable 
endothelial cells, resistance of tumors against treatment should be overcome (23). 
However, recent studies and our own results indicate the development of 
mechanisms that revoke tumors from metronomic scheduled chemotherapy (24). 
1.1.2 Gene therapy 
Gene therapy is part of a growing field of molecular medicine that will gain 
importance in the treatment of human malignant diseases. Until now, almost two third 
of all clinical trials performed in gene therapy are directed against cancer (25). As 
solid tumors exceeding a certain size rely on blood supply, the administration of 
particulate gene delivery vectors via the bloodstream is a promising concept. For 
systemic application, these delivery systems have to fulfill certain conditions like 
adequate circulation time and low immunogenicity (26). 
1.1.2.1 Therapeutic concepts for cancer gene therapy 
Gene therapeutic approaches for cancer treatment have the advantage of being 
potentially highly selective. Most approaches combine gene therapy with 
chemotherapeutic drugs, radiation or other treatments to achieve optimal effects. 
Several approaches based on gene therapy were investigated in terms of cancer 
treatment. Replacement and overexpression strategies of proapoptotic or tumor 
suppressor genes e.g. p53 were the prime fields of gene therapy (27). In the recent 
years also approaches based on the delivery of genes to modulate host immune 
response have been investigated (28). 
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The approach to combine gene delivery with the consecutive application of chosen 
small molecular drugs was investigated in this thesis. Within the GDEPT (gene 
directed enzyme prodrug therapy) concept an inactive prodrug is converted into the 
active, cytotoxic drug by conversion through a specific enzyme, which is 
overexpressed as a transgene at the tumor site. This concept results in high local 
concentrations of cytotoxic drugs within the tumor tissue due to selective expression 
of the relevant enzyme at the tumor site; the systemic burden of toxic metabolites is 
therefore lower compared to conventional chemotherapy (29). Often, prodrugs are 
used that are already in clinical use, making it easier for the concept to be approved 
by regulatory authorities. A major advantage for GDEPT is the bystander effect. 
Different from strategies to deliver proapoptotic or tumor suppressor genes which 
affect only the transfected cells, the GDEPT approach aims to affect also non 
transfected cells in the near vicinity of cells expressing the transgene. Enzymatic 
activation of anticancer prodrugs by successfully transduced cells also affects the 
surrounding tissue by diffusion of toxic metabolites. This bystander effect amplifies 
antitumoral activity (30). It is adequate to deliver the therapeutic gene only to a part of 
the target cell population which is a more reachable goal with available gene delivery 
systems. Several therapeutic gene/prodrug combinations were investigated (31). 
Approaches with encapsulated cells, stably expressing CYP2B1, are already in 
clinical trials (32). In this thesis, gene transfer of rat CYP2B1 combined with 
cyclophosphamide (CPA) was evaluated. 
1.1.2.2 CYP450/CPA combination 
The anticancer drug cyclophosphamide (CPA) is widely used for different forms of 
cancer. However CPA can be highly toxic due to non specific side effects, and host 
toxicity is the crucial limiting factor in conventional tumor therapy with CPA (33-35). 
CPA itself is a prodrug that is transformed by cytochrom P450 enzymes in the liver by 
hydroxylation. The activated metabolite hydroxycyclophosphamide (4-OH-CPA) 
undergoes spontaneous ?-elimination to generate the compounds phosphoramid 
mustard and acrolein. 
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Fig.: 1-3 Simplified diagram of CPA metabolism. CPA is activated by hepatic CYP P450 isoforms (e.g. 
2B1 in rat, 2B6 in humans) to form hydroxycyclophosphamide (4-Hydroxy-CPA) which is delivered via 
the blood stream to the tumor site. 4-Hydroxy-CPA is in equilibrium with its tautomer 
aldophosphamide. Aldophosphamide can decompose by spontaneous ?-elimination and form the 
alkylating compound phosphoramid mustard and the byproduct acrolein.  
 
These products are highly reactive species that alkylate DNA or proteins. In 
conventional chemotherapy activated metabolites are distributed systemically via 
blood stream, affecting cells at the tumor site but also in healthy tissues. Expression 
of CYP2B1 enzyme within the tumor site should activate CPA locally in order to 
achieve an adequate cytotoxic concentration range in the tumor area (36). Due to the 
local activation at the tumor site, applicated CPA doses should be lower at similar 
antitumoral efficiency, preventing the occurrence of side effects. 
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Fig.: 1-4 Comparison of conventional CPA antitumoral therapy and the GDEPT gene therapy 
approach. To reduce side effects and achieve higher local concentrations of cytotoxic 4-hydroxy-CPA 
a CPA activating CYP P450 isoform is delivered via gene transfer to the tumor site prior to CPA 
treatment to enable localized CPA bioactivation. 
1.1.2.3 Targeting strategies within the GDEPT concept 
Treatment of progressed malignant diseases is only effective if carried out via the 
systemic route. Systemic application of high dose chemotherapy is limited by side 
effects and toxicity in healthy tissue. Therapeutic concepts with higher specificity are 
therefore eligible. Gene therapy of already metastasized tumors is a promising 
approach to increase specificity and efficiency and may supplement already 
established treatment regimes. Both tumor cells and tumor vasculature are possible 
targets for the delivery of genes within the GDEPT concept (37). Approaches for the 
development of tumor- and tumor vasculature-targeted gene delivery systems are 
described in the annex. 
 A  B  C 
Fig.: 1-5 Different modes of action for the GDEPT bystander effect: A: Gene delivery to tumor cells 
affects transfected cells and surrounding tumor cells; B: Gene delivery to tumor cells in the vicinity of 
vessels affects transfected cells and endothelial cells in the near vicinity; C: direct targeting and 
transfection of endothelial cells can lead to an optimal bystander and antiangiogenic effect. Mode A is 
not working on chemoresistant tumors, mode B and C also affect angiogenic cells (yellow areas: 
transfected cells, Arrows: direction of bystander effect; stars: area of cytotoxic effect) 
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Tumor neoangiogenesis depends on different, complementary pathways and 
blocking a single pathway with conventional antiangiogenic therapy might be 
insufficient and compensated by another pathway (38). Further on, the expression 
pattern of neoangiogenic factors can differ between tumor types and even within the 
tumor; blocking a distinct factor can lead to the occurrence of compensation 
mechanisms. The GDEPT concept is not impaired by such compensation 
mechanisms, as the local activation of cytotoxic drugs mostly leads to DNA and/or 
protein damage of the affected cells. With the GDEPT approach the cytotoxic effect 
on the tumor endothelium is rather independent of tumor type and progression 
stadium and therefore exhibits a universal adaptive approach.  
1.1.2.4 PEI-polyplexes 
Polyethylenimine (PEI) is a polycation with a high density of positively charged amino 
groups. Therefore it interacts with negatively charged nucleic acid by electrostatic 
interaction. In 1995 it was first reported on the ability of PEI to deliver genes and 
oligonucleotides (39). PEI can be synthesized as a linear (Fig 1-6 A) as well as a 
branched (Fig 1-6 B) macromolecule in a wide range of molecular weight. The PEIs 
of different topology and molecular weights exhibit different binding affinities for DNA 
(40). Recently, difference in in vivo gene expression efficiencies were demonstrated 
for LPEI (linear PEI) and BPEI (branched PEI), whereas LPEI containing polyplexes 
resulted in significantly higher transfection efficiency than polyplexes with 
incorporated BPEI (41). 
By complexation with DNA, particles are formed (polyplexes) in which the condensed 
DNA is protected against physical and biochemical degradation. The particular 
polyplexes can enter the cells via endocytotic processes. PEI polyplexes mediate 
efficient gene delivery in vitro; however cellular uptake of plain PEI polyplexes is 
unspecific due to positive charge on the surface of the particles. Moreover, plain 
polyplexes tend to aggregate in salt containing biological fluids (42) and exhibit 
strong cellular and systemic toxicity in vivo (43). PEI can be covalently linked to 
different functional molecules such as hydrophilic polymers like polyethylene glycol 
(PEG) or functional peptides, in order to modify the surface of the polyplexes and 
reduce unspecific interactions, aggregation and induce specificity towards target cells 
(44). 
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Fig.: 1-6 Different Versions of Polyethylenimine (PEI): A) linear PEI (LPEI) B) branched PEI (BPEI) 
1.2 Tumor environment 
Solid tumors are characterized by several environmental properties that are different 
from healthy tissue. Blood vessel networks that are formed by tumor induced 
angiogenesis are poorly organized and exhibit in a heterogeneous distribution of 
blood flow. This results in hypoxic areas within the tumor tissue that are not 
sufficiently supplied with oxygen and nutrients (45;46). The propagation of hypoxic 
areas depends on tumor type and tumor stadium and can be characterized by 
measuring blood vessel density, intercapillary distance and the perivascular cuff (FIG 
1-7). 
 
Fig.: 1-7 Vertices of blood supply in tumor tissue. The microscopic picture (right) displays a functional 
blood vessel (blue staining: systemically applicated Hoechst33258 dye as a tracer; data source: 
current thesis). The distance between functional blood vessels is described as intercapillary distance 
(green arrow). The area around the blood vessels that is supplied by oxygen is called perivascular cuff 
(yellow arrow). 
 
Blood vessel
Tumor tissue
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Tumor hypoxia results in several effects in terms of resistance towards chemo- 
and/or radiotherapy, metastatic potential, angiogenesis and regulation of cell surface 
molecules (47-49). Moreover, tumor hypoxia may influence therapeutic approaches 
with delivered and expressed enzymes when the conversion of the prodrug is oxygen 
dependent. The activity of the CYP P450 2B1 enzyme (cytochrome P450 2B1), that 
was utilized in this thesis (GDEPT, gene delivered enzyme prodrug therapy) for CPA 
activation is strongly depending on sufficient oxygen supply (50). Therefore it was 
required to evaluate this gene therapy approach under tumor specific conditions 
including hypoxia and limited diffusion.  
1.3 Resistance to chemotherapy 
Despite advances in the treatment of progressed cancer via chemotherapeutic 
regimes, outcome is often unsatisfying. One obstacle in chemotherapy such as CPA 
treatment is the occurrence of resistance against the applied treatment regime (51). 
Resistance of tumors towards chemotherapeutic treatment are multifaceted (52;53) 
being primary (intrinsic) or secondary (acquired). In the case of intrinsic resistance, 
the tumor (and metastasis thereof) is not sensitive towards the treatment regime from 
the beginning of the treatment. Secondary resistance occurs as a consequence of 
adoption mechanisms of the tumor under treatment with chemotherapeutic drugs 
(54). Therefore primary and secondary resistance has to be further investigated and 
considered for choosing an adequate treatment regime. 
Evaluation of primary resistance towards chemotherapeutic treatment is difficult in 
conventional in vitro monolayer cell cultures because reasons for that kind of 
resistance are often based on multicellular community effects. Primary resistance can 
be mediated by interactions through cell-cell-contacts and/or by micro environmental 
properties. Therefore the phenomena of primary resistance is rather an effect of the 
collective of tumor cells than of the properties of individual cells (55;56). Therefore, 
tumor cells have to be cultured as multicellular spheroids to overcome the obstacles 
for investigation of primary resistance phenomena in vitro. Primary resistance was 
already described for tumor cells cultured as spheroid and treated with CPA (57).  
The reasons for secondary resistance are based either on properties of the individual 
tumor cells or may result out of changes in the interaction of tumor and tumor stroma 
cells in vivo. Classic secondary chemoresistance occurs due to adoption processes 
of individual tumor cells, and can be subdivided into typical multidrug resistance 
(MDR) and atypical resistance. In contrast to primary resistance phenomena, 
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classical secondary chemoresistance can be evaluated in standard monolayer 
cultures. Usually typical multidrug resistance results from effective efflux of the drug 
by overexpression of transporters of the unspecific ABC (ATP-binding cassette) 
transporter family (53). On the other hand, atypical secondary resistance of the 
individual tumor cells can be mediated by the expression of alternative ABC-
transporters, intracellular detoxication mechanisms, increased DNA repair, 
modification of drug target molecules or modulation of apoptotic and survival 
pathways (e.g. NF-?B modulation) (54;58-60). More recently, a form of acquired drug 
resistance based on changes in the interplay of tumor and tumor stroma cells is 
discussed (61;62). Tumor therapy approaches that do not target tumor cells directly 
but modulate cytokine expression and/or are antiangiogenic strategies should be, in 
theory, independent of drug resistance, due to the genetic stability of the targeted 
cells. Interestingly, acquired resistance occurs towards treatment approaches that do 
not directly target tumor cells. Failure of antiangiogenic treatment regimes may be 
due to the forming of so called mosaic vessels. In this situation tumor cells take over 
the function of endothelial cells to ensure tumor blood supply despite ongoing 
antiangiogenic treatment (63;64). For investigation of the complex process leading to 
failure of antiangiogenic treatment in vivo studies have to be carried out. 
1.3.1.1 Multicellular tumor spheroids 
Conventional monolayer culture of tumor cells is not suitable to evaluate phenomena 
of primary drug resistance due to the fact that these are strongly connected with 
interactions of tumor cells via cell-cell contacts and micro environmental properties. 
Therefore, cell culture systems are required that allow three dimensional growth of 
tumor cells. Multicellular tumor spheroid cultures represent such a cell culture system 
that is closer to the situation of in vivo tumors regarding cell contacts and 
environment (65). Multicellular spheroids of tumor cells can be generated by 
distribution of a single cell suspension in a matrix forming preparation containing the 
cell culture medium. In this thesis a modified chondrocyte cell culture system was 
used in order to establish three dimensional tumor spheroids (66;67). 
1.3.1.2 NF-?B 
NF-?B is a crucial factor in angiogenesis of tumors and in mediating resistance 
towards chemotherapeutic treatment (68-71). Antitumoral effects of cytotoxic 
anticancer drugs are often mediated by apoptotic processes initialized through 
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damage of DNA or proteins in cancer cells. Chemotherapy resistance evoking 
changes in apoptotic pathways can occur upstream of caspase activation and may 
be regulated by stress response mechanisms. NF-?B is one crucial stress responsive 
transcription factor controlling multiple pathways that are connected with apoptosis, 
cell survival and cytokine expression. Moreover, NF-?B is involved in several 
pathways regarding to the expression of proangiogenic cytokines (72;73). In order to 
evaluate a potential role of NF-?B in chemoresistance to CPA therapy, cancer cells 
were reisolated from in vivo tumors and monitored for NF-?B activity levels. 
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1.4 Objectives of this thesis 
To overcome current obstacles of tumor therapy, new anticancer strategies regarding 
efficiency, reduced side effects and resistance have to be investigated. Therefore, 
low dose CPA therapy was combined with a gene therapy approach (GDEPT 
concept). In this context studies were performed to provide i) a suitable in vitro tumor 
mimicking cell culture model and evaluation of the GDEPT approach in vitro and in 
vivo, ii) to evaluate effects of the CPA metabolite acrolein on antiangiogenic activity 
and iii) to elucidate limitations regarding primary and secondary resistance.  
1. Evaluation of the GDEPT concept with P450 CYP2B1 as the therapeutic gene 
in combination with low dose CPA treatment. A starting point was to establish 
an appropriate cell culture model mimicking tumor environment. In situ 
activation of CPA, enzymatic activity of the expressed transgene and 
influences regarding limited diffusion were to be studied and compared with 
experiments performed with conventional cell culture technique. Further on, 
bystander activity that is one of the basic principals of GDEPT had to be 
investigated in the new cell culture system. In the context of bystander activity 
an additional focus was on antiangiogenic strategies. Moreover, targeting and 
therapeutic gene delivery was investigated on primary endothelial cells 
(compare Annex to the thesis). 
2. Metronomic scheduled CPA was shown in several studies to affect tumor 
induced angiogenesis. It was already shown that activated CPA inhibits 
proangiogenic properties of cultured endothelial cells. A potential 
antiangiogenic role of the metabolite acrolein in a metronomic scheduled CPA 
therapy was investigated in this thesis. One additional aim was the 
development of a reliable method for measuring antiangiogenic effects in 
experimental tumors. 
3. Elucidation and classification of primary and secondary resistance of tumors in 
vivo. Resistance phenomena that occurred during CPA therapy were 
evaluated with special attention to changes in tumor vessel markers. 
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2 Materials and methods 
2.1 Chemicals and reagents 
2.1.1 Polyethylenimine (PEI) 
Branched PEI with an average molecular weight of 25kDa (BPEI) and linear PEI with 
an average molecular weight of 22kDa (LPEI) were obtained from Sigma-Aldrich 
(Munich, Germany) and Euromedex (Exgen 500, Euromedex, Souffelweyersheim, 
France), respectively. 
Both were dissolved in water, neutralized with HCl and gel filtrated on a Sephadex G-
25 superfine column using 20mM HEPES, 0.25M NaCl, pH 7.4. For polyplex 
preparation, LPEI and BPEI were used as a 1mg/ml working solution. 
2.1.2 Plasmid DNA 
Plasmid pCMV-LUC (Photinus pyralis luciferase under control of the CMV 
promoter/enhancer) described in (74) was produced endotoxin-free by Elim 
Biopharmaceuticals (San Francisco, CA, USA) or Aldevron (Fargo, ND, USA) or 
PlasmidFactory (PlasmidFactory GmbH & Co. KG, Bielefeld, Germany) or was 
purified with the EndoFree Plasmid Kit from Quiagen GmbH (Hilden, Germany). 
 
Plasmid pEGFP-N1 (encoding enhanced green fluorescent protein (EGFP) under the 
control of the CMV promoter/enhancer were purchased from Clontech Laboratories, 
Inc. (Heidelberg, Germany) or Elim Biopharmaceuticals.  
 
pCMV-CYP2B1 (rat cytochrome P450 under the control of CMV promoter/enhancer) 
described in (75) was produced endotoxin-free by Elim Biopharmaceuticals (San 
Francisco, CA, USA). 
 
Hypoxia response element HRE–luciferase reporter constructs pHRE-LUC (firefly 
luciferase) were synthesized as described in (76). 
Renilla LUC-expressing plasmid pRL-SV40, utilized as an internal control, was 
obtained from Promega GmbH (Mannheim, Germany). Both plasmids constructs 
were provided by Dr. A. Kurosh. 
 
Plasmid pNF?B-LUC (Luciferase under control of a NF-?B level sensitive 
promoter/enhancer) was obtained from Clontech Laboratories, Inc. (CA, USA). 
Negative control plasmid pTAL-LUC was also obtained from Clontech Laboratories, 
Inc. (CA, USA). 
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2.1.3 Recombinant proteins 
Recombinant human FGF-basic growth factor was obtained from Peprotech, London 
UK and was added to M199 medium (Invitrogen) for the cultivation of HUVEC cells in 
a final concentration of 20ng/ml. Human recombinant TSP-1 was obtained from 
Immun Diagnostik, Bensheim, Germany. 
2.1.4 Other reagents 
Natriumthiosulfate, glycerine, natriumcarbonate, silvernitrate, 3-aminophenol, 
natriumchloride and DMSO for MTT assay, were obtained from Merck KGaA, 
Darmstadt, Germany. Acrolein and cyclophosphamide-monohydrate were obtained 
from FLUKA Chemika, Milwaukee, WI. Collagenase Type II was obtained from 
Biochrom AG, Berlin, Germany; Agarose Ultrapure and Geneticin G418 were 
obtained from Invitrogen, Oregon, USA. 4-Hydroperoxy-CPA was obtained from Dr. 
Ulf Niedermeyer (Tel. +49 01726611870 or +49 05212080977). All other reagents 
were obtained from Sigma-Aldrich, Taufkirchen, Germany. 
2.1.5 Software 
Evaluation of receptor status and analysis of polyplex cell association was carried out 
by using the WINMDI 2.8 software (Windows Multiple Document Interface for Flow 
Cytometry). The software is downloadable at http://facs.scripps.edu/software.html.  
The MIPAV application (Medical Image Processing, Analysis, and Visualization) was 
used for measuring Hoechst33258 fluorescence levels in CT26 tumor slides after 
systemically application. The software was downloaded from http://mipav.cit.nih.gov/.  
Axio vision and Axio vision LE (Carl Zeiss, Jena, Germany) was used for presenting 
immunohistochemical analysis and for measuring migration capability. 
Microsoft Excel and WinStat (R. Fitch software, Bad Krozingen, Germany) were used 
for generating diagrams and performing statistical analysis. 
2.1.6 Antibodies 
Primary antibodies 
Rabbit-anti-laminin antibody was obtained from Chemicon Europe, Hampshire, UK. 
The mouse-anti-human CD51/CD61 complex antibody, anti-human CD71 receptor 
antibody, mouse-anti human Epidermal growth factor receptor (EGF) clone H11 
antibody and IgG1, negative control antibody were obtained from Dako, 
Copenhagen, Denmark. 
The rat-anti-mouse CD31 antibody was obtained from CALTAG, Burlingame, USA;  
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PE rat IgG control antibody and PE rat anti-mouse antibody were both obtained from 
Pharmingen, BD Biosciences, Canada. The mouse-anti-ratCYP2B1 antibody was 
obtained from Oxfordbiomedical Research, Oxford, UK; rat-anti-mouse CD51 was 
obtained from Biolegend, Biozol, Eching, Germany; anti-acrolein-antibody ACR, 
monoclonal antibody was obtained from JaICA, Japane and the Mouse anti TSP-1 
Ab-4 (Clone A6.1) was obtained from Lab vision, Neomarkers, Westinghouse, CA.  
 
Secondary antibodies 
Texasred labelled goat-anti-rabbit antibody was obtained from Vector, Burlingame, 
UK. The ALEXA488 labelled goat-anti-rat antibody and the ALEXA488 labelled goat 
–anti-mouse antibody were obtained from Invitrogen, Oregon, USA. ALEXA467-anti-
rat antibody and the ALEXA488-anti-mouse were obtained from Invitrogen, Oregon, 
USA. The Cy5 labelled anti-mouse antibody was purchased from Jackson 
ImmunoResearch Laboratories, Inc., Newmarket, England. 
2.1.7 Measurement of protein concentration 
BIO-RAD protein assay (BIO-RAD, Munich, Germany) 
The concentration of protein containing samples was measured with the BIO-RAD 
protein assay (BIO-RAD, Munich, Germany) according to the manufactures 
instructions. BSA was used for the protein standard curve. 
 
BCA protein assay (Pierce, Rockford, IL) 
The concentration of protein containing samples was measure with the BCA protein 
assay (Pierce, Rockford, IL) in the case of the TSP-1 induction experiment according 
to the manufactures instructions. BSA was used for the protein standard curve. 
 
2.2 Cell biological methods 
2.2.1 Cell culture 
Cell culture media, antibiotics, fetal bovine serum (FBS), G148 (geneticin) and 
trypsin/EDTA solution were purchased from Invitrogen GmbH (Karlsruhe, Germany). 
All cultured cells were grown at 37C in 5% CO2 humified atmosphere in incubators 
(Heracell) obtained from Kendro Laboratory products, Langenselbold. 
CT26/X39 cells were cultured in DMEM low glucose medium, supplemented with 
10% FBS, whereas X39 were established from the CT26 murine colon carcinoma 
cells (ATCC CRL-2638) by stable transfection with linearised pCMV-CYP2B1 plasmid 
DNA. Neuro2A murine neuroblastoma cells (ATCC Cl-131) were cultured in DMEM 
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low glucose medium, supplemented with 10% FBS. 9L and 9L-2DB1 were obtained 
from D. Waxman and were cultured in DMEM low glucose medium, supplemented 
with 10% FBS. 
HUH7 hepatocellular carcinoma (JCRB 0403; Tokyo, Japan) were grown in 
DMEM/F12 (1/1) with Glutamax I medium supplements with 10% FBS. PC3 human 
prostate carcinoma cells (CRL1435) were cultured in RPMI medium supplemented 
with 10% FBS. 
Endothelial cells HUVEC (pooled human umbilical vein endothelial cells) were 
obtained from ATCC (Manassas, Virginia) and PEC cells, which were provided by J. 
Pelisek were cultured on collagen G coated plates in M199 medium supplemented 
with 20ng/ml human bFGF and 10% FBS. Isolated primary fibroblasts from NF-?B-
luciferase-reporter mice, provided by C. Culmsee, were grown on collagen G coated 
plates in M199 medium supplemented with 10% FBS. 
For in vitro experiments, all cell lines and primary cells were grown in medium, 
supplemented with 100 U/ml penicillin and 100µg/ml streptomycin. 
2.2.2 Agarose overlay technique 
Cells were seeded either in 24-well (Hoechst 33258 diffusion experiment) or 48-well 
plates (all other assays) 24 h prior to addition of the agarose overlay. Culture medium 
was removed and replaced with 345 µl medium (24-well plates) or 200 µl medium 
(48-well plates) containing 0.5% (w/v) agarose. The agarose-containing medium was 
obtained by stepwise dilution of complete medium with melted agarose (10% agarose 
in PBS, w/v). Before applying the agarose-containing medium to the seeded cells, the 
medium was allowed to cool to 37°C. After solidification of the agarose, 1040 µl (24 
well-plate) or 600 µl (48-well plate) of complete culture medium without agarose (+/- 
CPA) was added to the cells. 
2.2.3 Multicellular spheroid culture (Agarose suspension culture) 
For generating agarose wrapped multicellular spheroids, a single cell suspension of 
the indicated tumor cells was mixed with 1% agarose (Ultrapure, Invitrogen) 
containing cell culture medium in a ratio of 1:1. 50µl of the obtained cell suspension 
was applied in an agarose coated 24 well plate (TPP, Switzerland). After solidification 
of the agarose, 500µl of the indicated standard cell culture medium was added to the 
well. Multicellular spheroids were cultured for several days, whereas replacement of 
cell culture medium was performed every third day. 
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2.2.4 Coculture in a transwell system 
Coculture experiments were partly performed by using a transwell system. Therefore 
target cells were seeded in a 24 well plate (TPP, Switzerland) and producer cells 
(X39 tumor cells) were seeded in a transwell insert with a pore size of 8µm (NUNC, 
Denmark) about 24h prior to the administration of CPA. For performing the coculture, 
the inserts were transferred to the 24 well plate with a sterile tweezers. 
2.2.5 Storage of isolated and other cells 
Cells were harvested with trypsin/EDTA, followed by removing supernatant by 
centrifugation for 5min at 150g (Haereus, Megafuge 1.0 R). Cells were resuspended 
in FBS containing 10% DMSO (Sigma) and freezing was carried out, whereas the 
temperature dropped 1°C per minute, until -80°C was reached. Frozen cells were 
then transferred to a nitrogen storage tank for long term storage. 
 
2.3 Molecular biological methods 
2.3.1 Restriction digestion of plasmid DNA 
pCMV-CYP2B1 plasmid DNA was incubated with restriction enzymes BamHI and 
XHO1 (Promega, Mannheim, Germany) for 2-3h. For digestion, 5 units of the desired 
restriction enzyme per µg DNA was used in the appropriate restriction enzyme buffer 
according to manufactures instructions. Success of digestion was tested by agarose 
gel electrophoresis.  
2.3.2 Linearizing of plasmid DNA 
Plasmid pCR3.1-CYP2B1 was linearized by digestion with XhoI, followed by agarose 
gel electrophoresis and Qiaprep? Spin MiniprepKit 250 (Qiagen) purification 
according to the manufacturer’s instructions. Plasmid DNA content was evaluated by 
UV absorption measurement at 260nm and 280nm respectively. 
2.3.3 Generation of stably transfected single cell clones 
CT26 and Neuro2A cells were seeded and transfected in 24-well plates. The 
transfection complex of linearized pCR3.1-CYP2B1 plasmid with PEI was generated 
at an N/P ratio (nitrogen in PEI/phosphate in DNA) of 6 in HBS (HEPES buffered 
saline: 20mM HEPES pH 7.1, 150mM NaCl) at a final DNA concentration of 20 
µg/ml. Forty eight h after transfection, cells were selected with 0.5 µg geneticin per ml 
culture medium. To obtain subclones, the surviving cells were re-seeded in a 96-well 
plate at 1 cell/well after 2 wk of geneticin selection. Subclones were analyzed and 
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characterized for CYP2B1 activity using 7-pentoxyresorufin as substrate. Clone X39 
gave the highest P450 activity and was used in all subsequent experiments. 
 
2.4 Polyplex formation and transfections 
In general, polyplexes were generated by condensing plasmid DNA encoding 
luciferase, EGFP-N1 or pCMV-CYP2B1 with LPEI at a molar ratio of PEI nitrogen to 
DNA phosphate (N/P) of 6. For this reason, plasmid DNA and PEI or PEI conjugates 
were each diluted in HBS (HEPES buffered saline, and rapidly mixed by pipetting up 
and down 10 to 20 times. DNA/PEI polyplexes were prepared at a final DNA 
concentration of 20µg/ml. Polyplexes were allowed to stand for at least 20min at 
room temperature before use. 
2.5 Gene expression assays 
2.5.1 Luciferase reporter gene expression in vitro experiments 
Cells were plated in the indicated densities either in 48 well- or in 24 well- plates 24h 
prior to transfection. In case of primary endothelial cells or fibroblasts well plates 
were coated with collagen G prior seeding. Transfection complexes with indicated 
amounts of plasmid DNA were added to the cells in 300µl of cell culture medium. 
Medium was replaced 4h after the transfection and gene expression was measured 
at the indicated time points (if not mentioned, measurement was performed 24h after 
transfection). Detection of luciferase activity  was carried out as described recently 
(77). Luciferase activity levels were expressed as relative light units (RLU) per 
seeded cells (mean ± SD from n=3, n=4 or n=6) or were normalized on activity levels 
of control cells. 2ng of recombinant luciferase (Promega, Mannheim, Germany) 
correspond to 107 relative light units (RLU).  
Detection of luciferase activity under the control of a NF-?B sensitive promoter in 
primary fibroblasts was carried out with a prolonged signal measure time of 30s. 
In the case of hypoxia induction studies, cells were plated in the indicated density on 
6 well plates prior to transfection. Detection of luciferase activity was carried out at 
the indicated time points with the Promega Dual Luciferase kit according to 
manufactures instructions. 
2.5.2 EGFP reporter gene expression  
Indicated number of cells was seeded 24 h prior to transient transfection in a 48-well 
plate (NUNC). Cells were transfected with the indicated amount of pCMV-EGFP-N1 
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using linear PEI (N/P 6 in HBS). Medium was replaced 4h after transfection. Forty 
eight h after transfection, the cells were washed with PBS and harvested by trypsin 
treatment. For analysis of EGFP expression, the cells were analyzed as described 
(78) or by counting GFP positive cells by fluorescence microscopical analysis. 
2.5.3 CYP2B1 gene expression 
Indicated number of cells was seeded 24 h prior to transient transfection in a 48-well 
plate (NUNC). Cells were transfected with the indicated amount of pCMV-CYP2B1 
using linear PEI (N/P 6 in HBS). Medium was replaced 4h after transfection. Forty 
eight h after transfection, the cells were washed with PBS and harvested by trypsin 
treatment. For analysis of CYP2B1 expression, the cells were analyzed after 
antibody-staining by FACS analysis as described (79) or by counting positively 
stained cells by fluorescence microscopical analysis. 
2.5.3.1 CYP2B1 Transgene expression analysis after 
  transient transfection 
HUH7 cells were seeded 24 h prior to transient transfection in a 48-well plate. Cells 
were transfected with 100 ng pCMV-CYP2B1 or pCMV-EGFPN1 using linear PEI 
(N/P 6 in HBS). Forty eight h after transfection, the cells were washed with PBS and 
harvested by trypsin treatment. For analysis of EGFP expression, the cells were 
analyzed as described (80). For analysis of CYP2B1 expression, cells were fixed with 
2% paraformaldehyde in PBS, followed by permeabilization with 0.1% (w/v) Triton X-
100 in PBS. Cells in 5% FBS in PBS were incubated with mouse monoclonal anti-rat 
CYP2B1 (Oxford Biomedical Research, Oxford, MI, USA) or, as a control, with non-
specific mouse isotype control antibody. Alexa488-conjugated goat anti-mouse IgG 
(Molecular Probes) was used as second antibody. Cells were analyzed on a Cyan 
MLE flow cytometer (Dako Cytomation, Kopenhagen, Denmark). As an additional 
control, non-transfected cells were similarly stained and analyzed.   
2.5.4 NF-?B activity studies 
NF-?B levels in primary endothelial cells 
Screening for NF-?B activity levels of primary endothelial cells (HUVECs) were 
performed in the absence or in the presence of different concentrations of acrolein in 
the medium. Therefore HUVEC cells were seeded on collagen coated (Collagen G, 
Biochrom) 24 well plates in a density of 15000 cells/well prior to transfection. HUVEC 
cells were transfected with LPEI polyplexes (N/P 6, HBS, 300ng/well) containing 
either pNF?B-LUC plasmid or pTAL-LUC plasmid DNA. Medium was replaced 4h 
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after transfection with 300µl of fresh medium and cells were cultivated for further 20h 
at standard conditions (37ºC, 5% CO2, 20.9 %oxygen). 24h after the transfection 
different amounts of acrolein (dissolved in PBS) were added to the cells. Control cells 
were vehicle treated (PBS). Cells were cultivated for further 24h and detection of 
luciferase activity was carried out as described in 3.5.1.1. NF-?B induced luciferase 
expression was normalised on pTAL-LUC activity levels.  
 
NF-?B levels in tumor cells (CT26) 
Screening for NF-?B activity levels of CT26 tumor was performed in the absence or in 
the presence of different concentrations of Acrolein in the medium. Therefore CT26 
cells were seeded on 24 well plates in a density of 15000 cells/well prior to 
transfection. CT26 cells were transfected with LPEI polyplexes (N/P 6, HBS, 
400ng/well) containing either pNF?B-LUC plasmid or pTAL-LUC plasmid DNA. 
Medium was replaced 4h after transfection with 300µl of fresh medium and cells were 
cultivated for further 20h at standard conditions (37ºC, 5% CO2, 20.9 %oxygen). 24h 
after the transfection different amounts of acrolein (dissolved in PBS) were added to 
the cells. Control cells were vehicle treated (PBS). Cells were cultivated for further 
24h and detection of luciferase activity was carried out as described in 3.5.1.1. NF-?B 
induced luciferase expression was normalised on pTAL-LUC activity levels.  
 
NF-?B levels in other tumor cells 
Screening for NF-?B activity levels of PC3 and reisolated PC3ID3 and PC3ID4 as 
well as HUH7 and reisolated HUH7 REISO and Neuro2A and Neuro2A REISO cells 
was performed by transfection with a NF-?B sensitive luciferase encoding plasmid. 
Therefore all mentioned parental and reisolated cells were seeded on 24 well plates 
in a density of 15000 cells/well 24h prior to transfection. Cells were transfected with 
LPEI polyplexes (N/P 6, HBS, 400ng/well) containing either pNF?B-LUC plasmid or 
pTAL-LUC plasmid DNA. Medium was replaced 4h after transfection with 300µl of 
fresh medium and cells were cultivated for 44h at standard conditions (37ºC, 5% 
CO2, 20.9 %oxygen). Detection of luciferase activity was carried out as described in 
3.5.1.1. NF-?B induced luciferase expression was normalised on pTAL-LUC activity 
levels.  
 
NF-?B levels in primary fibroblasts 
Primary fibroblasts expressing luciferase under the control of a NFKB sensitive 
promoter were obtained from transgene animals (NFKB-LUC-Mice). Fibroblasts were 
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seeded on collagen coated (Collagen G, Biochrom) 24 well plates in a density of 
15000 cells/well. 24h after the seeding cells were treated with different 
concentrations of acrolein (dissolved in PBS). Control cells were vehicle treated 
(PBS).  
2.6 Assays for detection of CYP2B1 enzymatic activity 
2.6.1 Resorufin assay 
A modified form of a previously described assay (81) was used to assay CYP2B1 
enzymatic activity. Cells were incubated in 48-well plates with 200 µl Optimem I 
medium containing 1.7 µM 7-pentoxyresorufin and 100 µM 3,3´-methylene-bis(4-
hydroxycoumarin) (‘substrate solution’) for 20 to 120 min. Following incubation, the 
cells were subject to a freeze-thaw-cycle to stop the enzymatic reaction. The 
supernatant was transferred to a 1.5 ml reaction tube, centrifuged at 15,000 g for 10 
min and 150 µl of the clear liquid was assayed for fluorescence using a Cary Eclipse 
fluorimeter (Cary, Mulgrave, Australia) with excitation and emission wavelengths set 
to 562 and 585 nm, respectively. Measurements were performed in triplicate and 
enzyme activity was expressed as relative fluorescence units (RFU). 
When measuring CYP activity under the agarose layer 200µl substrate solution was 
injected between the adherent cells and the agarose layer after solidification of the 
agarose (200µl). After 40min of incubation at 37°C the agarose layer was removed 
and resorufin content quantified in the supernatant. In the “–gel” samples, 200µl 
substrate solution was added to the cells under standard conditions, incubated for 
40min at 37°C and resorufin content quantified thereafter. In the case of the “gel 
removed” samples, cells were overlaid with 200µl agarose for 1h. Thereafter the gel 
was removed, 200µl substrate solution added to the cells and after incubation at 
37°C for 40min resorufin was quantified in the supernatant. No significant amounts of 
resorufin were found in the agarose layer, indicating that the majority of resorufin is 
localized in the solution between the cells and the agarose overlay. 
 When performing the pentoxyresorufin assay in a hypoxia chamber, 100,000 X39 
cells were seeded in a 3.5 cm culture dish. Twenty four h after seeding, the cells 
were incubated in the hypoxia chamber for 40 min with 500 µl of the substrate 
solution either under normoxia (21% O2) or under various decreased O2 
concentrations, with O2 replaced by a mixture of N2 and CO2. Oxygen partial 
pressure was measured with a digital oxymeter (GMH 3690, Greisinger Electronic, 
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Germany). Relative humidity and temperature (37°C) were similar under all 
conditions. 
For validation recovery of resorufin in biological fluidics was investigated. Therefore 
different amounts of resorufin (solved in PBS) were added to the resorufin incubation 
solution. The detection of the added resorufin was performed by fluorescence 
measurement as described above. 
Thereby, concentrations of added resorufin were chosen in an interval that is relevant 
for in situ released resorufin by CYP2B1 enzymatic reaction. FIG 2-1 demonstrates 
that measured fluorescence signal of the recovered resorufin in the incubation 
solution depends on its concentration in a linear manner. 
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Fig.: 2-1 Validation of recovery of 
resorufin in biological fluidics. Different 
amounts of resorufin were added to the 
resorufin incubation solution in order to 
achieve cell culture medium with 
increasing concentrations of resorufin. 
Resorufin recovery was performed by 
fluorescence measurement 
(562nm/585nm). Values are means 
±SE of duplicates 
 
 
Further evaluation of the resorufin assay was performed on the X39 cell line because 
of the high CYP2B1 enzymatic activity of the cell line. 
The amount of in situ produced resorufin was proportional to the incubation time (FIG 
2-2 A) and proportional to cell count (FIG 2-2 B). 
Materials and methods   29
0
100
200
300
400
500
600
700
800
900
0 50 100 150 200 250
incubation time [min]
fl
u
o
re
s
c
e
n
c
e
 [
F
L
U
]
 
y = 0,0097x
R2 = 0,9993
0
100
200
300
400
500
600
700
0 20000 40000 60000 80000
cell count
fl
u
o
re
s
c
e
n
c
e
 [
F
L
U
]
 
A         B 
Fig.: 2-2 Validation of the resorufin assay for detection of CYP2B1 activity in cultured cells. A) X39 
cells were cultured with resorufin assay incubation solution for different incubation times. Resorufin in 
the supernatant was determined by fluorescence measurement after a freeze-thaw-cycle. Values are 
means ± SD of triplicates. B) Different amounts of X39 cells were cultured with resorufin incubation 
solution for 60min. After a freeze-thaw cycle resorufin was determined in the supernatant by 
fluorescence measurement. Values are means ±SE of duplicates. 
 
2.6.2 Acrolein assay 
A modified form of an previously described assay (82-84) was used to measure 
CYP2B1 enzymatic activity in the context of CPA conversion. 
In contrast to the described assay, the cell incubation solution included 0.005M 
semicarbazide to reduce protein adduct forming in a FBS containing medium. After 
the incubation, cells were subjected to a freeze-thaw cycle, followed by removal of 
proteins by precipitation. Therefore, 500µl of the incubation solution was drugged 
with 200µl of a sated solution of barium hydroxide and 200µl of a sated solution of 
zinc chloride. After an centrifugation step, the acrolein in the supernatant was 
derivatized as described previously (85). Derivatised acrolein was detected by 
fluorescence measurement; measurements were performed by using a Cary Eclipse 
fluorimeter (Cary, Mulgrave, Australia) with excitation and emission wavelengths set 
to 350nm and 515nm, respectively. Measurements were performed in triplicate and 
enzymatic conversion capability was expressed as relative fluorescence units (RFU). 
 
For validation, recovery of acrolein in cell culture medium was investigated. Therefore 
indicated amounts of acrolein (solved in PBS) were added to the incubation solution. 
Protein precipitation, derivatising and the detection of added acrolein was performed 
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by fluorescence measurement as described above. Thereby, concentrations of added 
acrolein were chosen in an interval that is relevant for in situ released acrolein by 
CPA conversion. FIG 2-3 demonstrates that measured fluorescence signal of the 
recovered acrolein in the incubation solution depends on its concentration in a linear 
manner up to 30µM. 
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Fig.: 2-3 Validation of acrolein 
recovery in cell culture medium 
supplemented with 10% FBS. 
Different amounts of acrolein were 
added to cell culture medium 
(DMEM, low glucose, supplemented 
with 10% FBS) in order to achieve 
medium with increasing 
concentrations of acrolein. Acrolein 
recovery was performed with the 
acrolein assay described in 
materials and methods. Values are 
means ±SE of triplicates. 
 
 
2.7 Hypoxia induced HRE-responsible gene expression  
Control hypoxia induction studies were performed with CT26 and Neuro2A cells. 
20.000 CT26 or Neuro2A cells were seeded in 6 well plates (NUNC). 24h after the 
seeding cells were transfected with LPEI polyplexes (N/P 6, HBS, 1000ng/well) 
containing pHRE-LUC and pRL-SV40 plasmid DNA (400:1 w/w). Medium was 
replaced 4h after transfection and cells were cultivated for 20h at standard conditions 
(37ºC, 5% CO2, 20.9 %oxygen). Cells were cultured for further 24h at 37ºC in 
humified atmosphere containing either air (20.9% oxygen; normoxia) or air sufficient 
to give 1% oxygen. 5% CO2 was used in all normoxic and hypoxic incubators, with 
the balance being nitrogen in the hypoxic incubation. Oxygen partial pressure was 
measured with a digital oxymeter (GMH 3690, Greisinger Electronic, Germany).  
Firefly and Renilla luciferase expression levels were determined by the Promega 
Dual Luciferase kit according to the manufactures instructions. 
For hypoxia induction studies referring to the agarose overlay technique 200.000 
CT26 or Neuro2A cells were seeded in 6 well plates (NUNC). 24h after the seeding 
cells were transfected with LPEI polyplexes (N/P 6, HBS, 1000ng/well) containing 
pHRE-LUC and pRL-SV40 plasmid DNA (400:1 w/w). Medium was replaced 4h after 
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transfection and cells were cultivated for 20h at standard conditions (37ºC, 5% CO2, 
20.9 %oxygen). 24h after the transfection agarose overlay was performed with 1.6ml 
agarose (0.5% w/w) containing medium. 5.2ml agarose free medium was added after 
solidification to the well plates. Cells were cultured for further 24h in a humified 
atmosphere at 37ºC, 5% CO2, 20.9 %oxygen. Afterwards, agarose overlay was 
removed and cells were analyzed for firefly and renilla luciferase activity by the 
Promega Dual Luciferase kit according to manufactures instructions. The Renilla 
LUC-expressing plasmid pRL SV40 (Promega) was included in each transfection, as 
an internal control to normalize LUC expression.  
 
2.8 Angiogenesis assays 
2.8.1 Migration assay wound healing (scratch wound assay) 
HUVEC and PEC cells were plated onto collagen G (Biochrom AG) coated chamber 
slides (IBIDI, Munich, Germany) or glass cover slips (15000 cells/well) 24h prior 
performing the scratch wound assay. When cells were confluent, the monolayer was 
scratched by a yellow pipette tip. Detached cells were rinsed away with PBS and the 
medium was changed. Digital image of cells was taken immediately after scratching 
(t=0) and after the incubation time. Cells were cultivated for further 24h in the 
presence of indicated concentrations of acrolein or in cocultivation with CYP2B1 
expressing X39 cells with or without CPA. The distance between cells in the 
scratched area was measured using the Axio vision LE software (Zeiss, Jena, 
Germany). Ten measurements were performed for each data point. The results were 
calculated in% rate of migration, whereas time point 0 was considered as the starting 
point and the 24h time point in the control experiments was considered as 100% cell 
migration. 
2.8.2 Tube formation assay 
Cooled matrigel (Sigma, Germany) 50µl was added to each well of a 96 well plate 
(300µl to a 24well plate) and incubated at 37°C for 30min to allow polymerisation. 
HUVEC cells were harvested at a density of about 70% confluency and the cell 
suspension was added to each well of the plate and incubated for 4h in the absence 
or in the presence of indicated concentrations of CPA or acrolein, respectively. Cells 
were fixed with 4% paraformaldehyde (in PBS) and analyzed via transmitted light 
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microscopy. Total amount of tube like structures were detected, whereas only 
complete tubes were counted. 
2.8.3 Staining for integrin v 3 
Cells were cultured as described on collagen IV coated Lab-Tek chambered #1.0 
Borosilicate cover glass system from NUNC. After treatment for 4h with indicated 
concentrations of acrolein the supernatant was removed and cells were washed with 
prewarmed PBS, followed by fixing with paraformaldehyde containing PBS (4% w/w) 
for 10min. In case of simultaneous staining of the F-actin cytoskeleton as well as 
integrin receptors the fixation was followed by a Triton-X 100 (0.1% in PBS) 
treatment for 5min. Thereafter, cells were washed two times with PBS containing 
0.5% FCS. After the second washing step, cells were incubated for 10min with the 
FBS containing PBS to mask unspecific recognition sequences.  
The supernatant was removed and replaced by 200µl of antibody containing (mouse-
anti-human CD51/61 ((Dako, Copenhagen, Denmark)) PBS solution containing 0.5% 
FBS. The working dilution of the antibody was 1:200. After incubation for 2h at room 
temperature cells were washed for 3 times with PBS containing 0.5% FBS to remove 
unbound antibody. For simultaneous visualisation of the F-actin cytoskeleton and 
integrin receptors, cells were incubated with a solution containing Cy5 labelled anti 
mouse antibody (1:200) (Jackson ImmunoResearch Laboratories, Inc.) and 
Phalloidin-FITC with an end concentration of 0,165µM; the incubation was performed 
at room temperature for 1h in a humified atmosphere. Afterwards cells were washed 
repeatedly with PBS containing 0.5% FBS. Immediately after the washing procedure 
cells were embedded with vector shield mounting medium (Vector Labs, Burlingame, 
CA, USA) to avoid drying and bleaching processes. Pictures were obtained by using 
a Zeiss Axiovert 200 microscope. FITC-fluorescence was excited using a 470±20 nm 
bandpass filter and emission was collected using a 540±25 nm bandpass filter, 
whereas ALEXA467 was excited using a 640±20 nm bandpass filter and emission 
was collected using a 735±35 nm bandpass filter. 
2.8.4 Staining for F-actin 
Cells were cultured as described above on collagen IV coated Lab-Tek chambered 
#1.0 Borosilicate cover glass system from NUNC. After treatment for 4h with 
indicated concentrations of acrolein the medium was removed. Cells were fixed with 
PBS containing 4% (w/w) paraformaldehyde for 10min after washing with prewarmed 
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PBS. The fixing solution was removed completely and the cells were washed with 
prewarmed PBS again followed by a treatment with 0.1% Triton X-100 in PBS. After 
5min of Triton X treatment, cells were washed two times with PBS containing 0.5% 
FCS. After the second washing step cells were incubated for 10min with PBS 
containing 0.5% FBS. Afterwards the supernatant solution was removed and 
replaced by 200µl of a 0,165µM phallotoxin-FITC (Sigma-Aldrich, Germany) 
containing PBS/FBS solution. After incubation for 30min at room temperature in the 
dark cells were washed again for 3 times with PBS containing 0.5% FBS to remove 
unbound phallotoxin-FITC. Immediately after the washing procedure cells were 
embedded with vector shield mounting medium (Vector Labs, Burlingame, CA, USA), 
to avoid drying and bleaching processes. Pictures were obtained by using a Zeiss 
Axiovert 200 microscope and using a 470±20 nm bandpass filter for excitation; 
emission was collected using a 540±25 nm bandpass filter. 
2.8.5 Thrombospondin Elisa 
HUVEC cells were seeded on collagen G (Biochrom AG) coated 24 well plates (TPP, 
Switzerland) in a density of 15000 cells per well. 24h after the seeding, cells were 
cultured with indicated concentrations of acrolein in the medium for further 24h. After 
the incubation, cells were washed with PBS followed by cell lyses with 100µl/well 
Millipore water and a freeze-thaw cycle. Subsequent centrifugation at 16,000g for 
60min (4ºC) allowed removal of cell debris. 25µl of the supernatant was diluted with 
Diluent #2 (ChemiKine, Human TSP-1 EIA KIT, Chemicon, USA) to 100µl diluted 
sample. The samples were analyzed for TSP-1 level by the ChemiKine Human TSP-
1 EIA KIT according to manufactures protocol. 
Data thus obtained were normalized on protein content, measured by the BCA 
protein content assay (BCA, Protein Assay KIT, Pierce, Rockford, IL) according to 
manufactures protocol.  
 
2.9 Proliferation and viability assays 
2.9.1 Hoechst33258 DNA content assay 
To assay for DNA content, culture medium and agarose layer were removed and 
cells were washed with PBS. After the washing procedure, cells were harvested with 
Trypsin-EDTA (100µl) and lysed with Millipore water (100µl) followed by freeze-thaw-
cycle. 200µl of cell lyses buffer (20mM Tris, 2mM EDTA 5M NaCl, pH 7.4) containing 
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0.2µg/ml Hoechst 33258 dye were applied to each well, followed by another freeze-
thaw-cycle. 200µl of the cell suspension were transferred to a black bottom 96 well 
plate (Greiner-Bio One, Frickenhausen, Germany). The DNA content was measured 
by quantifying fluorescence signal with a SPECTRAFluor Plus plate reader (Tecan, 
Grödig, Austria),using excitation and emission filters centered at 360nm (excitation) 
and 465nm (emission), respectively. 
For verifying the qualification of this assay increasing cell numbers were transferred 
to Eppendorf tubes and centrifuged at 1000rpm. The pellets were analyzed by the 
Hoechst33258 based DNA content assay as described in materials and methods. 
Linear correlation between cell number and fluorescence signal in the DNA content 
assay was found. The correlation was verified for the following cell lines: 9L, 9L-
D2B1, CT26, X39, Neuro2A and HUH7. 
For safe cell count quantification at least 600 to 700 cells were required. (three fold 
fluorescence increase in comparison to signal to noise ratio) 
FIG 2-4 demonstrates that the Hoechst 33258 based proliferation assay is reliable for 
cell numbers ranging from 1x103 to 5x104. 
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Fig.: 2-4 Validation of the Hoechst33258 based proliferation assay. Neuro2A, CT26, X39, 9L, 9L-D2B1 
and HUH7 cells were harvested with trypsin/EDTA, followed by a freeze-thaw cycle. The assay was 
performed by incubating different cell numbers with TNE buffer containing Hoechst33258 in black 
bottom 96 well plates, fluorescence was determined at 465nm in a SPECTRAFluor Plus plate reader 
(excitation: 360nm). Values are means of duplicates. 
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Results obtained with the Hoechst33258 based DNA content assay correlate well 
with those of the MTT assay under normoxic conditions. However, cultivation of cells 
under long-term hypoxic conditions, results of the MTT assay were artificially low, 
indicating adaption mechanisms influencing metabolic activity in the MTT assay. 
2.9.2 MTT assay 
After removing the culture medium and, if applicable, the agarose layer, 300 µl of 
culture medium containing 0.25% MTT (w/v) was applied to each well after which the 
plates were incubated for 3 h at 37°C. MTT is converted to a colored, water insoluble 
formazan salt by the metabolic activity of viable cells. The culture medium was then 
removed and the cells were frozen at -80°C. After thawing the cells, 300 µl of DMSO 
was added to dissolve the insoluble formazan salt and absorbance at 590 nm was 
measured with a plate reader (Tecan, Grödig, Austria). A reference absorbance at 
630 nm was subtracted from the absorbance at 590 nm for each well. 
In order to verify the adequacy of this assay for the quantification of living cells 
different cell numbers were seeded and measured for metabolic activity by MTT 
assay as described above 24h after seeding. In a parallel experiment the seeded 
cells were harvested by treatment with trypsin/EDTA solution and cell number was 
determined by transmitted light microscopy. 
The reliability of the MTT assay was verified for CT26, Neuro2A, 9L and HUH7 cells. 
Linear correlation between cell number (living cells) and MTT absorbance was found 
in all assayed cell lines.  
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Fig.: 2-5 Validation of cell number (living cells) correlation with metabolic activity (MTT assay). Cell 
count of living cells was determined by transmitted light microscopy after addition of tryptan blue as a 
marker for viable cells. Values are means of duplicates. In a parallel performed MTT assay total 
metabolic activity of the cells was measured. Values are means of duplicates. 
 
2.10  Flow cytometric analysis and microscopy 
2.10.1 Flow cytometric analysis of EGF receptor 
 and CD71 on reisolated tumor cells 
Indicated reisolated tumor cells (PC3ID3, PC3ID4 and HUH7 REISO) and parental 
tumor cells (PC3 and HUH7) were seeded in 24 well plates (TPP, Switzerland) at a 
density of 40.000 cells per well 48h prior receptor status detection. Cells were 
washed with prewarmed PBS and harvested by treatment with trypsin/EDTA. The 
obtained cell suspensions were pooled and adjusted to 106 cells/ml with MACS buffer 
(PBS containing 2.5% FBS) after centrifugation for 5min at 150g (Haereus, Megafuge 
1.0 R). The cell suspension was divided up and exposed to the following antibodies 
at 4°C for 1h; mouse-anti-human-EGF antibody (Dako) and mouse-anti-human CD71 
antibody (Dako). Control staining was performed by using mouse IgG1, negative 
control antibody (Dako). All antibodies were applied at a total dilution of 1:200. 
After primary antibody exposition, cells were washed repeatedly with prewarmed 
MACS buffer (PBS containing 2.5% FBS) to remove unbound antibody. Secondary 
antibody staining was performed by exposing the cell suspension to ALEXA488 
labelled anti-mouse-antibody (Invitrogen), for 1h at 4°C. The secondary antibody was 
applied at a total dilution of 1:400. 
Reisolated Neuro2A tumor cells and parental Neuro2A tumor cells were seeded in 24 
well plates (TPP, Switzerland) at a density of 40.000 cells per well 48h prior receptor 
status detection. Harvesting and adjusting cell suspension to 106 cells/ml was 
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performed as described above. The cell suspension was divided up and exposed to 
the PE-labelled anti-mouse CD71 antibody (BD Pharmingen) at 4°C for 1h; control 
staining was performed by exposition to the corresponding PE-labelled rat-IgG-
control antibody (BD Pharmingen). Both antibodies were applied at a total dilution of 
1:200. 
Samples were kept on ice until analysis. Receptor status was assayed by flow 
cytometry using a CyanTM MLE flow cytometer (Dako). The fluorophore of ALEXA488 
labelled antibody was excited at 488nm and emission was detected by using a 
530/40nm bandpass filter, whereas PE was excited through a 750nm longpass filter 
and emission was detected using a 613/20 bandpass filter.  
To discriminate between viable and dead cells and to exclude doublets, cells were 
appropriately gated by forward/side scatter and pulse width. Antibody staining was 
evaluated via electronically analysis by using the WINMDI software.  
2.10.2 Flow cytometric analysis of integrin receptor 
  and aminopeptidase N on HUVEC cells 
Cells were seeded in collagen G (Biochrome AG, Germany) coated 24 well plates 
(TPP, Switzerland) at a density of 20.000 cells per well 48h prior receptor status 
detection. Cells were washed with prewarmed PBS and harvested by treatment with 
collagenase (Biochrom AG) (625 U/ml). The obtained cell suspensions were pooled 
and adjusted to 105 cells/ml with MACS buffer (PBS containing 2.5% FBS) after 
centrifugation for 5min at 150g (Haereus, Megafuge 1.0 R). The cell suspension was 
divided up and exposed to the following antibodies at 4°C for 1h; mouse-anti-human 
CD51/61 antibody (Dako) and mouse-anti-human aminopeptidase N (CD13) (Dako). 
Control staining was performed by using the mouse specific antibodies rat-anti-
mouse CD51 (Dako) and rat-anti-mouse CD13 (Biolegend). All antibodies were 
applied at a total dilution of 1:200. 
Afterwards, cells were washed repeatedly with prewarmed MACS buffer (PBS 
containing 2.5% FBS) to remove unbound antibody. Secondary antibody staining 
was performed by exposing the cell suspension to ALEXA488 labelled anti-mouse- or 
anti-rat-antibody (Invitrogen), respectively for 1h at 4°C. The secondary antibody was 
applied at a total dilution of 1:400. Receptor status was assayed as described in 
2.10.1. 
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2.10.3 Flow cytometric analysis of integrin receptor status 
  on CT26 tumor cells 
CT26 tumor cells were seeded in collagen G (Biochrome AG, Germany) coated 24 
well plates (TPP, Switzerland) at a density of 30000 cells per well 24h prior receptor 
status detection. Cells were washed with prewarmed PBS and harvested by 
treatment with collagenase (Biochrom AG) (625 U/ml). The obtained cell suspensions 
were pooled and adjusted to 106 cells/ml with MACS buffer (PBS containing 2.5% 
FBS) after centrifugation for 5min at 150g (Haereus, Megafuge 1.0 R). The cell 
suspension was divided up and exposed separately to the following antibodies at 4°C 
for 1h; mouse-anti-human CD51/61 antibody (Dako), rat-anti-mouse CD51 (Dako) 
and rat-anti-mouse CD13 (Biolegend). All antibodies were applied at a total dilution of 
1:200. Afterwards, cells were washed repeatedly with prewarmed MACS buffer (PBS 
containing 2.5% FBS) to remove unbound antibody. Secondary antibody staining 
was performed by exposing the cell suspension to ALEXA488 labelled anti-mouse- or 
anti-rat-antibody (Invitrogen), respectively for 1h at 4°C. The secondary antibody was 
applied at a total dilution of 1:400. Receptor status was assayed as described in 
2.10.1. 
2.10.4 Transmission light and epifluorescence microscopy 
Transmission light microscopy of living cells growing as monolayers or multicellular 
microspheroids wrapped in agarose was performed using an Axiovert 200 
microscope (Carl Zeiss, Jena, Germany) equipped with a Sony DSC-S75 digital 
camera (Sony Corporation, Tokyo, Japan). Light was collected through 5x0.12 NA, 
10x0.25NA or 32x0.40Na objectives (Carl Zeiss, Jena, Germany), and images were 
captured using phase contrast. 
Fluorescence microscopy of transiently EGFP expressing cells was carried out using 
an Axiovert fluorescence microscope (Carl Zeiss, Jena, Germany). CYP2B1 
expressing cells were stained with the mouse-anti-ratCYP2B1 antibody 
(Oxfordbiomedical Research, Oxford) followed by visualisation by the secondary 
ALEXA488 labelled goat-anti-mouse antibody (Invitrogen, Oregon, USA). EGFP and 
ALEXA488-fluorescence were excited using a 470±20 nm bandpass filter and 
emission was collected using a 540±25 nm bandpass filter. 
Fluorescence microscopy of stained cryosections was likewise carried out using an 
Axiovert 200 fluorescence microscope (Carl, Zeiss, Jena, Germany) equipped with a 
Zeiss Axiocam camera. Light was collected through a 20x0.4 NA or 63 x 1.4 oil 
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immersion objective (Zeiss). Hoechst33258 fluorescence was excited using a 365 nm 
bandpass filter and emission was collected using a 420 nm bandpass filter. ALEXA 
488 and FITC-fluorescence were excited using a 470±20 nm bandpass filter and 
emission was collected using a 540±25 nm bandpass filter, whereas ALEXA467 was 
excited using a 640±20 nm bandpass filter and emission was collected using a 
735±35 nm bandpass filter. Texas Red fluorescence was excited using a 530-585 nm 
bandpass filter and emission was collected by using a 615nm longpass filter. 
Cy3 fluorescence was excited using a 546 nm bandpass filter and emission was 
collected by using a 610±30 nm bandpass filter. Digital image recording and image 
analysis were performed with the Axiovision 3.1 software (Zeiss) or the Axiovision LE 
software (Zeiss), respectively.  
 
2.11 In vivo/ex vivo experiments 
2.11.1 Animals 
Mice were obtained either from breeders for lab animals (Harlan-Winkelmann, 
Borchen or Charles River, Sulzfeld) or own breeding. Up to 5 animals were kept in 
single individually ventilated cages (Type II, long, Techniplast ICV System, 
Buguggiate, Italy) under specified pathogen free conditions. Room temperature was 
21ºC, humidity was 60% and the night/day stages were 12h each. Food (Sniff) and 
water were autoclaved before use and were available for the mice ad libitum.  
The litter in the cages was saw mill waste (3/4 fiber, Abedd Koeflach, Austria); 
additionally cages were equipped with pulp, a red mouse house (Techniplast, Italy) 
and a tube of wood (Abedd, Koeflach, Austria). The cages were loaded with the 
equipment and autoclaved prior use. 
Mice obtained from breeders were kept at least one weak in the new environment for 
acclimatisation before admitting them to the experiments. 
The experiments with animals were approbated by the Bavarian government. All 
performed experiments were in line with the request for animal experiments 
“Gentherapeutische Behandlung von Tumoren im Tier-Model-System” (209.1/211-
2531-5/03, project leaders Prof. E. Wagner/Dr. M. Ogris and “Elektroporation zur 
Behandlung von Tumoren mit therapeutischen Nukleinsäuren“ (209.1/211-2531-
63/03) project leaders Dr. C. Culmsee/Dr. M. Ogris. 
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2.11.2 Providing tumor cells for in vivo implantation 
CT26 mouse colon carcinoma cells (ATCC CRL-2638), Neuro2A mouse 
neuroblastoma cells (ATCC CCl-131) and X39 CYP2B1 expressing CT26 cells were 
cultured as described above in DMEM low glucose supplemented with 10% FBS. 
HUH7-human hepatocellular carcinoma cells (JCRB 0403; Tokyo, Japan) were 
cultured in DMEM/F12 with Glutamax I medium supplemented with 10% FBS. 
PC3 human prostate carcinoma cells (CRL-1435) were cultured in RPMI medium 
supplemented with 10% FBS. 
All cell lines were cultured without antibiotics for at least 3-4 passages, before tumor 
implementation. Cells were harvested with trypsin/EDTA when confluency was about 
70%. 
2.11.3 Tumor cell implantation and tumor models 
The tumor cells were cultivated as described above. When a confluency of about 
70% was reached, medium was removed and cells were washed 2 times with 37C 
warm PBS, followed by harvesting with trypsin/EDTA (Invitrogen, Germany). 
The obtained cell suspension was mixed with medium containing 10% FBS in order 
to inactivate the present trypsin. Cells were counted by transmitted light microscopy 
with a Rosenberg count plate. Afterwards, the cell suspension was centrifuged 5min 
with 150g and resuspended in fresh PBS. This washing procedure was repeated 
before cells were suspended with PBS to the desired concentration. 
Mice were shorn before application of the tumor cell suspension with an electrical 
razor (Braun, Germany). 100µl of the tumor cell suspension was applicated 
subcutaneously with a 25G needle (Braun, Melsungen, Germany) into the flank of the 
animals.  
Animals were controlled regularly for tumor growth. When the tumor volume reached 
a size of at least 10mm3, tumor progression was monitored with a digital measuring 
slide (Digi-Met, Preisser, Gammertingen). For determination of tumor growth 3 
parameters (length, width and height) were measured and tumor volume was 
calculated via the following formula: a x b x c x 0.4 (whereas a, b and c are the 
measured parameters length, width and height). Accounting for measured thickness 
of the skin the correction factor 0.4 is required in order to calculate real tumor 
volume. 
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Syngeneic tumor models 
Neuro2A cells (1x106 tumor cells per animal) were applicated subcutaneously to 
about 8 to 9 weeks old A/J mice. The cells were suspended in PBS; total 
subcutaneous injection volume per animal was 100µl. 
  
Xenograft tumor models 
SCID mice were used for the CT26/X39, HUH7 and the PC3 tumor model due to 
disturbed function of the immune system (86). For establishing subcutaneous CT26, 
X39 and HUH7 tumors, male and female SCID mice were used when they were 
about 8 to 9 weeks old. 
For establishing the CT26/X39 tumor model 100 000 cells, for the HUH7 tumor model 
5x106 cells and for the PC3 tumor model 106 were applicated subcutaneously. The 
PC3 human prostate xenograft model was solely established on male SCID mice. All 
tumor cells were suspended in PBS. The total injected volume per animal was 100µl. 
2.11.4 Systemic application of Hoechst dye 33258 
For systemic application of the Hoechst33258 dye (2.5 mg/ml Hoechst33258 in PBS), 
as a marker for blood flow, procedure of injection was similar to the application of the 
polyplex formulations described above. After the injection mice were removed from 
the tube. 5min after the application of the Hoechst dye mice were sacrificed.  
2.11.5 Intraperitoneal application of CPA 
The chemotherapeutical drug CPA (Cyclophosphamide, Sigma, Taufkirchen) was 
solved in PBS at a concentration of 10mg/ml followed by steril filtration (0.22µm 
sterilfilter, Millex-GV, Millipore Carrigtwohill, Ireland). Application was performed 
intraperitoneally. Therefore mice were fixed by hand and turned in order to allow 
access to the ventral side. The CPA solution was administered with a 25G needle 
(Braun, Melsungen). The application of the CPA solution was carried out every 4th, 
6th or 7th day, respectively. The applicated volume was 80 to 350µl. The single dose 
of each application was based on animal body weight. Toleration of the treatment 
with CPA was monitored by regular measurement of body weight. 
2.11.6 Isolation of tumors/organs for histology 
For histological investigation of tumor and organs mice were sacrificed with CO2. 
Before organs were removed the vein to the liver was cut in order to reduce rest 
blood. After the removal, the organs were embedded in OCT Tissue Tek (Sakura, 
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USA) and frozen at -80C. In the case of fluorescence microscopic analysis of GFP 
expression tissue was fixed with 4% paraformaldehyde in PBS for 1 day prior to 
embedding in OTC medium and freezing. 
For immune histology, organs/tumor was cut into slides of 5 to 7µm thickness with a 
kryomicrotome (Leica CM 3050s) at -20C. For HE staining organs/tumor were cut 
into slides of 5 to 10µm thickness. Slides were transferred to a microscope slide and 
fixed with 4% paraformaldehyde (in PBS). Immune histological staining was 
performed as described. 
2.11.7 Haematoxilin/Eosin stain 
Cryosections of the tissue was fixed with 4% paraformaldehyde and stained with 
Haematoxilin (Sigma, St. Loius, USA) for 30 min. After a washing step with PBS and 
aqua dest., sections were incubated with a 1:100 dilution of Eosin (Sigma, St. Louis, 
USA) for 4 min. Afterwards, sections were washed with aqua dest., embedded with 
PBS and analyzed by transmission light microscopy. 
2.11.8 Vessel perfusion with fluorescent dye 
Hoechst 33258 was used as a marker for blood perfused areas in the tumor. After a 1 
min exposure to 200µl of 7.5mg Hoechst 33258 in PBS (given intravenously) the 
mice were sacrificed and the tumors were resected. Tumors were wrapped in OTC 
and immediately frozen. Frozen sections (10µm) were cut on a cryostat at three 
different levels between one pole and the equatorial plane. The slides were viewed in 
a light microscope under ultraviolet illumination. Blood perfusion was observed by 
Hoechst33258 stained nuclei and quantified by image-analysis. Nine sections per 
tumor were examined and 5 fields per section were randomly selected for image 
analysis. Fluorescence levels were analyzed with the MIPAV software. 
2.11.9 Antibody stain 
2.11.9.1 Staining for vascular markers 
Cryosections (5µm) were transferred to a microscope slide and fixed with 4% 
paraformaldehyde (in PBS) for 5min. Afterwards, tissue sections were rehydrated 
and washed with MACS buffer (PBS containing 5% FBS) prior to antibody incubation.  
 
Simultaneous staining for laminin and endothelial marker CD31 
Staining was performed with the rabbit-anti-laminin antibody (Chemicon Europe, 
Hampshire, UK) and simultaneous with the rat-anti-mouse CD31 (CALTAG, 
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Burlingame, USA) antibody; both antibodies were used in a 1:200 dilution (in MACS 
buffer). After an incubation time of 12h at 4ºC in a humified atmosphere sections 
were washed repeatedly with MACS buffer followed by secondary antibody staining. 
Therefore the sections were incubated with the Texasred labelled goat-anti-rabbit 
antibody (Vector, Burlingame, UK) and the ALEXA488 labelled goat-anti-rat antibody 
(Invitrogen, Oregon, USA); the staining was performed with a 1:200 dilution (in MACS 
buffer) of both antibodies for 2h at room temperature in a humified atmosphere.   
Before analysis by fluorescence microscopy, sections were washed with MACS 
buffer repeatedly. 
 
Simultaneous staining for laminin and CD13 
Staining was performed with the rabbit-anti-laminin antibody (Chemicon Europe, 
Hampshire, UK) and simultaneous with the rat-anti-mouse CD13 (Dako, 
Copenhagen, Denmark) antibody; both antibodies were used in a 1:200 dilution (in 
MACS buffer). After an incubation time of 12h at 4ºC in a humified atmosphere 
sections were washed repeatedly with MACS buffer followed by secondary antibody 
staining. Therefore the sections were incubated with the Texasred labelled goat-anti-
rabbit antibody (Vector, Burlingame, UK) and the ALEXA488 labelled goat-anti-rat 
antibody (Invitrogen, Oregon, USA); the staining was performed with a 1:200 dilution 
(in MACS buffer) of both antibodies for 2h at room temperature in a humified 
atmosphere.   
Before analysis by fluorescence microscopy, sections were washed with MACS 
buffer repeatedly. 
2.11.9.2 Staining for other epitopes 
Staining for expressed CYP2B1 protein in tumor tissue 
Cryo sections (5µm) were transferred to a microscope slide and fixed with 4% 
paraformaldehyde (in PBS) for 5min, followed by treatment with Triton X (0.1% in 
PBS) for further 5min. Afterwards, tissue sections were rehydrated and washed with 
MACS buffer (PBS containing 5% FBS). Washing procedure was repeated for 2 
times. Surplus supernatant was removed and the rehydrated tissue sections were 
incubated with the mouse-anti-ratCYP2B1 antibody (Oxfordbiomedical Research, 
Oxford, UK), used as a 1:200 dilution in MACS buffer (PBS containing 5% FBS). 
Control antibody staining was performed by the mouse IgG1, negative control 
antibody (Dako, Copenhagen, Denmark). Antibody bind
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humified atmosphere at room temperature for 2h, followed by a washing procedure 
with MACS buffer. For secondary antibody staining, tissue sections were incubated 
with ALEXA488 labelled goat –anti-mouse antibody (Invitrogen, Oregon, USA), used 
as a 1:200 dilution in MACS buffer, for 1h in a humified atmosphere at room 
temperature. Before analysis by fluorescence microscopy, sections were washed 
with MACS buffer (repeated for 2 times). 
 
Staining for integrin ?v 
Cryo sections (5µm) were transferred to a microscope slide and fixed with 4% 
paraformaldehyde (in PBS) for 5min, followed by treatment with Triton X (0.1% in 
PBS) for further 5min. Afterwards, tissue sections were rehydrated and washed with 
MACS buffer (PBS containing 5% FBS). Washing procedure was repeated for 2 
times. Surplus supernatant was removed and the rehydrated tissue sections were 
incubated with the rat-anti-mouse CD51 antibody (Dako), used as a 1:200 dilution in 
MACS buffer (PBS containing 5% FBS). Control antibody staining was performed by 
the mouse-anti-human CD51/61 antibody (Dako, Copenhagen, Denmark). Antibody 
binding was carried out in a humified atmosphere at room temperature for 2h, 
followed by a washing procedure with MACS buffer. For secondary antibody staining, 
tissue sections were incubated with the appropriated ALEXA488 labelled antibodies 
(Invitrogen, Oregon, USA), used as a 1:200 dilution in MACS buffer, for 1h in a 
humified atmosphere at room temperature. Before analysis by fluorescence 
microscopy, sections were washed with MACS buffer (repeated for 2 times). 
 
Staining for acrolein-adducts in tumor tissue 
Cryo sections (5µm) were transferred to a microscope slide and fixed with 4% 
paraformaldehyde (in PBS) for 5min, followed by treatment with Triton X (0.1% in 
PBS) for further 5min. Afterwards, tissue sections were rehydrated and washed with 
MACS buffer (PBS containing 5% FBS). Surplus supernatant was removed and the 
rehydrated tissue sections were incubated with the anti-acrolein-antibody (ACR, 
monoclonal antibody, JaICA, Japane) and simultaneous incubation was performed 
with the rat-anti-mouse-CD31 antibody (CALTAG, Burlingame, USA). Both antibodies 
were used in a 1:100 dilution (in MACS buffer). Antibody binding was carried out in a 
humified atmosphere at 4ºC over night. Control antibody staining was performed by 
the mouse IgG1, negative control antibody (Dako, Copenhagen, Denmark) instead of 
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the anti-acrolein-antibody (ACR) in the same manner. After removing of antibody 
containing supernatant, tissue sections were washed with 1ml MACS buffer. The 
washing procedure was repeated for five times. For visualizing binding of the firstly 
antibodies, staining was performed with a 1:200 dilution (in MACS buffer) of 
secondary antibodies, ALEXA467-anti-rat and ALEXA488-anti-mouse. Incubation 
was carried out for 2h at room temperature in a humified atmosphere. Before 
analysis by fluorescence microscopy, sections were washed with MACS buffer, 
followed by an additional washing step with demineralised water and embedding in 
glycerine. 
2.11.10 Reisolation of tumor cells 
For the reisolation of tumor cells, mice were sacrificed with CO2. The skin was 
cleaned and sanitized by isopropanol (70% in water V/V) followed by drying under 
steril conditions. Tumors were collected and immediately inserted in the indicated 
Penstrep (Biochrome, Germany) containing medium. In the case of Neuro2A tumors, 
DMEM low Glucose medium was used, whereas DMEM high glucose/F12 medium 
was used for HUH7 tumors and in the case of PC3, tumor tissue was inserted in 
RPMI medium. 
Tumor tissue was reduced to small pieces under steril conditions with a scalpel. This 
procedure was repeated until tumor tissue was homogenized. In the case of 
reimplantation of PC3 tumor cells, homogenized tumor tissue was directly injected 
subcutaneously to male SCID mice by use of a 25G needle (Braun, Mesungen, 
Germany) into the flank of the animals. 
The obtained homogenized cell suspension was diluted with fresh medium, followed 
a centrifugation step (150g/5min). The supernatant was removed and resuspension 
of the tumor cell containing pellet was performed with fresh, Penstrep containing 
medium. The tumor cell containing suspension was transferred to collagen coated 
(Collagen G, Biochrom) tissue flasks (TPP, Switzerland) and incubated under 
standard conditions (37ºC, 5% CO2) in a humified atmosphere for 2-3 days. When 
cells were attached to the bottom of the flasks, medium was replaced every second 
day, until cells reached a confluency of about 70%. Obtained cells were cultured for 2 
passages before harvested by tyrpsin/EDTA treatment and placed in storage as 
described in 2.2.5. 
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2.11.11 Isolation of PEC cells 
Pig aortas were obtained from the local slaughterhouse (Munich, Germany) and 
immediately inserted in Penstrep (Biochrome, Germany) containing medium (M199, 
Invitrogen). Adipose and loose tissue was removed carefully and the aorta was cut 
lengthwise into two pieces. Aortic tissue was fixed with the luminal, endothelial cell 
containing layer to the upper side and washed with prewarmed (37ºC) PBS. 
Afterwards, 5ml of collagenase type II CLS (625U/ml) (Biochrome, Germany) and 
trypsin/EDTA (Invitrogen, Germany) containing solution was added to the aortic 
tissue, followed by an incubation step at 37ºC for 15 to 20 minutes. 
The incubation solution was removed carefully and replaced by 5ml of M199 medium, 
containing 10% FCS (Invitrogen, Germany). Endothelial cells were obtained by 
repeated replacement of fresh M199 medium. Cell containing medium was pooled 
and the procedure was followed by a centrifugation step (150g, 8min) and 
resuspension of the obtained pellet in fresh, Penstrep containing M199 medium. 
Cells were seeded in tissue flasks (75 cm2, Costar, Sigma-Aldrich, USA) and 
incubated under standard conditions (37ºC, 5% CO2) in a humified atmosphere for 2 
to 5 days. When cells began to proliferate, medium was replaced every second day, 
until cells reached a confluency of 80 to 90%. Obtained PEC cells were harvested by 
tyrpsin/EDTA treatment and placed in storage as described in 3.2.5. 
2.11.12 Isolation of fibroblasts / NF-?B Animals 
NF-?B-luciferase-reporter mice were bred and used for the measurement of changes 
in NF-?B transcriptional activity as described previously (87). The NF-?B-luciferase 
transgene contained the firefly luciferase gene, driven by two NF-?B sites responding 
to p65/p50, p50/cRel and other dimer combinations of NF-?B as established in 
previous studies (88;89) 
Primary fibroblast cultures were obtained following a standard protocol for skin 
biopsies with slight modifications. Briefly, skin biopsies of E15 luciferase-reporter 
mouse embryos were placed in a culture dish containing 1 ml Dulbecco’s minimal 
essential medium supplemented with 10% FBS. Using two sterile scalpels and a 
crisscrossing motion the skin was cut into small pieces, not greater than 1 mm X 1 
mm. Afterwards media and tissue pieces were transferred as a suspension into a T25 
vented flask. The petri dish was rinsed with additional 1 ml medium and then 
transferred to the T25 flask. The T25 flask was then placed in a 5% CO 2 incubator at 
37°C, and the media was changed weekly until the fibroblast layer in the flask was 
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confluent. Confluent cultures were trypsinized following standard methods and grown 
in Dulbecco’s minimal essential medium supplemented with 10% FBS at 37°C in a 
humidified atmosphere with 5% CO2 in air. Cells were routinely seeded at a density 
of 104/cm2 and subcultured every 7 days upon reaching confluence. 
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3 Results 
3.1 Evaluation of tumor cells as producer cells 
  in the standard GDEPT concept 
3.1.1 Endogenous P450 activity of the used cancer cell lines 
The family of cytochrom P450 enzymes include isoforms that metabolize the 
anticancer prodrugs CPA (cyclophosphamide) and IFO (ifosphamide) by a 
hydroxylation reaction. This activation is the basic requirement for their antitumoral 
and cytotoxic activity. CYP2B1 is one of the P450 isoforms that convert CPA and 
IFO. Yet tumor cells usually exhibit rather low expression of endogenous CYP2B1 
activity (90); bioactivation of the prodrugs CPA and IFO is mainly localized in the liver 
so that the activated drugs have to be distributed over the blood stream to reach the 
tumor tissue. 
Localized activation of the prodrug in the context of GDEPT concept as studied in the 
current thesis would be more effective and less toxic and can be obtained by transfer 
of CYP2B1 encoding plasmid DNA into tumor cells. As a first step, endogenous 
CYP2B1 activity of the wild type (wt) cancer cell lines used in this thesis was 
evaluated by the acrolein assay and resorufin assay. 
3.1.1.1 Acrolein assay 
The acrolein assay is based on the detection of acrolein in biological fluids. Acrolein 
is one of the metabolites that is released by activated cyclophosphamide or 
ifosphamide, respectively. The amount of acrolein in the supernatant of cultured cells 
reflects therefore cellular cytochrom P450 enzymatic activity when cells are grown in 
the presence of CPA or IFO, respectively. 
Acrolein was not evident in the supernatant of the wt tumor cells CT26, Neuro2A 
HUH7 and 9L, indicating low cytochrom P450 enzymatic activity in terms of CPA or 
IFO conversion capability (FIG 3-1). 
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Fig.: 3-1 Conversion of CPA by wt tumor 
cell lines (acrolein assay). Detection of 
the metabolite acrolein was performed in 
the supernatant of cells incubated with 
2.0mM CPA for 24h. Values are means 
± SE of triplicates. 
 
3.1.1.2 Resorufin assay 
The different P450 cytochrom isotypes are catalysts for different biochemical 
reactions. The isoenzyme cytochrom P4502B1 exhibit also alkoxy-o-dealkylase 
activity. This catalytic activity provides the reaction of 7-pentoxyresorufin to the 
fluorescent compound resorufin (91). The CYP2B1 activity of cultivated cells is 
therefore reflected by the amount of in situ produced resorufin, which can be easily 
measured in the supernatant by its fluorescence signal. 
The tumor cell lines CT26, Neuro2A, HUH7 and 9L were again analyzed for their 
CYP2B1 enzymatic activity by the resorufin assay. Alkoxy-o-dealkylase activity was 
detected in HUH7 cells, whereas no enzymatic activity was evident in CT26, 
Neuro2A and 9L cells (FIG 3-2). 
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Fig.: 3-2 Detection of CYP2B1 
enzymatic activity in wt tumor cells by 
the resorufin assay. Cells were 
incubated with resorufin incubation 
solution and in situ released resorufin 
was detected in the supernatant of the 
cells after a freeze-thaw cycle by 
fluorescence measurement 
Measurements were normalized on 
cell count. Values are means ±SD of 
triplicates. *p<0.05, compared to 
vehicle treated system (Mann-Whitney 
U-test). 
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For further investigation of endogenous CYP2B1 activity in wt tumor cells, detected 
fluorescence signal was normalized for total metabolic activity measured by the MTT 
assay. 
CYP2B1 enzymatic activity of wt HUH7 cells was about 16 fold higher than CYP2B1 
activity of Neuro2A, CT26 and 9L cells, whereas total metabolic activity of HUH7 cells  
was about 4 times higher than metabolic activity of the other assayed cell lines (9L, 
CT26, Neuro2A). Therefore, HUH7 cells exhibited a higher specific endogenous 
alkoxy-o-dealkylase enzymatic activity than the other wt cell lines Neuro2A, CT26 
and 9L. Alkoxy-o-dealkylase level of the CT26, 9L and the Neuro2A cell line were on 
similar low levels and not detectable in the resorufin assay (FIG 3-3). 
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Fig.: 3-3 CYP2B1 alkoxy-o-dealkylase 
activity (resorufin assay) normalized on 
total metabolic activity (MTT assay). The 
wt cell lines Neuro2A, CT26, 9L and 
HUH7 were analyzed for CYP2B1 alkoxy-
o-dealkylase activity by the resorufin 
assay. In a parallel experiment the 
mentioned cell lines were analyzed for 
metabolic activity by the MTT assay. 
Values are means ±SE of duplicates 
(resorufin assay) or triplicates (MTT 
assay). *p<0.05, compared to vehicle 
treated system (Mann-Whitney U-test). 
 
3.1.1.3 Comparison of the acrolein and the resorufin assay 
The acrolein assay is based on the detection of acrolein as a metabolite released by 
activated cyclophosphamide and ifosphamide and reflects therefore directly CPA or 
IFO conversion capability. Yet, the resorufin assay exhibits higher sensitivity and 
lower signal to noise ratio. Moreover, enzymatic activity of the CYP2B1 may be 
decreased or regulated by cytotoxic metabolites over the time when cells are 
incubated with CPA or IFO. For that reason the resorufin assay was preferred in 
order to detect CYP2B1 activity in the following experiments. 
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3.1.2 Sensitivity of wt tumor cells against CPA treatment 
3.1.2.1 Assays for determination of cell survival and proliferation 
For investigation of biological activity of CPA and IFO, respectively, different 
concentrations of the anticancer drugs were assayed for reduction in proliferation and 
survival of each cell line. Proliferation and survival were investigated by the 
Hoechst33258 based DNA content proliferation assay and the MTT assay. 
Reliability and correlations of the used assays were verified (compare materials and 
methods). 
3.1.2.2 Survival and proliferation of CT26 and Neuro2A cells 
  after CPA or IFO treatment 
To determine the relevant CPA and IFO concentration range for further experiments 
wt CT26 and Neuro2A cells were treated with different concentrations of CPA and 
IFO ranging from 0.05mM to 10.0mM. The level of cell proliferation was determined 
on day 3 after the beginning of the treatment by the Hoechst 33258 based DNA 
content assay. The results demonstrate that CPA had no significant antiproliferative 
effects up to 1.0 mM on both tested wt cell lines. However IFO treatment resulted in 
decreased cell proliferation when IFO concentration was 0.25mM or higher, indicating 
a higher unspecific toxicity of the inactivated prodrug (FIG 3-4A and 3-4B). For that 
reason all further experiments with CYP2B1 expressing cells were performed with 
CPA. 
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Fig.: 3-4 Decrease in proliferation rate by a 3 day treatment of wt CT26 and wt Neuro2A cells with 
either CPA or IFO. Wt CT26 and wt Neuro2A cells were treated for with increasing concentrations of 
CPA or IFO. Proliferation rate was determined by Hoechst 33258 based DNA content assay. 
Measurements were normalized on untreated control cells. A) wt CT26 cells, B) wt Neuro2A cells. 
Values are means ±SD of triplicates. 
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3.1.3 Generation of CYP2B1 expressing tumor cells 
3.1.3.1 Stable Transfection 
3.1.3.1.1 Generation of the stably transfected X39 cell line 
The CT26 and the Neuro2A cell line were chosen for stable transfection due to their 
low endogenous CYP2B1 enzymatic activity. The cell lines were transfected with 
LPEI polyplexes (N/P=6, HBS) containing a linearized form of the pCMV-CYP2B1 
expression vector. G418-selected colonies were chosen for expansion and further 
evaluation for CYP2B1 activity. 
3.1.3.1.2 Pre-evaluation of CYP2B1 activity of the G418 
  resistant CT26 and Neuro2A clones 
G418 resistant CT26 and Neuro2A clones were expanded and CYP2B1 enzymatic 
activity was pre-evaluated by the resorufin assay. Measurements were normalized on 
cell count. G418 resistant CT26 clones exhibited higher enzymatic activity in the 
resorufin assay compared to the not transfected wt CT26 cell line (FIG 3-5). CYP2B1 
activity of Neuro2A sublines were on lower levels compared to stable transfected 
CT26 cells (data not shown). The highest expressing CT26 clone called X39 was 
chosen for further investigation. 
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Fig.: 3-5 CYP2B1 enzymatic activity of different 
stable transfected CT26 clones. CT26 cells were 
transfected with LPEI polyplexes containing a 
linearized form of the pCMV-CYP2B1 expression 
vector, followed by selection via G418 treatment. 
Resistant cells were subcloned and analyzed for 
CYP2B1 activity by the resorufin assay. 
Measurements were normalized on cell count. 
Values are means ±SE of duplicates. 
 
3.1.3.1.3 Confirmation of continuity of CYP activity 
In order to confirm constant CYP2B1 activity, enzymatic activity was correlated to the 
total metabolic activity of the X39 cells over a culture period of 7 days. Therefore 
CYP2B1 enzymatic activity and total metabolic activity were measured in parallel 
experiments on days 1, 3, 6 and 7 after seeding of the cells. The experiment was 
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performed in the absence of G418 in the culture medium. CYP2B1 enzymatic activity 
and total metabolic activity were correlating at every analyzed time point, indicating 
continued high CYP2B1 enzymatic activity of the X39 cells (FIG 3-6). 
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Fig.: 3-6 CYP2B1 enzymatic activity is 
continuous in X39 cells. CYP2B1 activity and 
total metabolic activity were analyzed at over 
a period of 7 days in cultured X39 cells. 
CYP2B1 enzymatic activity was determined 
on day 1, 3, 6 and 7 by performing the 
resorufin assay. In a parallel experiment total 
metabolic activity of the cultured X39 cells 
was determined by MTT assay. Values of 
CYP2B1 enzymatic activity are means ± SE 
of duplicates. Values of total metabolic 
activity (MTT assay) are means ± SD of 6 
values. 
 
 
3.1.3.1.4 Confirmation of CYP2B1 protein in X39 by antibody staining 
X39 cells were cultivated in G418 free medium for at least 5 passages. Expression of 
rat CYP2B1 protein in the X39 clone was confirmed by specific antibody staining 
against rat CYP2B1 protein, followed by FACS analysis. X39 cells showed a 
homogenous population of CYP2B1 expressing cells, indicated by one peak in the 
histogram, shifted in comparison to CT26 control cells. In this context, >80% of 
analyzed X39 cells were positive for CYP2B1 protein expression (FIG 3-7). 
 
 
 
 
 
Fig.: 3-7 Antibody staining of ratCYP2B1 
expression, followed by analysis via cell flow 
cytometry. Wt CT26 and CYP2B1 expressing 
X39 cells were subjected to antibody staining for 
ratCYP2B1 protein. Antibody staining was 
performed as described in materials and 
methods, followed by FACS analysis. 
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3.1.3.1.5 Characterisation of the X39 clone for CYP2B enzymatic activity 
   by resorufin assay and CPA conversion  
Alkoxy-o-dealkylase enzymatic activity of the stably transfected X39 cells was 
measured by the resorufin assay and compared to CYP2B1 expressing 9L-D2B1 and 
wt tumor cell lines. 
The highest alkoxy-o-dealkylase activity was detected for stably transfected X39 and 
9L-D2B1 tumor cells. Enzymatic activity of X39 cells were about 100 fold higher than 
the parental CT26 wt cells. In comparison to stably CYP2B1 expressing 9L-D2B1 
cells, alkoxy-o-dealkylase activity of X39 cells was about two times higher (FIG 3-8). 
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Fig.: 3-8 Detection of CYP2B1 enzymatic activity in the stable transfected X39 and 9L-D2B1 cells. 
Cells were incubated with resorufin incubation solution and in situ released resorufin was detected in 
the supernatant of the cells after a freeze-thaw cycle by fluorescence measurement. Black bars: stable 
CYP2B1 expressing cells; hatched bars: wt tumor cell lines. Measurements were normalized for cell 
count. Values are means ± SD of triplicates. 
 
CYP2B1 enzymatic activity was further evaluated by the acrolein assay in the 
supernatant of cells. The concentration of acrolein reflects directly the ability of the 
stable transfected cells to activate the prodrug by enzymatic hydroxylation. 
Similar to the results of the resorufin assay, X39 cells showed highest enzymatic 
activity for CYP2B1. The stably transfected 9L-D2B1 cells were about half times less 
effective in converting CPA. No acrolein was detectable in the supernatant of CT26 
wt and all other wt cells (FIG 3-9). 
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Fig.: 3-9 Detection of the metabolite acrolein in the supernatant of cells. Cells were grown in the 
presence of 2.0mM CPA for 24h. Supernatant was analyzed by the acrolein assay. Measurements 
were normalized on cell count. Values are means ± SD of triplicates. 
 
3.1.3.1.6 Suicidal effects of CYP2B1 expressing X39 and 9L-D2B1 tumor cells 
In order to compare suicidal effects in CYP2B1 stable expressing cell lines, CYP2B1 
expressing X39 and 9L-D2B1 cells were cultured in the absence or in the presence 
of 0.5mM CPA. Suicidal effects (decrease in proliferation and metabolic activity) were 
determined by Hoechst33258 based DNA content assay and by MTT assay. Control 
experiments were performed with the wt cells lines 9L and CT26. Suicidal effects in 
X39 cells were not significantly distinctive in comparison to the suicidal effects in 9L-
D2B1 cells at the same CPA concentration and incubation time. However, X39 as 
well as 9L-D2B1 exhibited increased sensitivity towards CPA treatment compared to 
the corresponding parental cell lines at 0.5mM CPA (FIG 3-10). 
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Fig.: 3-10 Suicidal effects of stable CPY2B1 expressing tumor cells cultured in the presence of 0.5mM 
CPA. X39 and 9L-2B1 tumor cells were cultured in the absence or in the presence of 0.5mM CPA. 
After an incubation time of 3 days, suicidal effects were determined by Hoechts33258 based 
proliferation assay (A). Additionally metabolic activity was measured by MTT assay (B). Control 
experiments were performed with wt CT26 and 9L tumor cells. Open bars: 0mM CPA, black bars: 
0.5mM CPA. Values are means ±SD of triplicates. *p<0.05, compared to vehicle treated system 
(Mann-Whitney U-test). 
 
Moreover, CYP2B1 expressing X39 tumor cells were cultivated with different 
concentrations of CPA that did not show any anti-proliferative effects on the CT26 wt 
cell line. Concentrations for CPA included in vivo relevant concentrations (0.05mM to 
1.0mM). Suicidal effects were quantified by DNA content (Hoechst33258 based DNA 
content assay) and total metabolic activity (MTT assay). Without CPA treatment X39 
cells grew to a confluent monolayer. X39 cells incubated with CPA showed significant 
decrease in cell proliferation (FIG 3-11). Decrease in metabolic activity was similar to 
the decrease in proliferation rate (data not shown). 
Sensitivity of the CYP2B1 stable expressing X39 cells towards CPA treatment was 
significantly increased in comparison to the CT26 wt cells (compare FIG 3-4). This 
indicates that the expression of the CYP2B1 in X39 cells catalyses the reaction of the 
non-toxic prodrug CPA to toxic metabolites and leads to reduction in proliferation and 
survival of the tumor cells. 
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Fig.: 3-11 High sensitivity of cultured 
CYP2B1 expressing X39 cells towards 
CPA treatment in terms of cell 
proliferation. X39 cells were treated 
with different concentrations of CPA in 
the medium for 3 days. Proliferation 
rate was determined by Hoechst33258 
based DNA content assay. 
Measurements were normalized on 
DNA content of non treated X39 tumor 
cells. Values are means ± SD of 
triplicates.  
 
3.1.3.1.7 Suicidal effects of CPA treatment in comparison to IFO treatment 
The prodrugs cyclophosphamide and ifosphamide are both metabolized by CYP2B1 
enzymatic activity to the active cytotoxic compounds. X39 cells were utilized to 
investigate the potential of CPA and IFO regarding to suicidal effects on CYP2B1 
expressing tumor cells. 
CPA treatment and IFO treatment did not show a significant difference in the 
inhibition of proliferation (FIG 3-12). However, non-activated CPA exhibited less 
unspecific toxicity to tumor cells than IFO (compare FIG 3-4). For that reason all 
further studies were carried out with CPA. 
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Fig.: 3-12 Sensitivity of stable 
CYP2B1 expressing X39 cells 
towards CPA and IFO treatment. 
X39 cells were cultured for 3 days 
either in the absence of CPA/IFO 
or in the presence of different 
concentrations of CPA/IFO 
(0.05mM, 0.25mM, 0.5mM 1.0mM, 
5.0mM and 10.0mM). Cell 
proliferation was determined by 
Hoechst 33258 based DNA 
content assay. Measurements 
were normalized on DNA content 
of non-treated X39 tumor cells. 
Values are means ±SD of 
triplicates. 
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3.1.3.1.8 Verification the presence of soluble cytotoxic metabolites 
   (Transwell system) 
In the GDEPT concept the bystander effect is one of the crucial factors for efficient 
antitumoral effects in the context of the CPA/CYP2B1 concept. In order to verify the 
presence of soluble cytotoxic metabolites, cells were cultured in a transwell system to 
avoid cell-cell contacts. Biological effects that occur in a transwell system are 
therefore caused by soluble compounds that are able to pass the porous membrane. 
To verify the presence of diffusible metabolites in this work, CYP2B1 expressing X39 
cells were cocultivated with wt CT26 cells in a ratio of 1:1, whereas the CPA 
concentration in cell culture medium was adjusted to 0.5mM. Control experiments 
were performed by replacement of X39 tumor cells by corresponding wt CT26 cells. 
After an incubation time of 3 days cell proliferation was separately assayed for cells 
at the bottom of the well plate (target cells) and in the well plate insert (producer 
cells). CPA did not show any anti-proliferative effects on the wt CT26 cells, when no 
CYP2B1 expressing X39 tumor cells were present in the coculture system. In the 
presence of 0.5mM CPA CT26 cells exhibited decreased proliferation rate when 
cocultivation was performed with X39 cells in the transwell system. No reduction in 
proliferation rate occurred when CT26 cells were cocultured with X39 cells in the 
absence of CPA (FIG 3-13). 
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Fig.: 3-13 Evidence of soluble 
cytotoxic compounds by in situ 
activated CPA.
Wt CT26 cells were cultivated with 
stably CYP2B1 expressing X39 cells 
in (ratios 1:1) in the absence or in the 
presence of 0.5mM CPA in a 
transwell coculture system. Control 
experiments were performed by 
exchange of X39 cells by wt CT26 
cells. After an incubation time of 3 
days, proliferation rate for cells in 
each compartment was performed 
separately by Hoechst33258 based 
DNA content assay. Open bars: 
vehicle treated. Black bars: 0.5mM 
CPA. Values are means ± SD of 
triplicates. *p<0.05, compared to 
vehicle-treated system (Mann-
Whitney U-test). 
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3.1.3.2 Transient transfection 
3.1.3.2.1 Expression kinetics and expression levels after transient transfection 
Wt tumor cell lines CT26, Neuro2A, and 9L were transfected with pCMV-CYP 
containing polyplexes (LPEI, N/P=6, 300ng total plasmid DNA/well, HBS). Control 
transfection experiment was performed with pEGFN1 plasmid DNA containing LPEI 
polyplexes. CYP2B1 enzymatic activity was determined at different time points after 
the transfection by the resorufin assay. Highest CYP2B1 enzymatic activity was 
detected about 60 hours after the transfection in Neuro2A cells (FIG 3-14 A). A 
moderate increased CYP2B1 enzymatic activity was detected in transiently 
transfected 9L cells 24h after the transfection. Transient CYP2B1 enzymatic activity 
in 9L cells was stable for 70h after transfection (FIG 3-14 B). No enzymatic CYP2B1 
activity was detectable in transiently transfected CT26 cells by the resorufin assay 
(data not shown). 
Control transfection with LPEI polyplexes containing plasmid DNA encoding for 
EGFP resulted in 38.5% transfection efficiency in Neuro2A cells, 8% in 9L and 8.5% 
in CT26 tumor cells (data not shown). 
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Fig.: 3-14 CYP2B1 enzymatic activity after transient transfection with pCMV-CYP2B1 containing LPEI 
polyplexes. Wt cells (A) Neuro2A and (B) 9L were transfected transiently with pCMV-CYP2B1 
containing LPEI polyplexes. Control transfection experiments were performed with pCMV-EGFP 
containing LPEI polyplexes (300ng/well, N/P=6, HBS). CYP2B1 enzymatic activity was determined at 
different time points after the transfection by resorufin assay. Values are means ±SD of triplicates. 
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3.1.3.2.2 Evaluation of CYP2B1 dependent activation of CPA in vitro 
For the detection of CYP2B1 dependent activation of CPA in wt cell lines after 
transient transfection with LPEI polyplexes containing pCMV-CYP2B1 plasmid DNA 
(N/P=6, HBS) the acrolein assay was performed. Detection of acrolein was 
performed for transiently transfected Neuro2A and 9L cells. Acrolein was not 
detectable in the supernatant of pCMV-CYP2B1 transfected cells (data not shown), 
indicating that activation of the prodrug CPA did not occur at considerable amounts.  
3.1.3.2.3 Evaluation of sensitizing tumor cells against CPA after transient
  transfection (conventional cell culture) 
Transient CYP2B1 expressing Neuro2A cells were analyzed for sensitization towards 
CPA treatment after transient transfection with pCMV-CYP containing LPEI 
polyplexes (N/P=6, HBS, 300ng DNA/well). Control experiment was performed with 
pCMV-LUC and pCMV-EGFP (EGFPN1) plasmid DNA. 
Forty eight hours after the transfection, when CYP2B1 enzymatic activity measured 
by the resorufin assay reached maximum values (compare FIG 3-14 A), CPA was 
administered. Cells were cultured for further 3 days in the absence or in the presence 
of 0.5mM CPA. Sensitivity against CPA treatment was determined by measuring total 
metabolic activity by the MTT assay. 
Transiently transfected cells were not sensitized against CPA treatment. No increase 
in sensitivity towards CPA was detectable in comparison to transfection with the 
control plasmids (FIG 3-15). 
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Fig.: 3-15 Transient 
transfection of Neuro2A 
tumor cells with LPEI 
polyplexes containing 
CYP2B1 encoding plasmid 
DNA did not result in 
increased sensitivity towards 
CPA treatment. Cells were 
treated with indicated 
concentrations of CPA for 3 
days. Metabolic activity was 
determined by MTT assay. 
Values are means ± SD of 
triplicates. 
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Despite CYP2B1 enzymatic activity as measured by the resorufin assay no 
sensitizing towards CPA treatment was evident after transient transfection in 
conventional cell culture. Due to the reason that this failure might result from the 
artificial cell culture environment, development of a new cell culture technique was 
essential for further evaluation of the GDEPT concept. 
3.1.3.3 Bystander effect in a tumor environment mimicking 
  cell culture system: Agarose overlay technique 
Diffusion of drugs is far more limited within a tumor in vivo than in tumor cells cultured 
in vitro. In addition, tumor cells are often subjected to a hypoxic environment. These 
factors are both likely to affect CYP prodrug activation and bystander cytotoxicity. To 
better mimic the tumor microenvironment, tumor cells seeded in tissue culture plates 
were covered with a thin layer of agarose dissolved in cell culture medium. Oxygen, 
nutrients and drugs can reach the cells by diffusion through the agarose layer. We 
anticipated that the activated metabolites of CPA would form a concentration gradient 
in the vicinity of the drug-activating cells, similar to the situation in a solid tumor. 
3.1.3.3.1 Diffusion in the agarose layer 
To test the agarose overlay technique in terms of limited diffusion, a small amount of 
the membrane-permeable DNA stain Hoechst 33258 was added to the cells (FIG. 3-
16). When the stain was added to normal culture medium, the concentration was too 
low for detection of fluorescent cell nuclei by fluorescence microscopy. However, 
when a similar amount of Hoechst stain was injected in the agarose layer covering 
the cells, bright fluorescent nuclei were observed near the injection site. More distant 
cells were less fluorescent but still visibly stained. Thus, the agarose layer is likely to 
limit diffusion of low molecular weight drugs and their metabolites, thereby 
establishing a concentration gradient. Hoechst33258 is indeed a good model for CPA 
in terms of diffusion within a gel as both drugs have a low molecular weight, 
(Hoechst33258 624Da, CPA 250Da) and are both hydrophilic. 
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Fig.: 3-16 Diffusion and concentration effects of an agarose overlay using Hoechst 33258. CT26 cells 
were seeded at 40,000 cells per well of a 24-well plate 24 h before addition of an agarose overlay. The 
agarose was added as described in materials and methods. Hoechst 33258-containing solution (1 µl 
at 0.02 ng/ml in PBS) was injected into the agarose layer and cellular fluorescence was monitored 30 
min after the injection using a Zeiss Axiovert 200 microscope equipped with appropriate excitation 
(365 nm) and emission (420 nm long pass) filters. Cells were viewed with a 10X objective and phase 
contrast pictures were obtained for transmitted light. A control experiment was performed without 
agarose overlay, with the same amount of Hoechst 33258 dye added to a similar volume of culture 
medium. Application of Hoechst 33258 without agarose overlay (A: transmitted light, B: fluorescence); 
injection of Hoechst 33258 into the agarose layer (C: transmitted light, D: fluorescence). Similar 
exposure times were used for B and D (X: point of dye injection). 
3.1.3.3.2 Cell morphology under the agarose layer 
CT26 cells and Neuro2A cells were grown in conventional cell culture and under an 
agarose layer (0.5% agarose distributed in cell culture medium, 200µl/well, 48 well 
plate). After 3 days cell morphology was assayed by transmitted light microscopy. No 
obvious differences in cell morphology were detected when cells were grown under 
the agarose layer in comparison to cells cultured in conventional cell culture systems. 
   
A 
   
B 
   
C                  D 
Fig.: 3-17: Cell morphology is not significantly 
influenced by the agarose overlay. Neuro2A (A and 
B) and CT26 cells (C and D) were cultured either 
under conventional cell culture conditions (A and 
C) or with agarose overlay for 3 days (B and D). 
Cells were viewed with a 20X objective and phase 
contrast pictures were obtained for transmitted 
light. 
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3.1.3.3.3 Influence of the agarose layer on cell proliferation 
In order to evaluate the impact of the agarose overlay on cell proliferation and 
survival, CT26 and Neuro2A cells were cultured either with or without the agarose 
overlay technique. Cell proliferation and survival were assayed at several time points 
by the Hoechst33258 based DNA content assay and by MTT assay over a period of 
5 days. In the case of the agarose overlay, the agarose layer was removed just 
before performing Hoechst33258 based DNA content and MTT assays. 
Both cell lines exhibited decreased proliferation rates in the Hoechst33258 based 
DNA content assay as well as in the MTT assay when cell culturing was carried out 
under an agarose layer (FIG 3-18). Additional performed analysis by transmitted light 
microscopy did not give any evidence for cell death (data not shown) indicating the 
decrease in metabolic activity resulted from decreased proliferation rate. 
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Fig.: 3-18 Influence of the agarose overlay on proliferation and survival of CT26 and Neuro2A cells. 
CT26 and Neuro2A cells were cultured for 5 days either under standard cell culture conditions or with 
the agarose overlay. Cell proliferation and survival were measured at several time points by (A) 
Hoechst33258 based DNA content assay and (B) by determination of metabolic activity (MTT assay). 
Values are means ± SD of triplicates. 
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3.1.3.3.4 Investigation of the agarose overlay technique in terms of  
  hypoxic stress 
Hypoxic environment might change gene expression profiles and therefore influences 
sensitivity of tumor cells to chemotherapeutic drugs. Therefore, it was essential to 
investigate if hypoxia responsive gene expression was evident under the agarose 
overlay. Therefore CT26 and Neuro2A cells were transfected in a cotransfection 
experiment with LPEI polyplexes (N/P=6, HBS) containing two different luciferase 
encoding plasmid constructs. Expression of the Renilla luciferase plasmid was 
controlled by the CMV promoter, a hypoxia unresponsible promoter, whereas the 
expression of the firefly luciferase was under the control of a hypoxia responsible 
promoter HRE (hypoxia responsive element). After the removal of medium or 
agarose layer, respectively, luciferase activity was measured in a dual-luciferase 
assay. 
No hypoxia induced increase in firefly luciferase activity was detected. The ratio of 
CMV-controlled luciferase expression and HRE controlled luciferase expression was 
not changed by the agarose layer within 24h, indicating that gene expression was not 
strongly influenced by the potential hypoxic environment under the agarose layer. 
Control experiments for positive activation of the hypoxia responsible promoter were 
performed in an atmosphere with 1% O2 in a hypoxia chamber (data not shown). 
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Fig.: 3-19 Regulation of hypoxia responsible elements under conditions of the agarose overlay. 
Activation of hypoxia responsible elements in cells cultured under the agarose layer was investigated 
by a dual luciferase assay. Cells were transfected in a cotransfection experiment with 2 different 
luciferase encoding plasmids. Expression of firefly luciferase encoding plasmid was therefore 
controlled by a hypoxia sensitive promoter, whereas the expression of the Renilla luciferase encoding 
plasmid was controlled by the CMV promoter. The diagram shows the relative ratios between both 
luciferase levels controlled by hypoxia-sensitive and hypoxia insensitive CMV-promoter controlled 
expression.Open bars: conventional cell culture, black bars: agarose overlay. Values are means ± SE 
of duplicates. 
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3.1.3.3.5 Dependency of the CYP2B1 on sufficient oxygen supply 
The CYP2B1 enzyme exhibits monooxidase enzymatic activity. Therefore its 
functionality critically depends on the presence of oxygen. CPY2B1 enzymatic activity 
in X39 cells was assayed under different oxygen partial pressures. Therefore cells 
were incubated with the CYP2B1 substrate 7-pentoxyresorufin in a hypoxia chamber 
under defined ambient oxygen concentrations. Temperature was adjusted to 37°C 
and humidity was kept constant during incubation time. CYP2B1 enzymatic activity 
was directly dependent on the oxygen content, as indicated by the near linear 
correlation between O2 concentration and fluorescence signal, resulting from in situ 
converted 7-pentoxyresorufin (Fig. 3-20). Based on this calibration curve, CYP2B1 
enzymatic activity was reduced to ~25% of the normoxic control level at 5% O2, and 
to 7% in the absence (<0.1%) of O2. 
 
 
 
 
 
 
Fig.: 3-20 Influence of oxygen 
concentration on CYP metabolic activity. 
CYP2B1 enzymatic activity was measured 
in X39 cells under different concentrations 
of O2 as described in materials and 
methods. Resorufin production determined 
at 21% O2 was set to 100%; mean values 
from triplicates ± SD are shown. 
 
3.1.3.3.6 CYP2B1 enzymatic activity under the agarose layer 
To evaluate CYP2B1 enzymatic activity under the agarose layer, X39 cells, cultured 
under standard conditions or under an agarose layer, respectively, were assayed for 
CYP2B1 activity by the resorufin assay. 
The substrate, 7-pentoxyresorufin: 1) was added directly to the culture medium (‘- 
gel’); 2) was carefully injected into the space between the cells and the agarose 
overlay (‘+ gel’); or 3) was added to cells cultured under agarose after the gel was 
removed (‘gel removed’). The DNA content of each well was quantified to ensure that 
similar cell numbers were present in the individual wells. The CYP activity of cells 
grown under standard conditions was similar to that of cells cultured under agarose 
with removal of the agarose prior to substrate incubation. In contrast, CYP activity 
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assayed in cells under the agarose layer was reduced to 12% compared to cells 
without the agarose (FIG 3-21), despite the presumed substrate concentration effect 
of the agarose overlay. This CYP activity level corresponds to an oxygen 
concentration of about 1-2% based on the calibration curve shown in FIG. 3-20. To 
rule out artifacts due to diffusion of resorufin into the agarose gel, a control 
experiment with resorufin injected under the agarose layer in the absence of cells 
was carried out. Approximately 83% of the fluorescent dye was found in the solution 
under similar incubation conditions (data not shown). CYP2B1 protein levels were not 
influenced by the agarose overlay, as determined by antibody staining and flow 
cytometry analysis (data not shown). Hence, the agarose layer does not influence 
expression of CYP2B1. Thus, the agarose overlay technique apparently mimics the 
tumor environment regarding hypoxic conditions. 
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Fig.: 3-21 Twenty four h prior to agarose overlay, 30000 X39 cells were seeded per well of a 48-well 
plate. CYP activity was measured as described in materials and methods (‘- gel’). When performing 
the resorufin-assay under the agarose overlay (‘+ gel’), 200 µl of the incubation solution was injected 
under the agarose layer 1 h after solidification of the agarose overlay. After the incubation, 
fluorescence measurements were performed in the same way as described above. In ‘gel removed’ 
samples, CYP activity with pentoxyresorufin was determined for cells cultured under agarose after 
removal of the agarose overlay. Resorufin production by cells without agarose overlay (‘-gel’) was set 
to 100%. Mean values from triplicates ± SD are shown. 
 
3.1.3.3.7 Enhancement of bystander activity by the agarose  
  overlay technique in a coculture system 
Coculture experiments were carried out to determine the impact of the conditions 
imposed by the agarose overlay, i.e., limited drug and metabolite diffusion and 
hypoxic conditions, on bystander anti-tumor activity. Different ratios of X39 and CT26 
cells (FIG. 3-22A and 3-22B) or X39 and murine neuroblastoma Neuro2A cells (FIG. 
3-22C and 3-22D) were seeded in multi well plates. The cells were treated with 0.5 
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mM CPA in standard cell culture medium (A and C) or after coating the cells with a 
layer of 0.5% agarose (B and D). After CPA treatment for 5 days, cell proliferation 
was measured using the DNA content assay. Under standard culture conditions, 
CT26 cells were quite resistant to the cytotoxic effects of CPA activated by X39 cells. 
Thus, 50% killing of the overall cell population was only achieved when the 
population was comprised of 75% CYP2B1-expressing (X39) cells (FIG. 3-22A). 
Neuro2A cells exhibited somewhat greater sensitivity to activated CPA, with 50% cell 
killing achieved in cocultures containing ~60-65% X39 cells (FIG. 3-22C). By 
contrast, a remarkable bystander effect was achieved when agarose overlaid 
cocultures were treated with CPA. In particular, CPA killed ~ 80% of the Neuro2A + 
X39 mixed cell population in cultures containing 25% CYP-expressing cells, and 
almost complete eradication of the Neuro2A + X39 mixed cell population was 
achieved in cultures containing 50% CYP-expressing cells (FIG. 3-22D; also see 
CT26 cells in FIG. 3-22B). 
 
 
  
Fig.: 3-22 Impact of agarose overlay on bystander effect in mixed cell populations: Different ratios of 
CT26 cells (A and B) or Neuro2A cells (C and D) mixed with the CYP2B1-expressing X39 cells were 
treated for 5 d with 0.5 mM CPA. The DNA content of each well was assayed, and absolute DNA 
content values expressed as RFU x 1000 are shown on the y-axis. A and C: conventional cell culture; 
B and D: agarose overlay cell culture; mean values from triplicates ± SD are shown. Open symbols, no 
CPA treatment; closed symbols, treatment with 0.5 mM CPA 
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3.1.3.3.8 Kinetic of cell death induced by CPA treatment 
To investigate if the agarose layer has an influence on the kinetic of cell death by in 
situ activated CPA, coculture experiments were performed with and without the 
overlay technique. CT26 cells and Neuro2A cells were grown as a coculture system 
with 25% of CYP2B1 expressing X39 cells. The medium was removed 24h after the 
seeding and exchanged by either 200µl of fresh medium or the agarose layer was 
applied. Afterwards 600µl CPA containing medium was added to each well; the 
resulting concentration of CPA was 0.5mM CPA. Cell proliferation and survival was 
analyzed for the following 6 days by Hoechst33258 based DNA content assay and a 
parallel performed MTT assay. Analysis was performed every 24h. 
The coculture systems without the overlay technique showed the most distinctive 
decrease in cell survival at day 3 after the CPA administration, indicated by 
decreased fluorescence signal in the Hoechst33258 based proliferation assay and a 
decreased absorbance in the MTT assay. Likewise, the coculture systems with the 
agarose layer showed a decrease in proliferation at day 3 of treatment. Yet, reduction 
in proliferation and survival was more pronounced in the system with the agarose 
layer. Beside detection of pronounced reduction on cell proliferation in the coculture 
systems with the agarose overlay, no time dependent effects regarding cell death in 
comparison to conventional cell culture technique were evident in the agarose 
overlay system. 
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Fig.: 3-23 Time dependency of CPA based reduction in tumor cell proliferation in cocultures with 
CYP2B1 expressing cells (A: Neuro2A/X39; B: CT26/X39; C: Neuro2A/ X39; D: CT26/X39). 
Cocultures were treated with 0.5mM CPA for 6 d in conventional environment or under an agarose 
layer. Proliferation was determined by (A and B) DNA content measured or by (C and D) performing 
the MTT assay. Relative DNA content or metabolic activity is shown, with control levels set tovehicle 
treated cells. Black symbols: cells cultured with agarose overlay; white symbols: cells cultured without 
agarose overlay; mean values from triplicates ± SD are shown. 
3.1.3.3.9 Bystander effect in cocultures with a fixed ratio of CYP2B1 
   expressing cells 
The CPA concentration achieved in tumor tissue in vivo can be quite low (< 0.5 mM) 
due to rapid clearance of the drug from the blood stream (half-life <30 min (92)). We 
therefore investigated if a bystander effect of activated CPA can also be obtained at 
low CPA concentrations. CT26, HUH7 and X39 cells, and mixtures of X39 cells and 
either CT26 cells or HUH7 cells (25%/75%) were treated for 5 days with 0.01 to 10.0 
mM CPA in culture medium, with or without an agarose overlay. The CYP2B1-
deficient CT26 and HUH7 cells were quite resistant to CPA, both in the absence and 
in the presence of the agarose layer, and significant cell killing was only observed at 
CPA concentrations >3 mM (FIG. 3-24). No beneficial effect of the agarose layer was 
observed in cultures conatining X39 cells alone, as all the cells express CYP2B1 and 
generate 4-OH-CPA intracellularly, and thus no bystander effect is required for cell 
killing (Fig. 3-24C). In cocultures of 25% X39 cells and 75% CT26 cells, the presence 
of an agarose overlay markedly increased CPA-induced cell killing (FIG. 3-24D). At 
0.05 mM CPA, ~40% cell killing was observed, both with and without the agarose 
overlay. As the X39 cells grow slightly faster than the parental cell line (data not 
shown), the 40% reduction in DNA content most probably reflects the killing of the 
25% X39 cells seeded initially. A clear bystander effect was observed for the cells 
under the agarose layer at CPA concentrations between 0.1 and 1.0 mM, which 
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corresponds to a pharmacologically relevant concentration range. In cocultures of 
X39 cells with HUH7 hepatoma cells, 50% cell killing was achieved at very low 
concentrations of CPA (0.05 mM) and this effect was further enhanced by the 
agarose overlay (Fig. 3-24E). 
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Fig.: 3-24 Effect of CPA concentration on tumor 
cell proliferation in cocultures with CYP2B1 
expressing cells (A: CT26; B: HUH7; C: X39; D: 
CT26/X39 75%/25%; E: HUH7/X39  75%/25%) 
were treated with different concentrations of CPA 
for 5 d and the DNA content measured thereafter. 
Relative DNA content is shown, with the cells 
without CPA treatment set to 100%. Black 
symbols: cells cultured with agarose overlay; 
white symbols: cells cultured without agarose 
overlay; mean values from triplicates ± SD are 
shown. 
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3.1.3.3.10 Enhancement of bystander activity by the agarose overlay technique 
   in transient transfection experiments 
To investigate the impact of the agarose overlay on bystander activity under 
conditions where CYP2B1 encoding plasmid DNA is expressed in tumor cells after 
transient transfection, HUH 7 cells were transfected with CYP2B1 encoding plasmid 
DNA using LPEI; transient transfection resulted in ~13 % transfection efficiency, as 
shown by using EGFP as a reporter gene and confirmed by antibody staining for 
CYP2B1 (data not shown). Using similar conditions, HUH7 cells were transfected 
with plasmid encoding CYP2B1, or luciferase, followed by treatment with 0.5 mM 
CPA. 
In cells transfected with CYP2B1 and agarose overlay, >90% of the cells were killed 
after only a 5 h CPA treatment, as judged in by MTT assay 3 days after the 
treatment. Control cells, transfected with luciferase, exhibited non-significant 
increased sensitivity. 
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Fig.: 3-25 Influence of agarose overlay on 
cytotoxicity of CPA toward transiently 
transfected tumor cells. HUH7 cells were 
transfected with LPEI polyplexes containing 
either pCMV-LUC (Luc) or pCMV-CYP2B1 
(CYP). Forty eight h after transfection, the cells 
were treated for 5 h with 0.5 mM CPA either 
with agarose overlay (black bars) or under 
standard culture conditions (white bars). Culture 
medium and agarose overlay were then 
removed and replaced by CPA free medium. 
Three days after CPA treatment, cell viability 
was measured by the MTT assay.. Data are 
normalized to control cells treated in the same 
way but without CPA. Open bars: vehicle 
treated, black bars: 0.5mM CPA. Data shown 
are mean values for triplicates, ± SD. *p<0.05, 
compared to vehicle treated system (Mann-
Whitney U-test). 
 
For further investigation of the GDEPT concept, with attention to transient 
transfection and short CPA exposure time, in vivo experiments were performed. In 
this context, the therapeutic gene pCMV-CYP2B1 was delivered to the tumor tissue 
of established subcutaneous CT26 tumors by electroporation, followed by systemic 
CPA treatment. 
3.1.4 In vivo approach 
The in vivo studies were performed in SCID mice bearing subcutaneous CT26 
tumors to evaluate effects of local CPA prodrug activation after gene transfer in 
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addition to liver metabolism. Therefore the subcutaneous CT26 tumor model in SCID 
mice was chosen because of low endogenous cytochrom enzymatic activity of CT26 
cells and already established efficient gene transfer via electroporation in the 
subcutaneous CT26 tumor model. 
3.1.4.1 Characterisation of tumor histology and tumor growth 
For the in vivo investigation of CPA treatment after CYP2B1 gene transfer, the 
subcutaneous CT26 tumor model was established in SCID mice to avoid possible 
immune response on expressed rat CYP2B1 protein. Tumor growth was initialized by 
implantation of 100000 CT26 cells in the flank of the animals and tumor growth was 
determined; additionally mice were monitored for body weight loss. 
3.1.4.1.1 Tumor histology 
For characterization of the established subcutaneous CT26 tumors, tumor tissue was 
collected and analyzed by Haematoxylin/Eosin staining. Positively charged 
haematoxilin binds to DNA resulting in blue stained nuclei, whereas negatively 
charged eosin binds to plasma proteins and is therefore used as plasma stain. CT26 
xenografts own a very compact and homogenous tissue structure. Tumor cell nuclei 
are large in comparison to the cytoplasm. The tumor tissue was encased in a layer of 
connective tissue (FIG 3-26A). In tumors of an average cross section dimension of 
10mm and larger necrotic areas were detected in the central areas of the tumors.  
  
A B 
Fig.: 3-26 Histology of subcutaneous CT26 xenografts in SCID mice (H/E stain). Cryosections (8µm) 
were fixed with 4% paraformaldehyde and subjected to H/E staining. Sections were viewed on a Zeiss 
Axiovert 200 transmitted light microscope and pictures were taken by a Sony DSC-S75 digital camera. 
A, B) 20x0.4 NA objective 
 
3.1.4.1.2 Tumor growth and body weight 
In order to initialize growth of CT26 xenografts in SCID mice, CT26 tumor cells were 
implanted subcutaneously in the flank of SCID mice as described in materials and 
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methods. After a lag time of about 7 days tumors were palpable in most of the mice. 
At this stage tumor volume increased in an exponential manner for the next two 
weeks (FIG 3-27A). Average tumor volume doubling time was 3.5 days. When the 
tumors reached a cross section dimension of 15mm in one of the measured 
variables, mice were sacrified. 
Tumor bearing mice were additionally monitored for changes in body weight over the 
time of tumor growth. Body weight was constant for about 20 days after tumor 
implantation (FIG 3-27F). When average tumor size reached 300 to 400 mm3 mice 
began to loose body weight (data not shown). At more than 20% loss of body weight 
mice were sacrified. 
3.1.4.2 Tumor response to metronomic scheduled CPA treatment 
In order to find a dose interval for metronomic scheduled CPA that is adequate for 
combination with CYP2B1 gene transfer, CPA dose response rates were determined 
in the CT26 SCID xenograft model. When the average tumor size reaches 40mm3 at 
day 9 after the tumor implantation CPA treatment was started. Different doses 
(mg/kg) CPA were administered in a 6 day schedule. Tumor size and body weight 
were monitored over the time of treatment. When tumors reached a cross section 
dimension of 15mm in one of the measured variables or when body weight loss was 
more than 20%, mice were sacrified. 
Metronomically scheduled CPA treatment in a 6 day regime caused a slower 
increase in tumor volume of the treated tumors in comparison to the untreated control 
group. The tendency of decreased tumor growth was already evident when mice 
were treated with 75mg/kg CPA intraperitoneally every 6 days. Average tumor 
volume double time was 6 days versus 3.5 days of the non-treated control group (FIG 
3-27C). When animals were treated with 50mg/kg CPA every 6th day, influence on 
tumor volume doubling time was slight (FIG 3-27B). Treatment of mice with 
120mg/kg and 150mg/kg CPA intraperitoneally resulted in pronounced decrease in 
tumor growth. Average tumor double time was increased up to 13 to 14 days at both 
CPA dosages (FIG 3-27D and 3-27E). Average loss in body weight was not 
detectable in any treated group up to day 23 after tumor cell implantation (FIG 3-27 
F). 
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Fig.: 3-27 Tumor growth curves of CT26 xenografts in SCID mice and body weight analysis. CPA 
administration, tumor volume measurement and body weight elevation were carried oust. (A) 
untreated control; (B) treated with 50mg/kg CPA; (C) treated with 75mg/kg CPA; (D) treated with 
120mg/kg CPA; (E) treated with 150mg/kg CPA; (F) average changes in body weight. (n=5 or n=4 for 
120mg/kg group) 
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To further evaluate suitable CPA treatment regimes for gene therapy combinations, 
the treatment free interval between CPA applications was shorted to 3 days with half 
dosage of the 6 day schedule. Subcutaneous CT26 bearing mice were treated with 
either 40mg/kg every third day or 80mg/kg every 6th day. Tumor growth and body 
weight was monitored over the time of treatment. 
No difference was evident in the 3 day regime with 40mg/kg in comparison to the 6 
day schedule with 80mg/kg in terms of tumor growth and body weight (FIG 3-28C 
and 3-28D). Therefore the time between the CPA applications was shortened for the 
combination with CYP-gene therapy in the following experiment.  
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Fig.: 3-28 Tumor growth curves of CT26 xenografts in SCID mice and body weight analysis. CPA 
administration, tumor volume measurement and body weight elevation were carried out. (A) untreated 
control; (B) average body weight (C) treated with 40mg/kg CPA every third day; (D) treated with 
80mg/kg CPA every 6th day.  
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3.1.4.3 Metronomic scheduled CPA treatment combined with 
precedent CYP2B1 gene transfer 
CT26 tumors were initialized in SCID mice as described in materials and methods. In 
separately performed studies parameters for electroporation were optimized via 
luciferase reporter gene expression (S. van der Piepen and M. Ogris, unpublished). 
When average tumor volume reached 40mm3 on day 11, the combined gene transfer 
plus CPA treatment regime was started. Intratumoral injections of plasmid (either 
pCYP2B1 or an empty control plasmid (pNull) with subsequent electroporation were 
performed to achieve transgene expression within the tumor tissue. Animals were 
treated with low dose CPA (40mg/kg) on both following days after the gene transfer. 
In addition to the control electroporation group a further control group with animals 
which were not subjected to the electroporation procedure was set; CPA application 
was performed as in both electroporation groups. Tumor growth and body weight was 
monitored over the whole period of treatment. The schedule was repeated every 4 
days. No significant change in body weight was observed for all treated groups 
compared to the control (data not shown). From day 17 on, after tumor cell 
implantation, CPA treated tumors showed a decreased growth rate to untreated 
control. The decrease in tumor growth was more pronounced for the combination of 
electroporation and CPA treatment. Interestingly also the transfection with the control 
plasmid (pNull) had a similar effect on growth retardation. There was no significant 
difference in tumor growth retardation between the pCYP4502B1 and pNull groups 
(FIG 3-29). 
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Fig.: 3-29 Tumor growth of 
subcutaneous CT26 tumors, treated 
with CPA only or in combination 
with pP450CYP2B1/pcontrol gene 
transfer by electroporation. SCID 
mice bearing subcutaneous CT26 
tumor were treated either a 
combination of gene transfer via 
electroporation (pP4502B1 or pNull) 
and CPA treatment on both 
following days or only CPA 
treatment. Broad arrows indicate 
days of gene transfer via 
electroporation, light arrows indicate 
days of CPA application (40mg/kg, 
intraperitoneally). 
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3.2 Evaluation of tumor cells as producer cells in the 
  antiangiogenic GDEPT concept 
3.2.1 Endogenous CYP activity in endothelial cells 
In order to evaluate endothelial cells for endogenous CYP activity, HUVEC and PEC 
cells were evaluated for enzymatic activity by the resorufin assay. Measured 
fluorescence signal was on background levels; no enzymatic activity was detectable 
in HUVEC and in PEC cells by the resorufin assay (data not shown). 
3.2.2 Sensitivity of primary endothelial cells against CPA 
  treatment  
To determine the toxic profile of the prodrug CPA on endothelial cells, HUVEC and 
PEC cells were incubated for 3 days with different concentrations of CPA (0.05mM, 
0.5mM, 1.0mM and 10.0mM) in the medium. Sensitivity against CPA treatment was 
then evaluated by measuring proliferation rate by the DNA content assay. 
Additionally total metabolic activity was determined by the MTT assay (data not 
shown). Reduction in proliferation rates of HUVEC and PEC cells were not observed 
when CPA concentrations were adjusted up to 1.0mM CPA in the cell culture 
medium, indicating low unspecific toxicity of the prodrug on primary endothelial cells. 
However, treatment with 10.0mM CPA resulted in significantly decreased proliferation 
rates due to relevant unspecific toxic effects of CPA prodrug at this concentration. 
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Fig.: 3-30 Effects of the prodrug CPA on 
the proliferation rate of endothelial cells. 
HUVEC and PEC cells were incubated 
for 3d with different concentrations of 
CPA. Proliferation levels were 
determined by the Hoechst33258 based 
proliferation assay. The values are 
means ± SD of triplicates. 
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3.2.3 Coculture of endothelial cells with CYP2B1 
  expressing tumor cells 
3.2.3.1 Evaluation of proliferation and survival 
The sensitivity of endothelial cells to in situ activated CPA was evaluated in coculture 
experiments with CYP2B1 expressing tumor cells (X39). Coculture experiments were 
performed in conventional coculture systems (cell-cell-contacts between tumor and 
endothelial cells were possible) and in transwell systems with prevented cell-cell-
contacts. 
3.2.3.1.1 Proliferation of endothelial cells in a coculture 
HUVEC cells and PEC cells were cocultured with different rates of CYP2B1 
expressing tumor cells (X39) at a constant CPA concentration of 0.5mM for 3 days. 
The concentration of 0.5mM CPA in the medium was chosen because proliferation 
rate of evaluated endothelial cells was not influenced at this concentration in a 
monoculture system. After the incubation time of 3 days, proliferation rate of the 
coculture system was determined by measuring DNA content by the Hoechst33258 
based proliferation assay. X39 cells are nearly completely removed by suicidal 
effects when treated with 0.5mM CPA for 3 days. Measurements were corrected for 
background by remaining X39 DNA content. The resulting DNA, measured by the 
Hoechst33258 based proliferation assay therefore reflects the proliferation of the 
endothelial cells in the coculture system. 
In HUVEC cells, 50% of CYP2B1 expressing tumor cells were required in order to 
decrease total proliferation rate in the coculture system extending suicidal effects of 
X39 cells (FIG 3-31). In PEC cells, 25% of CYP2B1 expressing tumor cells 
decreased total proliferation rate extending suicidal effects of X39 cells (FIG 3-32). 
This indicates higher sensitivity of PEC cells to treatment with in situ activated CPA in 
terms of proliferation. 
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Fig.: 3-31 Proliferation levels of coculture systems with different rates of endothelial HUVEC and 
CYP2B1 expressing tumor cells in the presence of 0.5mM CPA. Cocultures were treated in the 
presence of CPA for 3 days. Proliferation rate was determined by DNA content based Hoechst33258 
proliferation assay. Measurements are corrected for X39 DNA content. Values are means ± SD of 
triplicates. *p<0.05, compared to the HUVEC monoculture system (Mann-Whitney U-test). 
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Fig.: 3-32 Proliferation levels of coculture systems with different rates of endothelial PEC and CYP2B1 
expressing tumor cells in the presence of 0.5mM CPA. Cocultures were treated in the presence of 
CPA for 3 days. Proliferation rate was determined by DNA content based Hoechst33258 proliferation 
assay. Measurements are corrected for X39 DNA content. Values are means ± SD of triplicates. 
*p<0.05, compared to the HUVEC monoculture system (Mann-Whitney U-test). 
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3.2.3.1.2 Proliferation and survival in a transwell system 
For further evaluation of in situ activated CPA on primary endothelial cells, coculture 
studies were performed in a transwell system preventing direct cell-cell contacts; 
antiproliferative effects of soluble CPA metabolites should be detectable. Therefore 
endothelial cells (HUVECs and PECs) were cultured in the bottom chamber of the 
transwell system (target cells). CYP2B1 expressing X39 and CT26 control tumor cells 
were seeded in the insert of the transwell system (producer cells). 
Culturing was performed in the absence or in the presence of 0.5mM CPA. After an 
incubation time of 3 days, proliferation rate of endothelial cells in the bottom 
compartment was determined by the Hoechst33258 based proliferation assay. 
Additionally metabolic activity of endothelial cells was measured in a parallel 
experiment.  
Proliferation rate of PEC cells was decreased when the coculture was performed in 
the presence of CYP2B1 expressing X39 cells and 0.5mM CPA for 3 days (FIG 3-
33). In contrast, coculturing with wt CT26 cells in the absence or in the presence of 
0.5mM CPA did not result in antiproliferative effects on PEC cells. Also, no 
antiproliferative effects were detectable when the coculture experiment was 
performed with X39 cells in the absence of CPA. Decrease in metabolic activity of 
PEC cells cocultured with X39 cells in the presence of 0.5mM CPA was in the same 
range than the decrease in proliferation rate (data not shown). 
The incidence of antiproliferative effects in the coculture system with CYP2B1 
expressing X39 cells in the presence of 0.5mM CPA indicates in situ activation of 
CPA and soluble CPA metabolites bothering the proliferation of cocultured PEC cells. 
When HUVECs were cocultured in the transwell system with CYP2B1 expressing 
X39 cells for 3 days in the absence or in the presence of 0.5mM CPA, no anti-
proliferative effect was evident in comparison to the control system with wt CT26 cells 
(FIG 3-34). Moreover no decrease in metabolic activity was detectable when HUVEC 
cells were cocultured with X39 cells in the presence of 0.5mM CPA (data not shown). 
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Fig.: 3-33 In situ activated CPA decreases proliferation rate of PEC cells in a transwell system. PEC 
cells were cocultured with CYP2B1 expressing X39 and wt CT26 tumor cells in the absence or in the 
presence of 0.5mM CPA. Proliferation rate of the PEC cells was determined by Hoechst 33258 
proliferation assay. Open bars: Cocultivation with wt CT26 cells; black bars: Cocultivation with 
CYP2B1 expressing X39 tumor cells. Values are means ± SD of triplicates. *p<0.05, compared to 
control systems (Mann-Whitney U-test). 
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Fig.: 3-34 In situ activated CPA did not decrease proliferation rate of HUVEC cells in a transwell 
system. HUVEC cells were cocultured with CYP2B1 expressing X39 and wt CT26 tumor cells in the 
absence or in the presence of 0.5mM CPA. Proliferation rate of the HUVEC cells was determined by 
Hoechst 33258 proliferation assay. Open bars: Cocultivation with wt CT26 cells; black bars: Co-
cultivation with CYP2B1 expressing X39 tumor cells. Values are means ± SD of triplicates. 
 
3.2.3.2 Anti-migrative effects in an endothelial  
  cell – tumor cell coculture system 
Anti-migrative effects of in situ activated CPA by CYP2B1 expressing X39 tumor cells 
was evaluated by performing the wound scratch assay in an endothelial – tumor – 
cell coculture system. Migration rate of HUVEC and PEC cells was decreased when 
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the coculture was performed with X39 cells in the presence of 0.5mM CPA. No 
antimigrative effects were evident when the migration assay was performed in the 
absence of CPA or when the coculture was carried out with wt CT26 cells. HUVEC 
cells and PEC cells exhibited similar decrease in mean migration rates when 
cocultured with X39 cells in the presence of 0.5mM CPA. Yet, these antimigrative 
effects were not statistically significant (data not shown). 
3.2.3.3 Coculturing endothelial cells with X39 cells in the  
  presence of CPA disturbed the tube forming process 
PEC cells were cocultured with CYP2B1 expressing X39 cells and with control wt 
CT26 tumor cells on collagen coated glass dishes. The mixed coculture (75% PEC, 
25% tumor cells) was seeded in the presence of 0.5mM CPA in the cell culture 
medium. Control experiments were performed in the absence of CPA. 
When PEC cells were cultured as a monoculture system on collagen coated glass 
dishes a monolayer was formed and no tube forming process was evident within 24h 
(FIG 3-35A). However, endothelial cells exhibited tube forming processes when co-
culturing was performed with wt CT26 or X39 cells within 24h (FIG 3-35B and FIG 3-
35C) in the absence of CPA. 
In the presence of CYP2B1 expressing X39 cells the process of tube formation was 
disturbed significantly in the presence of 0.5mM CPA. Further on, the intensity of F-
actin staining was decreased, indicating degradation of the F-actin cytoskeleton (FIG 
3-35E). Tube forming process was not negatively influenced by coculturing PEC cells 
with control wt CT26 cells in the absence or in the presence of 0.5mM CPA (FIG 3-35 
B and FIG 3-35D).  
  
A B 
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Fig.: 3-35 Tube forming and F-actin staining of PEC cells cultured on collagen coated glass dishes. A) 
PEC cells in the absence of X39/CT26 cells, B) PEC cells cocultured with 25% wt CT26 cells in the 
absence of CPA, C) PEC cells cocultured with 25% CYP2B1 expressing X39 cells in the absence of 
CPA, D) PEC cells cocultured with 25% wt CT26 cells in the presence of 0.5mM CPA and E) PEC 
cells cocultured with 25% CYP2B1 expressing X39 cells in the presence of 0.5mM CPA. The 
experiment was performed in duplicates. Figures show representative sections. 
 
3.2.3.4 Coculturing of endothelial cells with CYP2B1 
  expressing tumor cells in the presence of CPA results in 
  modifications of the F-actin cytoskeleton 
The F-actin cytoskeleton of PEC and HUVEC cells showed modifications, when 
coculturing with CYP2B1 expressing X39 cells was performed in the presence of 
CPA. Therefore F-actin filaments were further analyzed by epifluorescence 
microscopy after staining. F-actin staining did not result in distinguishable F-actin 
fibres, indicating a breakdown of the endothelial F-actin cytoskeleton when 
coculturing was performed in the presence of CYP2B1 expressing tumor cells and 
CPA (FIG 3-36D and 3-36H). No breakdown of the F-actin cytoskeleton was 
detectable when endothelial cells were cocultured with X39 in the absence of CPA 
(FIG 3-36C and 3-36G). Further on endothelial cells cocultured with wt CT26 cells in 
the absence or in the presence of 0.5mM CPA did not result in disturbance in the F-
actin cytoskeleton (FIG 3-36A, 3-36B and 3-36E, 3-36F). 
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This finding indicates that in situ activated CPA or metabolites of activated CPA, are 
responsible for the disturbance in the F-actin cytoskeleton of the endothelial cells. 
 A  B 
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Fig.: 3-36 F-actin cytoskeleton of endothelial cells after coculturing with CYP2B1 expressing X39 or wt 
CT26 cells in the absence or in the presence of 0.5mM CPA for 24h. For optimal visualization of F-
actin fibres light was collected through a 63x1.4 NA oil immersion objective (Zeiss). A) PEC cells 
cocultured with CT26 cells in the absence of CPA, B) PEC cells cocultured with CT26 cells in the 
presence of 0.5mM CPA, C) PEC cells cocultured with X39 cells in the absence of CPA, D) PEC cells 
cocultured with X39 cells in the presence of 0.5mM CPA, E) HUVEC cells cocultured with CT26 cells 
in the absence of CPA, F) HUVEC cocultured with CT26 cells in the presence of 0.5mM CPA, G) 
HUVEC cells cocultured with X39 cells in the absence of CPA and H) HUVEC cells cocultured with 
X39 cells in the presence of 0.5mM CPA. Figures show representative sections. 
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3.3 Role of acrolein in CPA therapy at  
  metronomic schedule 
Acrolein is one of the metabolites released by in situ activated CPA. This metabolite 
is considered to be very toxic; however, no impact on tumor growth is accredited to 
acrolein, at least in conventional high dose CPA regimes. In order to investigate a 
possible role for contribution of acrolein to the total antitumoral effect in metronomic 
scheduled CPA therapy, in vivo and in vitro experiments were performed. 
3.3.1 Significant reduction in tumor blood flow and tumor growth  
  in CPA treated mice 
The ability of CPA to delay tumor growth in a metronomic schedule was evaluated in 
colon carcinoma CT26. Treatment of mice bearing CT26-tumors with CPA (40mg/kg 
on two consecutive days followed by two days without treatment) resulted in a 
significant growth delay as indicated by a lagged increase in tumor volume compared 
to the untreated control (FIG 3-29). Treatment was well tolerated as no significant 
decrease in body weight was observed (data not shown). 
Changes in blood supply were measured by using Hoechst33258 as a tracer. This 
method was preferred because previous results showed a great discrepancy 
comparing CD31 antibody staining with actual functional blood flow (data not shown). 
Measurements were performed either at the end of the experiment (day 28 after 
tumor setting) or when tumor size exceeded 15mm in one dimension. CPA treatment 
resulted in a decreased blood supply in all three indicated areas of the tumors. The 
decrease in fluorescence was significant, indicating reduced blood flow compare to 
untreated animals. 
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Fig.: 3-37 Decrease in blood supply induced by low dose scheduled CPA treatment of SCID mice 
bearing subcutaneous CT26 tumors. Cryo-sections (10µm) were humidified with a drop of PBS, 
provided with a cover slip and immediately analyzed for fluorescence signal of intravenously injected 
Hoechst 33258 stain. For analysis 5 sections of the tumor regions (central, middle and tumor 
periphery) of each tumor, and 5 areas of each section were chosen in a randomized assortment. 
Analysis was performed with a Zeiss Axiovert 200 fluorescence microscope equipped with a 20x0.4 
Zeiss objective and a Zeiss Axiocam. Quantification was performed with the MIPAV (Medical Image 
Processing, Analysis and Visualisation) software. Values are medians ± SD of six animals in the 
control group and ten animals in the CPA treated group. ***p<0.001; **p<0.01; *p<0.05, compared to 
control tumors (Mann-Whitney U-test). 
 
3.3.2 Acrolein adducts in tumor tissue of treated mice 
Conversion of CPA to its activated metabolites is mainly taking place in the liver. In 
situ activated CPA and metabolites are then distributed all over the body via the 
blood stream. In order to investigate if relevant amounts of acrolein reach the tumor, 
cryosections were screened for acrolein adducts by specific antibody staining. Cryo-
sections (5µm) of two randomly chosen CPA treated tumors of the experiment 
described in 3.3.1 were stained with an antibody that is specific for acrolein modified 
protein structures. In addition tumor sections were stained for endothelial cells with a 
rat-anti-mouse CD31 antibody in order to visualize tumor blood vessels. 
Acrolein protein adducts were detected in both CPA treated tumor tissues by 
antibody staining, in tumor cells and in endothelial cells (FIG 3-38B). No staining was 
detectable with the control IgG (data not shown) and only slight staining appeared in 
the untreated control tumors (FIG 3-38A). It is noteworthy that acrolein adducts were 
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often localized in tumor areas of low blood supply, indicated by low Hoechst33258 
signal. 
Staining for acrolein adducts in the liver did not give a significant difference in CPA 
treated versus untreated animals. In both groups only slight positive staining for 
acrolein-protein adducts was detectable (data not shown). These results indicate that 
the metabolite acrolein reaches the tumor site via blood stream in detectable 
amounts and therefore may contribute to antitumoral effects of metronomic 
scheduled CPA therapy.  
  
A B 
Fig.: 3-38 Distribution of acrolein modified proteins in the tumor tissue of CPA treated (B) versus 
untreated control tumors (A). Cryo-sections (5µm) were fixed with 4% paraformaldehyde and stained 
with specific antibodies for endothelial cells (rat-anti-mouse CD31 (red)) and acrolein modified proteins 
(yellow). The intravenously injected Hoechst 33258 stain was visualized as well (blue). Analysis was 
performed with a Zeiss Axiovert 200 fluorescence microscope equipped with a 20x0.4 Zeiss objective 
and a Zeiss Axiocam. 
 
3.3.3 Antiangiogenic properties of acrolein in vitro  
For further investigation of possible antiangiogenic properties of acrolein, effects of 
this metabolite were investigated on primary endothelial cells regarding proliferation, 
migration and differentiation. In addition, effects of acrolein on NF-?B levels in 
endothelial cells and tumor cells were investigated because NF-?B seems to be a key 
regulator in angiogenic processes. Moreover, acrolein was evaluated for the potential 
of modulation on thrombospondin-1 levels due to thrombospondin-1 was identified as 
a possible mediator of antiangiogenic scheduled CPA therapy (93). 
3.3.3.1 Changes of cell morphology 
Primary endothelial cells (HUVECs) were analyzed for morphological changes due to 
acrolein treatment. Therefore, HUVEC cells were seeded 24h prior treatment at a 
density of 15000 cells/well on collagen G coated 24 well plates. Cells were cultured 
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with acrolein containing medium for 24h and morphology of cells was analyzed by 
transmitted light microscopy. Cell morphology was different in comparison to the 
control, when cell culture was performed in the presence of 30µM and 40µM acrolein 
(FIG 3-39 D and E) whereby cells appeared spindle-shaped at 30µM and rounded at 
40µM Acrolein. Morphological changes were not evident when HUVEC cells were 
cultured in the presence of 10µM and 20µM acrolein (FIG 3-39 B and C). 
   
A B C 
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Fig.: 3-39 Morphology of HUVEC cells cultured in the presence of different concentrations of acrolein 
for 24h. 15000 HUVEC cells were seeded on collagen coated 24 well plates. 24h after the seeding 
different amounts of acrolein (dissolved in PBS) were added to the wells to adjust increasing 
concentrations of acrolein in the medium; (A) vehicle (PBS) 0µM acrolein, (B) 10µM acrolein, (C) 
20µM acrolein, (D) 30µM acrolein and (E) 40µM acrolein. Cells were visualized 24h after the acrolein 
addition by transmitted light microscopy. 
3.3.3.2 Acrolein is antiproliferative on endothelial cells 
Primary endothelial cells (HUVECs and PECs) were investigated for antiproliferative 
properties of acrolein. Therefore cells were cultured for 24h in the absence or in the 
presence of different concentrations of acrolein in the medium (7.5µM, 10µM, 
12.5µM, 25µM and 50µM). Survival and proliferation was determined by MTT assay 
as described in materials and methods. 
Acrolein inhibited the proliferation and survival of vascular endothelial cells in a dose 
dependent manner. Effects in HUVEC cells were less pronounced than in PEC cells. 
(FIG 3-40) 
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Fig.: 3-40 Proliferation and survival 
of primary endothelial cells cultured 
with different concentrations of 
acrolein. HUVEC and PEC cells 
were cultured in the absence or in 
the presence of 7.5 to 50µM 
acrolein in the medium. Proliferation 
and survival was determined by 
MTT assay. Values are means ±SD 
of triplicates. 
3.3.3.3 Acrolein inhibits endothelial cell migration 
Primary endothelial cells were further analyzed for sensitivity towards acrolein 
regarding migration. Migration of cells HUVEC cells was decreased by 50% in the 
presence of 20µM acrolein and even to 80% when the scratch wound assay was 
performed in the presence of 25µM acrolein (FIG 3-41A). In the case of the PEC cells 
migration decreased to 40% when the scratch wound assay was performed in the 
presence of 15µM acrolein (FIG 3-41B). 
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Fig.: 3-41 Treatment of HUVEC cells (A) and PEC cells (B) for 24h with increasing concentrations of 
acrolein resulted in a dose dependent inhibition of migration in the scratch wound assay. A confluent 
cell layer of endothelial cells was scratched with a pipette tip and analyzed by transmitted light 
microscopy (t=0). After 24 h of incubation with increasing concentrations of acrolein cells were fixed 
and analyzed again (t=24). In the absence of acrolein HUVEC cells as well as PEC cells grow to a 
confluent monolayer. Values are means ± SD of ten values. *p<0.05, compared to untreated control 
cells (Mann-Whitney U-test). 
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3.3.3.4 Acrolein inhibits endothelial tube formation 
The ability of primary endothelial cells to differentiate and form vessel like structures 
was analyzed in the matrigel tube formation assay. HUVEC cells usually form tube 
like structures within 4h when seeded on the polymerised matrigel. Performing the 
tube formation assay in the presence of acrolein inhibited the formation of tube like 
structures in a dose dependent manner (FIG 3-42).  
A B C
 
Fig.: 3-42 Matrigel tube formation assay in the presence of acrolein. The matrigel tube formation assay 
was carried out in the absence (A) or in the presence of 10µM (B) and 30µM (C) acrolein. Tube 
formation was analyzed by transmitted light microscopy. 
 
Quantification of tube like structures was carried out; only tube like structures, without 
interruptions, were counted in each well. Even at 10µM acrolein the number of tube 
like structures without defects decreased by approximately 70% (FIG 3-43). 
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Fig.: 3-43 Disturbance of tube like structure 
formation in the matrigel assay. Matrigel tube 
formation assay was performed with HUVEC 
cells in the absence or in the presence of 10µM 
to 30µM acrolein in the medium. Forming of tube 
like structures was quantified by transmitted light 
microscopy. Values are means ±SE of duplicates 
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3.3.3.5 Subacute cytotoxic acrolein concentrations disrupt 
  endothelial F-actin cytoskeleton 
To further investigate the impact of acrolein on migration of primary endothelial cells, 
F-actin cytoskeleton analysis was performed. HUVEC cells were seeded 24h before 
treatment. Cells were cultured for further 12h in the absence or in the presence of 
different concentrations of acrolein (5µM to 20µM). Afterwards cells were fixed and 
staining of the F-actin cytoskeleton was performed. Control cells contained thick long 
fibres of actin filaments, often spanned across the entire cytoplasm. Incubation of 
proliferating HUVECs with non acute cytotoxic concentrations of acrolein (0-20µM) 
resulted in cytoskeletal disorganisation and disruption of F-actin filaments within 12h 
of incubation. The extent of cytoskeleton damage was dose dependent (FIG 3-44). 
Damaged cells were able to remodel F-actin cytoskeleton to a certain degree within 
24h after acrolein removal (data not shown). 
  
A B C 
Fig.: 3-44 Disorganisation of F-actin cytoskeleton in primary endothelial cells (HUVECs) due to 
acrolein treatment. F-actin cytoskeleton of cultured HUVEC cells on a collagen G coated glass surface 
in the presence of 10% FBS and 10ng/ml bFGF is well organized (A). Treatment of HUVEC cells with 
acrolein leads to disruption of the F-actin cytoskeleton and F-actin plugs are formed in the cells (10µM 
acrolein (B) and 20µM acrolein (C)). 
3.3.3.6 Acrolein inhibits integrin v 3 clustering 
  on endothelium filopodiae 
Integrin ?v?3 plays a crucial role in the angiogenic process. Clustering of the integrin 
?v?3 receptor induces several signalling cascades in endothelial cells, regulating cell 
survival, migration and differentiation properties of angiogenic endothelial cells 
(94;95). 
Therefore the impact of acrolein on the integrin ?v?3 receptor systems of primary 
endothelial cells (HUVECs) was investigated. Cells were screened for integrin ?v?3  
clustering and total receptor levels on the surface of the cells were determined. 
HUVEC cells were seeded on collagen IV coated Lab-Tek slides 24h before 
treatment. Cells were cultured for further 12h in the absence or in the presence of 
Results   92
different concentrations of acrolein (5µM to 20µM). Afterwards cells were fixed and 
staining of the integrin ?v?3 receptor was performed. Additionally cells were stained 
for F-actin cytoskeleton. Integrin clustering and changes in the cytoskeleton were 
analyzed by fluorescence microscopy. 
Incubation of HUVECs with acrolein for 12h leads to disarrangement of integrin ?v?3 
receptors and clustering at the filopodia of the cells was inhibited (FIG 3-45). 
Additionally F-actin staining consolidated the absence of functional filopodia when 
the cells were cultured with 20µM acrolein in the medium. 
  
A B 
Fig.: 3-45 Acrolein treatment disturbs integrin ?v?3 (violet) receptor clustering and the formation of 
focal adhesions in primary endothelial cells (HUVECs). (A) Vehicle (PBS) treated HUVEC on a 
collagen coated surface show a well organized F-actin cytoskeleton (green) with F-actin 
accumulations in the area of focal adhesions). Moreover, clustering of integrin ?v?3 receptors at focal 
adhesions is seen. (B) Incubation of HUVEC with 20µM acrolein for 12h results in destruction of the F-
actin cytoskeleton in the area of focal adhesion and as well in a disturbance of integrin ?v?3 receptor 
clustering. 
 
Integrin ?v?3 receptor status was also determined by flow cytometry. HUVEC cells 
were cultured for 12h in the absence or presence of 20µM acrolein, and antibody 
staining was carried out, followed by FACS analysis. No change in total amount of 
integrin ?v?3 receptor on the surface of the endothelium cells was detectable when 
cells were cultured for 12h with 20µM acrolein (data not shown). 
3.3.3.7 Acrolein modulates NF-?B activity 
  in cultured human endothelial cells 
NF-?B plays a crucial role in angiogenesis and cell survival. Therefore, effects of 
acrolein on NF-?B activity levels in primary endothelial cells were determined. 
HUVEC cells were transiently transfected with LPEI polyplexes (HBS, N/P 6) 
containing an NF-?B dependent expression vectors for luciferase (pNF?B-LUC). 
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Control experiments were performed with similar LPEI polyplexes (HBS, N/P 6) 
containing a luciferase encoding plasmid without NF-?B enhancer areas in the 
promoter region (pTAL-LUC). Twenty four hours after transfection acrolein was 
added to the supernatant and luciferase activity was measured 48h after the 
transfection. 
Treatment of HUVEC cells with 10µM and 20µM acrolein decreases basal NF-?B 
activity within 24h of acrolein treatment (FIG 3-46). Interestingly, NF-?B activity was 
upregulated after cells were treated with 30µM acrolein for 24h. 
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Fig.: 3-46 Modulation of NFKB activity in HUVEC cells by acrolein. HUVEC cells were transfected with 
LPEI polyplexes contained an expression vector for luciferase with NFKB sensitive binding sites in the 
promoter region. Control experiments were performed with a similar vector, yet without NFKB binding 
sites. 24 h after the transfection cells were cultured for further 24h in the absence or in the presence of 
10µM, 20µM or 30µM acrolein. Luciferase measurement was performed as described in materials and 
methods. Ratios of luciferase expression obtained with pNF?B-LUC and control plasmid pTAL-LUC in 
HUVEC cells are shown. Mean values of eight transfections per condition ± SD are shown. 
***p<0.001, compared to control tumors (Mann-Whitney U-test). 
3.3.3.8 Acrolein modulates thrombospondin-1 
  levels in primary endothelial cells (HUVECs) 
For investigation of modulation effects on thrombospondin-1 levels by acrolein in 
HUVEC cells, thrombospondin-1 levels were analyzed in HUVEC cell lysates by a 
competitive ELISA. Moreover total protein content was measured by the BCA-
protein-content assay (Pierce). Thrombospondin-1 levels were modulated by acrolein 
in cultured primary HUVEC cells. Interestingly, incubation of HUVECs with only 5µM 
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acrolein for 24h results in highly increased thrombospondin-1 levels (11-fold). High 
induction of TSP-1 levels was also evident when cells were treated with 10µM and 
20µM acrolein. Decreasing Thrombospondin-1 levels were detected when cells were 
cultured in the presence of 30µM acrolein and higher. The total protein content (BCA 
assay) was similar at all indicated concentrations.  
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Fig.: 3-47 Modulation of thrombospondin-1 levels in HUVEC cells by acrolein. HUVEC cells were 
cultured in the presence of different concentrations of acrolein for 24h. After the incubation time, cells 
were washed with PBS and 100µl/well water was added, followed by a freeze-thaw-cycle. 
thrombospondin-1 contents were determined by the competitive thrombospondin-1 ELISA (Chemicon). 
Moreover cell lysates were analyzed for total protein content (BCA-protein-assay). Thrombospondin-1 
levels were normalized on total protein content. Values are means ± SE of duplicates. 
 
3.3.4 Impact of acrolein on CT26 tumor and 
  tumor stroma cells (fibroblasts) 
3.3.4.1 Proliferation and survival of CT26 tumor cells 
In order to evaluate direct antitumoral effects of acrolein on tumor cells, CT26 cells 
were cultured in the absence or in the presence of different concentrations of acrolein 
(5µM to 40µM). After 24h of incubation survival and proliferation was determined by 
measuring total metabolic activity via MTT assay as described in materials and 
methods. Values were normalized to vehicle treated cells (PBS). 
Total metabolic activity was decreased in a dose dependent manner. When CT26 
cells were cultured with 40µM acrolein in the medium, metabolic activity was 
decreased to 50% compared to vehicle treated cells (FIG 3-48). 
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Fig.: 3-48 CT26 cells were cultured 
with increasing concentrations of 
acrolein (0µM to 40µM) for 24h. 
Survival was determined by 
measuring total metabolic activity 
via MTT assay. Values are means 
±SD of four samples. *p<0.05, 
compared to untreated control cells 
(Mann-Whitney U-test). 
 
3.3.4.2 Regulation of NF-?B activity levels in CT26 tumor cells 
Several tumor relevant cytokines regulating angiogenic processes, like VEGF or 
bFGF, are also controlled by NF-?B activity (96-98). Therefore the impact of acrolein 
on NF-?B activity levels was investigated in CT26 tumor cells. In contrast to the 
effects of acrolein on NF-?B levels in HUVEC cells, no obvious modulatory effects 
were detected in CT26 tumor cells. 
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Fig.: 3-49 Modulation of NF-?B activity 
in CT26 tumor cells by acrolein. CT26 
cells were transfected with LPEI 
polyplexes containing an expression 
vector for luciferase with NF-?B 
sensitive binding sites in the promoter 
region (pNF?B-LUC). Control 
experiments were performed with a 
similar vector, but without NF-?B 
binding sites (pTAL-LUC). 24 h after 
the transfection cells were cultured for 
further 24h in the absence or in the 
presence of 5µM or 40µM acrolein. 
The ratio of luciferase expression 
obtained by pNF?B-LUC to pTAL-LUC 
is shown. Values ± SD are means of 
eight values. 
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3.3.4.3 NF-?B regulation and survival of fibroblasts 
Tumor stroma cells, particularly fibroblasts, have great influence on the angiogenic 
process in tumors due to their output of proangiogenic cytokines such as bFGF. NF-
?B is a crucial factor in the regulation of these cytokines. Therefore the influence of 
acrolein treatment on NF-?B levels in fibroblasts was evaluated. Moreover, cell 
survival was investigated and correlated with NF-?B activity levels. 
Fibroblasts expressing luciferase under the control of a NF-?B sensitive promoter 
were obtained from transgenic animals (NF-?B-LUC mice) (99;100). The luciferase 
expressing fibroblasts were cultured with different concentrations of acrolein for 6 and 
up to 24h. Luciferase expression levels were measured by performing a luciferase 
assay after 6 and 24h of treatment; in a parallel experiment cell survival was 
determined by performing the MTT assay. 
Decreased NF-?B activity levels were detected after 6h of acrolein treatment at 30µM 
and above. Cell survival was not influenced at this time point, indicated by constant 
total metabolic activity (FIG 3-50A). 
After 24h of acrolein treatment NF-?B levels and cell survival were decreased when 
the acrolein concentration in the medium was beyond 20µM (FIG 3-50 B). Correlation 
of NF-?B activity, indicated by luciferase expression levels, and cell survival, 
indicated by metabolic activity was evident after 24h, but not after 6h of treatment, 
indicating that decrease in NF-?B levels occur prior to cell death. 
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Fig.: 3-50 NF-?B activity levels, indicated by luciferase expression levels and cell survival, indicated by 
metabolic activity (MTT) of mouse fibroblasts treated with different concentrations of acrolein. 
Fibroblasts were obtained from transgenic mice expressing luciferase under the control of a NF-?B 
sensitive promoter. Luciferase levels were analyzed after 6h (A) and 24h (B) of treatment with 
acrolein. Total metabolic activity (MTT) was monitored in a parallel experiment also after 6h (A) and 
24h (B) of acrolein treatment. Values are means ± SD of 6 measurements. 
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3.4 Chemoresistance in metronomic CPA therapy 
Resistance to chemotherapy is a major hindrance for classical chemotherapy and 
also occurs in metronomic scheduled chemotherapy. Therefore investigating 
mechanisms of chemoresistance is an important objective. During evaluation of 
different CPA regimes in this thesis, chemoresistance occurred in different syngeneic 
and xenograft in vivo tumor models. Moreover, primary chemoresistance occurred 
when chemosensitive X39 tumor cells were grown in a three dimensional cell culture 
model or in SCID mice as subcutaneous tumors. For investigation of resistance in 
CPA treated tumors, histological changes were analyzed and tumor cells were 
isolated of for further characterisation. 
3.4.1 Resistance in the CT26/X39 tumor model 
3.4.1.1 CT26/X39 sensitivity to CPA treatment in a coculture system 
In order to evaluate primary resistance of CYP2B1 expressing X39 tumor cells, their 
sensitivity towards CPA treatment was determined both in a multicellular spheroid 
culture model and in standard monolayer culture. CT26 cells were cocultured with 
X39 cells at different ratios in a system combining monolayer and spheroid culture in 
the absence or in the presence of 0.5mM CPA. For three dimensional cell culture 
system, different ratios of CT26 and X39 cells were suspended in agarose containing 
medium. After solidification of the agarose, medium was added and spheroids were 
grown for 10 days (FIG 3-51). 
  
X39 cells day 3 X39 cells day 10 
Fig.: 3-51 X39 and CT26 tumor cells, suspended in agarose containing medium, grow to multicellular 
spheroids within 10 days. 
 
Similar ratios of CT26 and X39 cells were cultivated as a standard monolayer. 
Twenty four hours after monolayer culture ten day old spheroids were added to the 
monolayer cultures. Thereafter the mixture was treated for 3 days with 0.5 mM CPA. 
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This combination of monolayer culture and spheroid culture in the same incubation 
medium ensured similar concentration of metabolites for monolayers and spheroids.  
Cell proliferation and survival was determined by measuring total metabolic activity 
by the MTT assay. Analysis of metabolic activity were performed separately for 
monolayer and spheroid cultures. 
An increasing ratio of X39 cells resulted in elevated sensitivity of the coculture in the 
monolayer. Coculturing 25% X39 cells in the system reduced metabolic activity of the 
monolayer to 50%. When 50% of X39 were present in the system, metabolic activity 
of the monolayer was even reduced to 25% compared to the control system without 
CPA treatment. The strong reduction in the monolayer may result from additional 
diffusible CPA metabolites produced by the spheroids. In a pure monolayer system 
reduction in metabolic activity was not as pronounced (FIG 3-27). 
In contrast, metabolic activity of cells in the microspheroid section was decreased in 
a lesser degree by the CPA treatment. Even when 100% of CYP2B1 expressing X39 
cells were present in the system, decrease in total metabolic activity was only 40% 
(FIG 3-52). 
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Fig.: 3-52 Sensitivity of wt CT26 tumor cells, cocultured with CYP2B1 expressing X39 cells in a 
combined system of monolayer and multicellular microspheroids, against CPA treatment. Metabolic 
activity was determined separately for the monolayer and for the agarose wrapped spheroids by MTT 
assay. The values are means ±SD of triplicates. *p<0.05, compared to untreated control cells (Mann-
Whitney U-test). 
 
When agarose embedded CYP2B1 expressing X39 cells were treated with CPA prior 
to spheroid forming, X39 cells were as sensitive towards treatment as X39 cells in a 
standard monolayer system (data not shown). This indicates that diffusion of CPA 
and decreased enzymatic activity of CYP2B1 are not limiting factors in the three 
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dimensional system, but rather decreased sensitivity that results from modifications 
of the tumor cells when they grow as multicellular spheroids. 
3.4.1.2 CYP2B1 expression of X39 microspheroids 
To further investigate the mechanism of resistance towards CPA treatment in the 
three dimensional cultivated X39 cells, antibody staining against CYP2B1 protein was 
performed after the CPA treatment. Therefore X39 cells were grown as 
microspheroids in agarose containing medium. Agarose wrapped microspheroids 
were subject to CPA treatment for 3 days. Afterwards agarose wrapped spheroids 
were embedded in OTC medium and frozen at -80°C. Frozen spheroids were cut 
with a cryostat to slides of 5µm thickness, following antibody staining against 
CYP2B1 protein as described in materials and methods. Cell nuclei were stained with 
Hoechst 33258. Control spheroids were treated in the same manner except for the 
CPA treatment. CYP2B1 expression was evident both in CPA treated and in control 
spheroids (FIG 3-53), indicating that decreased sensitivity does not result from 
downregulation of CYP2B1 or selection processes by the CPA treatment. 
 
 
control spheroid CPA treated spheroid 
Fig.: 3-53 CYP2B1 expression in CYP2B1 expressing X39 cells grown as multicellular spheroids in the 
absence (control) or in the presence of 0.5mM CPA for 3 days. Cell nuclei were stained by 
Hoechst33258, fragmented nuclei are marked ( ) 
 
In CPA treated X39 microspheroids DNA fragmentation was detected by 
fluorescence microscopy after staining with Hoechst 33258 dye. According to these 
results resistance of three dimensional grown X39 cells to CPA treatment is not due 
to decreased CYP2B1 expression. 
3.4.1.3 Decreased sensitivity of CT26 microspheroids 
  towards treatment with 4OOH-CPA  
CT26 cells were analyzed for changes in sensitivity towards 4OOH-CPA treatment 
comparing cells were grown as microspheroids or monolayer. Established CT26 
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microspheroids wrapped in agarose and CT26 cells grown as a monolayer were 
treated with medium containing different concentrations of 4OOH-CPA. 
After incubation for 3 days metabolic activity of CT26 cells was significantly reduced 
even at the lowest 4OOH-CPA concentration tested whereas CT26 microspheroids 
did not show response to the treatment up to concentrations of 20µM 4OOH-CPA 
(FIG 3-54). 
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Fig.: 3-54 Sensitivity of CT26 cells towards CPA treatment, cultivated either as multicellular spheroids 
or as a monolayer. Metabolic activity was measured by MTT assay and normalized to cell without CPA 
treatment. Values are means ± SD of four measurements. *p<0.05, **p<0.01, compared to untreated 
control cells (Mann-Whitney U-test). 
 
3.4.1.4 Sensitivity of established X39 tumors in vivo 
In order to investigate sensitivity of CYP2B1 expressing tumor cells in vivo, 
subcutaneous CT26 and X39 tumors were established in SCID mice. 
Before implantation of X39 cells into the flank of the SCID mice CYP2B1 expression 
was confirmed by antibody staining followed by FACS analysis (data not shown). 
Further on X39 cells were analyzed for sufficient CYP2B1 enzymatic activity by the 
resorufin assay; fluorescence levels in the resorufin assay indicated sufficient 
CYP2B1 activity (FIG 3-55). 
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Fig.: 3-55 Confirmation of CYP2B1 enzymatic 
activity in stable transfected X39 cells prior to 
implantation. Cells were incubated with resorufin 
incubation solution and in situ released resorufin 
was detected in the supernatant of the cells after 
a freeze-thaw cycle by fluorescence 
measurement. Hatched bars: stable CYP2B1 
expressing cells; open bars: wt CT26 tumor cell 
line. Measurements were normalized to cell 
count. Values are means ± SD of triplicates. 
 
The X39 tumors showed later onset of tumor growth compared to CT26 tumors. 
When tumors reached a volume of 35mm3 80mg/kg CPA was administered every 
sixth day intraperitoneally. Tumor size and body weight was measured regularly 
during treatment period. 
Treatment was well tolerated in CT26 and in X39 tumor bearing mice indicated by no 
significant weight loss (data not shown). Despite high CYP2B1 expression in X39 
tumors the response to the CPA treatment was not significantly different from CPA 
response in CT26 tumors (FIG 3-56). 
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Fig.: 3-56 Growth delay of 
subcutaneous CT26 and 
CYP2B1 expressing X39 tumors 
in SCID mice treated with 
80mg/kg intraperitoneally every 
6th day. (n=5 for CT26 bearing 
animals and n=3 for X39 bearing 
mice) *p<0.05, compared to 
untreated control cells (Mann-
Whitney U-test). 
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3.4.1.5 Detection of CYP2B1 expression in CPA treated X39 tumors 
To clarify if the moderate response to CPA treatment in terms of tumor growth delay 
is due to in vivo selection of CYP2B1 negative tumor cells, antibody staining against 
ratCYP2B1 protein was performed at the endpoint of the treatment. No difference in 
CYP2B1 expression was detectable in CPA treated X39 tumors compared to 
untreated X39 tumors (FIG 3-57). 
  
Control tumor CPA treated tumor 
Fig.: 3-57 CYP2B1 expression in subcutaneous grown X39 tumors after CPA treatment with 80mg/kg 
CPA every six days. Control tumors were obtained of non-treated SCID mice. 
3.4.1.6 Integrin ?v expression in subcutaneous CT26 xenografts 
Integrins were shown to modulate apoptotic signaling (101) and preventing CPA 
induced cell death in endothelial and epithelial cells (102). Therefore integrin 
expression levels of subcutaneous grown CT26 tumors were compared to monolayer 
cultured CT26 cells. Interestingly, ?v expression was detectable in tumors in vivo but 
not on the cell surface of cultured CT26 tumor cells. 
 
 A B 
Fig.: 3-58 (A) Cryo sections (5µm) were fixed with 4% PFA and stained with specific antibodies for rat-
anti-mouse CD51 (red). Secondary antibodies were labelled with Alexa 488. The intravenously injected 
Hoechst 33258 stain was visualized as well (blue). (B) CD51 expression levels on in vitro cultured CT26 
cells. Staining was performed with the indicated antibody, followed by FACS analysis. Secondary 
antibodies were labelled with Alexa 488. 
 
untreated control 
(red) 
Control IgG 
(black) 
Mouse anti human 
CD51/61 (blue) 
Rat anti mouse 
CD51 (green) 
Results   103
3.4.2 Resistance in the PC3 tumor model 
Subcutaneous human PC3 tumors were established in male SCID mice by injection 
of 1x106 PC3 cells in the flank of the animals. CPA treatment was started on day 11 
after tumor implantation when tumors reached an average volume of 37 mm3. Tumor 
bearing mice were treated with 120mg/kg CPA every six days. Metronomic 
scheduled CPA treatment resulted in a significant tumor growth delay. Tumor volume 
of treated mice was constant up to day 50 after the tumor cell implantation whereas 
tumors in the control group exhibited a tumor volume doubling time of 2.5 days. 
Around day 50 after tumor implantation tumor volume began to increase in the CPA 
treated group despite ongoing treatment with a tumor doubling time of 9 days (FIG 3-
59). 
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Fig.: 3-59 Tumor growth in a human PC3 xenograft model with and without metronomic scheduled 
CPA treatment. Tumor bearing SCID mice were treated intraperitoneally with 120mg/kg CPA every 
sixth day. (n=4 for untreated control animals and n=6 for CPA treated animals) 
 
Metronomic scheduled CPA therapy was well tolerated indicated by constant animal 
body weight up to day 67. Further CPA treatment resulted in significant loss of body 
weight observed in all CPA treated animals. Treatment was stopped and animals 
were sacrificed when average loss in body weight reached 20%. 
For further investigation tumors were collected and subject to histological analysis. 
Further on, tumor cells were extracted from tumor tissue for characterisation and cell 
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culture experiments. Part of the reisolated tumor cells were reimplanted into male 
SCID mice.  
3.4.2.1 Histological analysis of PC3 tumors 
For characterisation and evaluation of histological changes induced by CPA 
treatment, tumors were collected, embedded in OTC medium and frozen at -80ºC. 
Cryostat were stained with Haematoxylin/Eosin and analyzed by transmitted light 
microscopy. Untreated PC3 xenografts own a very compact tissue structure and only 
small areas of condensed and fragmented cell nuclei were detected (FIG 3-60A). In 
contrast, CPA treated tumors exhibited larger areas of condensed and fragmented 
cell nuclei, indicating a higher degree of cell death (FIG 3-60B). 
  
A B 
Fig.: 3-60 Histology of subcutaneous PC3 xenografts in male SCID mice (H/E stain). Control tumors 
were collected at day 32 (A), CPA treated tumors on day 67 (B) after tumor setting. Cryosections 
(8µm) were fixed with 4% paraformaldehyde and subjected to H/E staining. Sections were viewed on a 
Zeiss Axiovert 200 transmitted light microscope with a 20x0.4 NA objective. Pictures were taken by a 
Sony DSC-S75 digital camera. 
3.4.2.2 Immunohistological analysis of PC3 tumors 
To further evaluate possible reasons for the occurred resistance towards CPA 
treatment, PC3 tumors were analyzed for immunohistological changes. Due to the 
antiangiogenic metronomic schedule of CPA, attention was focussed on vascular 
markers. Functional blood flow was visualized by intravenous application of Hoechst 
33258 dye and antibody staining against laminin, CD31 and CD13 was performed. 
Functional blood flow was decreased in CPA treated tumors, indicated by decreased 
Hoechst33258 fluorescence signal within the tumor tissue (FIG 3-61B and D). No 
significant changes in the arrangement of laminin and CD31 positive endothelial cells 
was detected in CPA treated tumors in comparison to control tumors. Moreover, 
colocalisation of laminin and CD31 positive endothelial cells remained unchanged 
(FIG 3-61A and B). Tendency of tumor cell lined vessels (vascular mimicry) was not 
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detected. However staining for CD13 positive cells, a marker for angiogenic active 
endothelial cells, was increased in CPA treated tumors, whereas colocalisation of 
laminin and CD13 staining was decreased compared to untreated control (FIG 3-61C 
versus 3-61D). 
 
A B 
 
C D 
Fig.: 3-61 Cryo sections (5µm) of untreated (A and C) and CPA treated tumors (B and D) were fixed 
with 4% paraformaldehyde and stained with specific antibodies for rat-anti-mouse CD31 (green) and 
anti laminin (red) (A and B), or for rat-anti-mouse CD13 (green) and anti laminin (red) (C and D). 
Secondary antibodies were labelled with Alexa 488 (CD31/CD13) or Texasred (laminin). The 
intravenously injected Hoechst 33258 stain was visualized as well (blue).Analysis was performed with 
a Zeiss Axiovert 200 fluorescence microscope equipped with a 10x 0.4 Zeiss objective and a Zeiss 
Axiocam. 
 
3.4.2.3 Characterisation of reisolated tumor cells 
3.4.2.3.1 Morphology 
Reisolated PC3 tumor cells (PC3ID3 and PC3ID4) and parental PC3 cells were 
analyzed for cell morphology by transmitted light microscopy. Twenty four hours after 
seeding no obvious changes in cell morphology were detectable (FIG 3-62).  
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A B C 
Fig.: 3-62 Morphologies of wt PC3 cells (A) and reisolated PC3ID3 (B) and PC3ID4 cells (C).  
3.4.2.3.2 EGF and CD71 status 
To verify the identity of reisolated PC3 cells, antibody staining against huEGFR and 
human CD71 was performed and analyzed by cell flow cytometry. Receptor status of 
reisolated cells was similar to the receptor status of wt PC3 cells regarding EGF 
receptor and human CD71 expression (FIG 3-63). 
A  
 
 
 
 
red: parental PC3 cells; control IgG 
black: PC3Id4 control; IgG 
green: PC3Id3 control; IgG 
dark blue: parental PC3; anti human-EGF 
violet: PC3ID3; anti human-EGF 
light blue: PC3ID4; anti human-EGF 
B      
 
 
 
 
red: parental PC3 cells; control IgG 
black: PC3ID4; control IgG 
green: PC3ID4; control IgG 
dark blue: parental PC3; anti human CD71 
violet: PC3ID3; anti human CD71 
light blue: pc3id4; anti human CD71 
Fig.: 3-63 Antibody status for EGF- (A) and transferrin receptor (CD71) (B) on parental and reisolated 
PC3 cells. Parental and reisolated PC3 tumor cells were stained for human EGF- and human 
transferrin-receptor, followed by FACS analysis. 
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3.4.2.3.3 Proliferation rate 
In order to investigate whether the resistance towards CPA treatment occurred due to 
changes in the proliferation rate, reisolated tumor cells were compared to parental 
PC3 cells in terms of proliferation by the Hoechst 33258 based DNA content assay. 
The proliferation rate was determined over a period of 5 days. Reisolated tumor cells 
PCID3 and PCID4 exhibited a slightly increased proliferation rate compared to the 
parental PC3 cells, however increase in proliferation rate was not significant (p>0.05, 
Mann-Whitney U-test). 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
2 3 4 5 6
day after seeding [d]
fl
u
o
re
s
c
e
n
c
e
 [
F
L
U
]
PC3 cell line
ID3
ID4
 
 
 
 
Fig.: 3-64 Proliferation of parental 
and reisolated PC3 cells (PCID3 
and PCID4). Parental PC3 and 
reisolated tumor cells were seeded 
in a 48 well plate (1500 cells/well) 
and medium was changed every 
second day. Proliferation was 
determined by Hoechst33258 
based DNA content assay over a 
period of 5 days. Open symbols: 
parental PC3 cells, closed symbols: 
reisolated PC3 cells. Values are 
means ± SD of four measurements. 
3.4.2.3.4 NF-?B expression level 
NF-?B is reported to be a critical factor in the response of tumors to chemotherapy; 
increased expression levels of NF-?B are able to protect tumor cells from drug 
induced cell death (68-71). Therefore, reisolated cells PC3ID3 and PC3ID4 were 
compared to the parental PC3 cell line in terms of NF-?B expression levels. 
Parental and reisolated cells were transiently transfected with LPEI polyplexes (LPEI, 
N/P=6, HBS, 400ng/well) containing an NF-?B sensitive luciferase encoding plasmid.  
Control experiments were performed with similar LPEI polyplexes (HBS, N/P 6) 
containing a luciferase encoding plasmid without NF-?B enhancer areas in the 
promoter region. The reisolated cells PC3 ID3 and PC3 ID4 showed a significant 
increase in NF-?B activity in comparison to the parental PC3 cell line. 
Results   108
0
0,5
1
1,5
2
2,5
3
3,5
fo
ld
 e
x
p
re
s
s
io
n
 b
y
 N
F
K
B
 a
c
ti
v
it
y
parental PC3
PC3 ID3
PC3 ID4
 
 
 
Fig.: 3-65  Increased NF-?B 
activity levels in reisolated 
PC3ID3 and PC3ID4 cells. 
Data were corrected by control 
luciferase expression of 
parental PC3 cells. Mean 
values ± SD of four 
measurements are shown. 
*p<0.05, compared to parental 
PC3 NF-?B levels (Mann-
Whitney U-test). 
 
3.4.2.3.5 Sensitivity to 4OOH-CPA treatment 
For further investigation of secondary resistance, the effect of 4OOH-CPA treatment 
on survival of parental PC3 cells and reisolated PC3ID3 and PC3ID4 tumor cells was 
investigated. Therefore parental PC3 cells and reisolated tumor cells were seeded as 
a monolayer and incubated with different concentrations of 4OOH-CPA for 3 days. 
Survival was analyzed by measuring total metabolic activity (MTT assay). The 
reisolated PC3ID3 and PC3ID4 cells exhibited comparable sensitivity to the 4OOH-
CPA induced reduction of cell survival as the parental PC3 cells in the monolayer 
system (FIG 3-66). 
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Fig.: 3-66 Sensitivity of parental 
PC3 and reisolated PC3ID3 and 
PC3ID4 cells towards treatment 
with 4-OOH-CPA. Parental and 
reisolated cells were treated with 
different concentrations of 4-OOH-
CPA for 3 days. Survival was 
determined by measuring total 
metabolic activity. Control 
experiments were performed in the 
absence of 4-OOH-CPA. Mean 
values ± SD of four measurements 
are shown. 
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3.4.2.3.6 Tumor growth of reimplanted PC3 tumor cells 
For further evaluation of resistance phenomena, in vivo experiments were performed. 
Reisolated PC3 tumor cells were again implanted in the flank of other male SCID 
mice. On day 17 after the tumor implantation, when average tumor volume reached 
28mm3, mice were subject to CPA treatment (120mg/kg, every six days). 
Tumor volume and body weight were measured regularly over the period of the 
treatment. In contrast to the achieved growth delay of the tumors in the first CPA 
treatment (see FIG 3-59), no difference in tumor growth between the treated group 
and the control group was detectable. Control tumors as well as treated tumors had 
an average tumor volume doubling time of approximately three days (FIG 3-67). 
Metronomic scheduled CPA was again well tolerated, indicated by no significant loss 
in body weight (data not shown). 
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Fig.: 3-67 Tumor growth of reisolated PC3 tumor cells. Cells from resistant CPA treated tumors were 
obtained and again implanted subcutaneously in male SCID mice. Mice were treated again with 
120mg/kg every sixth day. (n=4 for untreated control animals, n=5 for CPA treated animals) 
3.4.2.4 Immunohistochemical analyses of reimplanted tumors 
Reimplanted PC3 xenografts were analyzed for immunohistological changes in 
comparison to parental PC3 tumors. Again, attention was concentrated on vascular 
markers. Functional blood flow was visualized by intravenous application of Hoechst 
33258 dye and antibody staining against laminin, CD31 and CDE13 was performed. 
Blood supply in reimplanted PC3 tumors was homogenous, indicated by 
homogenous staining of cell nuclei by systemically applied Hoechst 33258 dye. No 
significant changes in the arrangement of laminin and CD31 positive endothelial cells 
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was detected in reimplanted tumors in comparison to parental control tumors. 
Moreover, colocalisation of laminin and CD31 positive endothelial cells remained 
unchanged (FIG3-68A). Tendency of structural modifications or tumor cell lined 
vessels (vascular mimicry) as a possible mechanism of resistance were not detected. 
In parental PC3 tumors CD13 positive cells and laminin staining was partly 
colocalized (FIG 3-61C), whereas in the reimplanted tumors no colocalisation was 
detectable (FIG 3-68B). 
  
A B 
Fig.: 3-68 Immunohistochemical analysis of reimplanted PC3 tumors. Cryo sections (5µm) were fixed 
with 4% paraformaldehyde and stained with specific antibodies for A) rat-anti mouse CD31 (green) 
and anti laminin (red), respectively for B) rat-anti mouse CD13 (green) and anti laminin (red). 
Secondary antibodies were labelled with Alexa 488 (CD31/CD13) or Texasred (laminin). The 
intravenously injected Hoechst 33258 stain, indicating functional blood flow, was visualized as well 
(blue). 
 
3.4.3 Resistance in the HUH7 tumor model 
3.4.3.1 HUH7 tumor model 
Subcutaneous human HUH7 tumors were established in SCID mice by injection of 
5x106 HUH7 cells in the flank of the animals. When tumors reached an average 
tumor volume of 32 mm3 CPA treatment was started on day 12 after the tumor 
implantation. Tumor bearing mice were treated with 75mg/kg CPA every 6th day. 
Tumor volume and body weight was measured over the time of CPA treatment. 
Metronomic scheduled CPA treatment resulted in a significant delay in tumor growth. 
Tumor volume was constant up to day 75 after the tumor cell implantation, whereas 
tumors in the control group showed tumor progression. When CPA treated HUH7 
tumor began to grow despite ongoing CPA therapy, tumor double time was 3.5 days.
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Fig.: 3-69 Tumor growth in a human HUH7 xenograft model with and without metronomic scheduled 
CPA treatment.  Tumor bearing SCID mice were treated with 75 mg/kg CPA every 6th day. (n=3 
animals per group) 
 
Metronomically scheduled CPA therapy was well tolerated indicated by constant 
animal body weight up to day 85. Further CPA treatment resulted in significant loss of 
body weight pertaining to all CPA treated animals (data not shown). Treatment was 
stopped and animals were sacrified when average loss in body weight reached 20%. 
Tumors were collected and subjected to histological analysis. Further on, tumor cells 
were extracted from rebounded tumors for characterisation and cell culture 
experiments.  
3.4.3.1.1 Macroscopic differences between tumors 
The embedded and frozen tumor tissue was analyzed for macroscopical changes 
because treated tumors were obviously different in their appearance compared to 
non-treated control. The tumor tissue of non-treated tumors was compact and 
homogenous (FIG 3-70A and B), whereas resistant CPA treated tumors exhibited an 
inhomogeneous and sponge like structure. Moreover the tissue of treated tumors 
appeared darker resulting from incorporated blood lakes within the tissue (FIG 3-70C, 
D, E and F). 
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Fig.: 3-70 Macroscopic appearance of relapsed CPA treated HUH7 tumors. Tumor tissue was 
collected on day 112 after implantation in case of treated tumors (C, D, E and F) and on day 27 in the 
case of control tumors (A and B). Frozen, embedded tumor tissue was cut with a cryostat until the 
centre of the tumors was reached. Photos were taken with a SONY DSC-75 digital camera. Pictures 
B, D and F are enlarged details from overview pictures A, C and E (  ) 
 
3.4.3.1.2 Histology (HE) 
For characterisation and evaluation of histological changes induced by CPA 
treatment, tumors were collected and histological analyses by H/E staining and 
transmission light microscopy were performed. 
Untreated HUH7 xenografts own a very compact and homogenous tissue structure 
(FIG 3-71 A). In contrast, relapsed CPA treated tumors appeared inhomogeneous 
and exhibited a spongy structure with large cell free areas (FIG 3-71 B). These cell 
free areas were identified as intratumoral blood lakes, characterized by the presence 
of erythrocytes. Interestingly, larger areas of condensed or fragmented cell nuclei 
were neither found in control tumors nor in relapsed CPA treated tumors, indicating a 
similar degree of cell death (FIG 3-71A and B). 
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Fig.: 3-71 Histology of subcutaneous HUH7 xenografts in male SCID mice (H/E stain). Control tumors 
were collected at day 27 (A) and CPA treated tumors on day 112 (B) after tumor cell implantation. 
Cryosections (10µm) were fixed with 4% paraformaldehyde and subjected to H/E staining as 
described in materials and methods. Sections were viewed on a Zeiss Axiovert 200 transmitted light 
microscope with a 20x0.4 NA objective. Pictures were taken by a Sony DSC-S75 digital camera. 
 
To evaluate, if integrated blood lakes contribute to blood supply Hoechst33258 was 
applied systemically as a tracer. Several blood lakes exhibited Hoechst 33258 
stained lining (blue), indicating connection with systemic blood supply (FIG 3-72B). 
Blood supply of non treated HUH7 tumors was investigated with the same technique 
(FIG 3-72A). Counterstain of nuclei was performed with propidium iodide. 
 A  B 
Fig.: 3-72 Blood supply in HUH7 xenografts. Cryo sections (10µm) were fixed with 4% 
paraformaldehyde and counter stain was performed with propidium iodide (red). Blood supply is 
indicated by blue staining of intravenously applied Hoechst 33258 dye. Analysis was performed with a 
Zeiss Axiovert 200 fluorescence microscope, equipped with a 10x0.4 Zeiss objective and pictures 
were taken with a Zeiss Axiocam. 
 
3.4.3.1.3 EGF-receptor status 
For further evaluation of potential changes responsible for resistance against CPA 
treatment, HUH7 tumors were analyzed for immunohistological modifications. Due to 
the antiangiogenic metronomic schedule of CPA, attention was focussed on vascular 
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markers. Functional blood flow was visualized by intravenous application of Hoechst 
33258 dye and antibody staining against laminin, CD31 and CD13 was performed. 
Functional blood flow was decreased in relapsed CPA treated tumors, indicated by 
decreased Hoechst33258 fluorescence signal within the tumor tissue (FIG 3-73 B 
and D); moreover vessel density was decreased. Less CD31 and laminin positive 
vessels were detected in comparison to the control tumors. Colocalisation of laminin 
and CD31 positive endothelial cells remained unchanged (FIG 3-73A and B). 
However, in contrast to control tumors, in CPA treated tumors vessels were not 
continuously lined with CD31 positive endothelial cells. Tumor cell lined vessels 
(vascular mimicry) for a possible reason of resistance towards the metronomic 
scheduled CPA treatment was evident in these relapsed tumors. 
Staining for CD13 positive cells, a marker that indicates angiogenic active endothelial 
cells, resulted in slightly decreased fluorescence signal compared to non-treated 
control tumors. Similar to evaluated PC3 tumors, colocalisation of laminin and CD13 
staining was decreased in relapsed CPA treated HUH7 tumors. In the case of HUH7 
tumors colocalisation was even completely diminished. In contrast to organized 
structures of CD13 positive cells in the control tumors, CD13+ endothelial cells 
exhibited manifest trappings of disorganisation. In treated tumors CD13+ cells were 
scattered distributed over the tumor tissue whereas CD13+ cells were colocated with 
the established vessel network in control tumors (FIG 3-73C and D). 
  
A B 
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Fig.: 3-73 Immunohistochemical analysis of HUH7 tumors (A,C) untreated control tumors and (B,D) 
CPA treated. Cryo sections (5µm) were fixed with 4% paraformaldehyde and stained with specific 
antibodies for A,B rat-anti mouse CD31 (green) and anti laminin (red), respectively for C,D rat-anti 
mouse CD13 (green) and anti laminin (red). Secondary antibodies were labelled with Alexa 488 
(CD31/CD13) or Texasred (laminin). The intravenously injected Hoechst 33258 stain was visualized 
as well (blue). 
 
3.4.3.1.4 Morphology of reisolated HUH7 tumor cells 
Reisolated HUH7 tumor cells and cells from the HUH7 parental cell line were 
analyzed for cell morphology by transmitted light microscopy. Parental HUH7 cells 
and reisolated cells from relapsed CPA treated tumors were seeded in well plates. 
24h after the seeding pictures were taken. No obvious changes in cell morphology 
were detectable. 
 
 
A B 
Fig.: 3-74 Morphology of parental HUH7 cells (A) and reisolated HUH7 (HUH7 REISO) cells (B). 
 
3.4.3.1.5 EGF-receptor expression 
To verify the identity of reisolated human HUH7 tumor cells, antibody staining against 
human EGFR receptor was performed and analyzed by cell flow cytometry. 
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Receptor status of reisolated cells was very similar to the receptor status of parental 
HUH7 cells regarding human EGF receptor. The EGF receptor was detected in a 
similar density on the reisolated cells compared to parental HUH7 cells (FIG 3-75). 
 
A 
 
 
 
 
 
 
 
 
 
 
red: parental HUH7; control IgG 
black: parental HUH7; anti huEGF 
 
B 
 
 
 
 
 
 
 
 
red: HUH7 REISO; control IgG 
black: HUH7 REISO; anti huEGF 
Fig.: 3-75 Antibody status for human EGF receptor on parental and reisolated HUH7 cells. Parental 
and reisolated PC3 tumor cells were stained for human EGF- and human Transferrin-receptor as 
described in materials and methods, followed by FACS analysis. A) parental HUH7 cells, B) reisolated 
HUH7 cells. 
 
3.4.3.1.6 Proliferation rate of reisolated HUH7  
In order to test whether the non response towards CPA treatment is due to changes 
in the proliferation rate, reisolated tumor cells were compared to the parental cell 
lines in terms of proliferation rate by the Hoechst DNA content assay. Proliferation 
rate was determined over a period of 4 days. No difference in proliferation rate was 
found in the reisolated HUH7 cells compared to proliferation rate of parental HUH7 
cells. 
Results   117
0
5000
10000
15000
20000
25000
30000
2 3 4 5 6
day after seeding  [d]
D
N
A
 c
o
n
te
n
t 
[F
L
U
]
HUH7 cell line HUH7 REISO
 
 
 
 
 
 
Fig.: 3-76 Proliferation of 
parental and reisolated HUH7 
cells (HUH7 REISO). Parental 
HUH7 and reisolated tumor cells 
were seeded in a 48 well plate 
(1500 cells/well). Medium was 
changed every second day. 
Proliferation was determined by 
Hoechst33258 based DNA 
content assay over a period of 4 
days. Values are means ± SE of 
five measurements. 
 
3.4.3.1.7 CYP activity in HUH7 
Since HUH7 cells have endogenous CYP enzymatic activity in the resorufin assay, 
non response to CPA therapy might be a result of changes in endogenous activity. 
Therefore HUH7 REISO cells were compared to parental HUH7 cells in terms of 
endogenous CYP enzymatic activity in the resorufin assay. Enzymatic CYP activity 
was indeed reduced in the HUH7 REISO cells in comparison to the HUH7 parental 
cell line (FIG 3-77). The reduction of CYP2B1 enzymatic activity leads to decreased 
CPA activation in the cells and therefore may contribute to a non CPA responsive 
phenotype. Reduction in endogenous CYP2B1 activity was significant referring to cell 
count and total metabolic activity. (p=0.049; Mann-Whitney U-test).
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Fig.: 3-77 Decreased CYP2B1 
activity levels in reisolated HUH7 
tumor cells. Data were corrected by 
cell count or metabolic activity 
(MTT) of parental HUH7 cells. 
Mean values ± SD of triplicates are 
shown. *p<0.05, compared to 
parental HUH7 CYP activity levels 
(Mann-Whitney U-test). 
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3.4.3.1.8 NF-?B activity 
Reisolated HUH7 tumor cells were compared to parental cells in terms of NF-?B 
activity levels. Determination of NF-?B activity levels was performed similar as in PC3 
and Neuro2A cells. The increase in luciferase expression by transfection with the 
plasmid containing NF-?B responsive elements in the promoter region was most 
pronounced in HUH7 cells compared to other cell lines (see chapters 2 CT26:10,1 
and chapter 4, Neuro2A: 2,2 , PC3: 1,6). Moreover reisolated cells HUH7 REISO 
shows a significantly increased NF-?B activity in comparison to the parental HUH7 
cell line, indicating that NF-?B activity might contribute to decreased sensitivity 
towards cytotoxic treatment. 
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Fig.: 3-78 Increased NF-?B activity levels in 
reisolated HUH7 tumor cells. Data were 
corrected by control luciferase expression of 
parental HUH7 cells. Mean values ± SD of four 
measurements are shown. *p<0.05, compared to 
parental HUH7 NF-?B activity levels (Mann-
Whitney U-test). 
 
3.4.3.1.9 Sensitivity of HUH7 towards CPA treatment in a coculture model 
For further investigation of resistance phenomena, reisolated HUH7 cells were 
exposed to in situ activated CPA in a coculture system with CYP2B1 expressing X39 
tumor cells. Reisolated or parental HUH7 cells were seeded with X39 cells in a ratio 
of 75:25 and incubated with different concentrations of CPA for 5 days. Control 
experiments were performed in the absence of CPA. Cell survival was analyzed by 
measuring total metabolic activity (MTT assay). The reisolated cells exhibited 
comparable sensitivity to the CPA induced reduction of cell survival as the parental 
HUH7 cells in a monolayer system. 
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Fig.: 3-79 Sensitivity of parental HUH7 
and reisolated HUH7 REISO cells 
towards treatment with in situ activated 
CPA. Parental and reisolated cells co-
cultivated with X39 cells and treated 
with different concentrations of CPA for 
5 days. Survival was determined by 
measuring Hoechst DNA content assay. 
Control experiments were performed in 
the absence of CPA. Mean values ± SD 
of six measurements are shown. 
 
3.4.3.2 Reimplantation of reisolated HUH7 cells 
For the reimplantation of HUH7 tumors, cells obtained from one relapsed CPA 
treated tumor were isolated, passaged four times in vitro and injected in the flank of 
SCID mice. On day 12 when average tumor volume reached 40mm3 CPA treatment 
was started (75mg/kg, every sixth day). 
In contrast to significant growth delay of tumors established with parental HUH7 cells 
due to CPA treatment, tumor progression of treated and control animals were not 
significantly different when tumors were established with reisolated HUH7 tumor cells 
(Mann-Whitney U-test). Metronomic scheduled CPA was again well tolerated 
indicated by no significant loss in body weight (data not shown). 
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Fig.: 3-80 Tumor growth of reisolated 
HUH7 tumor cells. Cells from relapsed 
CPA treated tumors were obtained 
and reimplanted subcutaneously in 
SCID mice. Mice were treated with 
75mg/kg every sixth day. (n=3 for 
untreated control group, n=4 for CPA 
treated group). 
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3.4.3.3 Histology of reimplanted tumors 
Reimplanted HUH7 xenografts were analyzed for immunohistological changes in 
comparison to parental HUH7 tumors. Blood supply in reimplanted HUH7 tumors was 
heterogeneous and insufficient, indicated by large areas without staining after 
systemic application of Hoechst 33258 dye. Moreover, a considerable fraction of 
tumor vessels was dilated and tissue structure was rather spongy in comparison to 
parental HUH7 tumors. No significant changes in the arrangement of laminin and 
CD31 positive endothelial cells was detected in reimplanted tumors in comparison to 
parental control tumors. Moreover, colocalisation of laminin and CD31 positive 
endothelial cells remained unchanged (FIG 3-81A). Tendency of tumor cell lined 
vessels (vascular mimicry) for a possible reason of resistance towards the 
metronomic scheduled CPA treatment was detected in some tumor areas (FIG 3-
81B). Colocalization of CD13 positive cells and laminin was detectable in some tumor 
areas (FIG 3-81C). However, colocalisation of laminin and CD13 staining was 
significantly decreased in considerable areas of tumor tissue in comparison to 
parental HUH7 tumors (FIG 3-81D). 
 A  B 
 C  D 
Fig.: 3-81 Cryo sections (5µm) were fixed with 4% paraformaldehyde and stained with specific 
antibodies for rat-anti mouse CD31 (green) and anti laminin (red) (A and B), respectively for rat-anti- 
mouse CD13 (green) and anti laminin (red) (C and D). Secondary antibodies were labelled with Alexa 
488 (CD31/CD13) or TexasRed (laminin). The intravenously injected Hoechst 33258 stain was 
visualized as well (blue). 
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3.4.4 Resistance in the syngeneic Neuro2A tumor model 
3.4.4.1 In vivo treatment of Neuro2A tumors 
Subcutaneous Neuro2A tumors were established in A/J mice by subcutaneous 
injection of 1x106 Neuro2A cells in the flank of the animals. On day 11 after the tumor 
implantation when tumors reached an average tumor volume of 50mm3, combined 
electroporation with plasmid DNA encoding for CYP2B1 enzyme and CPA treatment 
(75mg/kg every seventh day) was started (GDEPT concept, chapter 1). Tumor 
volume and body weight was measured at constant intervals during CPA treatment. 
Electroporation combined with metronomic scheduled CPA treatment (application two 
day after electroporation) resulted in a significant delay in tumor growth. Tumor 
progression of the treated animals was diminished up to day 62 after the tumor cell 
implantation whereas tumors of the control group showed an average tumor doubling 
time of about 3 days. When electroporated and CPA treated Neuro2A tumors began 
to re-grow despite ongoing therapy tumor doubling time was 6 days. 
Combined electroporation with metronomic scheduled CPA therapy was well 
tolerated indicated by constant animal body weight up to day 65. Further treatment 
resulted in significant weight loss in all treated animals. Treatment was stopped and 
animals were sacrified when average weight loss reached 20% (data not shown). 
For further investigation of treatment non-responding, tumors were collected and 
cells were extracted from the tumor tissue for further characterisation. 
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Fig.: 3-82 Tumor growth in a 
Neuro2A tumor model with and 
without metronomic scheduled 
CPA combined with electroporation 
treatment. (n=3 animals per group) 
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3.4.4.2 Morphology of reisolated Neuro2A tumor cells. 
Reisolated Neuro2A tumor cells and parental cells from the Neuro2A cell line were 
analyzed for cell morphology by transmitted light microscopy. Therefore parental cells 
and reisolated cells, obtained from the treatment non responsive tumors, were 
seeded in well plates. 24h after the seeding pictures were taken. No obvious 
changes in cell morphology were detectable. 
  
A B 
Fig.: 3-83 Morphology of parental Neuro2A cells (A) and reisolated Neuro2A cells (Neuro2A REISO) 
(B). 
3.4.4.3 CD71 status of reisolated Neuro2A tumor cells 
To verify the identity of reisolated Neuro2A tumor cells, antibody staining against 
CD71 was performed and analyzed by cell flow cytometry. The parental Neuro2A 
cells and as well the reisolated cells were positively stained for CD71 receptor. A 
slightly increased CD71 density was detected on Neuro2A REISO cells compared to 
parental Neuro2A cells. 
 
 
 
 
 
 
 
red: isotype control IgG-PE 
black: parental Neuro2A; anti mouse CD71-PE 
green: Neuro2A REISO; anti mouse CD71-PE 
 
Fig.: 3-84 Antibody status for mouse CD71 on parental and reisolated Neuro2A cells. Parental and 
reisolated Neuro2A tumor cells were stained for mouse transferrin receptor (CD71) as described in 
materials and methods, followed by FACS analysis. 
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3.4.4.4 Proliferation rate of reisolated Neuro2A cells 
In order to test whether the non response towards CPA treatment is due to changes 
in the proliferation rate, reisolated tumor cells were compared to the parental cell 
lines in terms of proliferation rate by the Hoechst DNA content assay. Proliferation 
rate was determined over a period of 4 days. No difference in proliferation between 
reisolated and parental Neuro2A was detected. 
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Fig.: 3-85 Proliferation of parental and reisolated Neuro2A cells (Neuro2A REISO). Parental Neuro2A 
and reisolated tumor cells were seeded in a 48 well plate (1500 cells/well). Medium was changed 
every second day. Proliferation was determined by Hoechst33258 based DNA content assay over a 
period of 4 days. Values are means ± SD of six measurements. 
3.4.4.5 CYP activity in reisolated Neuro2A tumor cells 
Due to the fact that mice were treated with a combination of CYP2B1 gene transfer 
and metronomic scheduled CPA therapy, reisolated tumor cells were analyzed for 
CYP activity by the resorufin assay. Neuro2A REISO cells did not exhibit increased 
CYP activity in comparison to parental Neuro2A cells (data not shown). 
3.4.4.6 NF-?B expression levels 
To evaluate a potential role of NF-?B activity in resistance of the Neuro2A tumor 
model, reisolated Neuro2A tumor cells were investigated regarding to their NF-?B 
activity levels. Determination of NF-?B levels was performed similar as in PC3 and 
HUH7 cells. Reisolated Neuro2A cells exhibited no significantly increased NF-?B 
activity in comparison to parental Neuro2A cells (p=0.078, Mann-Whitney U-test). 
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Fig.: 3-86 NF-?B activity levels in parental 
Neuro2A and reisolated Neuro2A 
(Neuro2A REISO) cells. Mean values ± SD 
of six measurements are shown. 
3.4.4.7 Sensitivity towards 4OOH-CPA treatment 
For further evaluation of resistance in the Neuro2A tumor model, the effect of 4OOH-
CPA treatment on the survival of parental Neuro2A and reisolated Neuro2A REISO 
cells was investigated in vitro. Therefore, parental Neuro2A cells and reisolated 
tumor cells were seeded as a monolayer and incubated with different concentrations 
of 4OOH-CPA for 3 days. Survival was analyzed by measuring total metabolic activity 
(MTT assay). 
Reisolated cells exhibited comparable sensitivity to the 4OOH-CPA induced 
reduction of cell survival as the parental Neuro2A cells in a monolayer system. 
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Fig.: 3-87 Sensitivity of parental Neuro2A and 
reisolated Neuro2A REISO cells towards 
treatment with 4-OOH-CPA. Parental and 
reisolated cells were treated with different 
concentrations of 4-OOH-CPA for 3 days. 
Survival was determined by measuring total 
metabolic activity. Control experiments were 
performed in the absence of 4-OOH-CPA. Mean 
values ± SD of four measurements are shown. 
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3.4.5 CPA treatment of reimplanted Neuro2A REISO cells 
For the reimplantation of Neuro2A tumors, cells from one CPA treated tumor were 
recultivated and 106 cells were injected subcutaneously in the flank of A/J mice. 
When the average tumor volume was 46.5 mm3 on day 8 after tumor implantation, 
mice were subjected to CPA treatment (75mg/kg, every 6th day). Electroporation 
prior to CPA application was not performed in this experiment. Tumor volume and 
body weight were measured regularly over the period of the treatment. 
CPA treated tumor bearing mice exhibited a strong decrease in tumor growth 
whereas control tumors exhibited an average tumor volume double time of 2 days.  
Metronomic scheduled CPA was again well tolerable, indicated by no significant loss 
in body weight (data not shown). 
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Fig.: 3-88Tumor growth of reimplanted 
Neuro2A tumor cells in A/J mice. Cells from 
one rebounded CPA treated tumor were 
obtained and subjected to recultivation. 10
6
 
reisolated tumor cells were again implanted 
subcutaneously. Mice were treated with 
75mg/kg every 6th day. Difference in tumor 
volume was significant at day 14 and day 17 
after tumor cell implantation. (n=4 for the 
control group and n=5 for treated group) 
**p<0.01; *p<0.05, compared to non treated 
control tumors (Mann-Whitney U-test). 
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4 Discussion 
Therapy of malignant diseases was continuously improved over the last decades. 
Drugs and treatment regimes were optimized in order to achieve adequate anti 
cancer activity combined with tolerable side effects. However, treatment with 
conventional antitumor drugs is still marked by a balance between antitumoral and 
side effects due to insufficient specificity. In particular, widely used low molecular 
drugs are distributed in similar quantity in healthy tissue, when administration is 
performed systemically. 
Recently, a change towards more specific drugs is noticeable. Moreover, tumor 
vasculature as a promising target in anticancer strategies emerged in the last years. 
According, investigation of tumor angiogenesis and antiangiogenic approaches was a 
main issue in new antitumor strategies. Treatment regimes with conventional 
cytotoxic antitumoral drugs were evaluated and changed experimentally from high 
dose therapies to low dose metronomic schedules. In addition more specific 
approaches with antibodies, e.g. Herceptin® and Avastin®, thyrosin kinase inhibitors 
(Clivec®), or proteasom inhibitors (Velcade®) were recently developed and entered 
the clinic. New treatment regimes such as nucleic acid therapies including siRNA and 
gene therapy are investigated because of their potential of selectivity. 
However, several limitations for cancer therapy exist up to now. The occurrence of 
primary and secondary resistance towards treatment regimes is still a major obstacle 
in tumor therapy. Approaches for cancer therapy have to be further improved 
regarding to specificity, antitumoral efficiency and resistance. A major obstacle for 
evaluation of new therapeutic strategies is the lack of reliable model systems and/or 
evaluation of potential strategies without incorporating tumor specific environmental 
properties. 
Main issues in this thesis were therefore the evaluation of a potential specific gene 
therapeutic approach (GDEPT) in a tumor mimicking environment. Moreover, 
attention was turned towards metronomic scheduled CPA and acrolein as one of the 
metabolites that potentially support antiangiogenic activity. During the investigations 
chemoresistance towards CPA therapy was observed in tumor models in vitro and in 
vivo and was characterized by histological analysis and evaluations in reisolated 
tumors. 
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4.1 Classic GDEPT concept 
A major obstacle for the improvement of CPA/IFO treatment regimes in regards to 
specificity and side effects is activation of CPA/IFO prodrug by liver enzymes and the 
systemic distribution of cytotoxic metabolites via the vasculature. Enzymatic 
conversion of CPA/IFO in the tumor site is in general prevented due to low 
endogenous CYP P450 activity in tumor cells. Conversion of CPA prodrug in the 
tumor area would result in relocation of cytotoxic metabolites in terms of high local 
concentrations of antitumoral active metabolites combined with a lower systemic 
burden compared to conventional CPA/IFO treatment regimes. Therefore, delivery of 
plasmids encoding for CPA/IFO converting enzymes to tumor cells, is a promising 
approach in improving CPA/IFO treatment (GDEPT, gene directed enzyme prodrug 
therapy). 
While several hundreds of isoenzymes pertain to the family of P450 enzymes, only 
some of them contribute to the conversion of CPA and IFO. Primary, CPA/IFO 
activation by 4-OH hydroxylation reaction is catalyzed by P4502B and P4502C 
isoforms (103). P4502C isoforms exhibit fast conversion, however, application in the 
classic GDEPT concept is prevented due to saturation effects (104). Human CYP3A4 
and CYP2B6 were found to activate the CPA prodrug very efficiently (105), however, 
CYP3A4 conversion resulted beneath hydroxylation of CPA in neurotoxic and 
nephrotoxic side products. In contrast, enzymatic activity of CYP2B1 and CYP2B6 is 
restricted on hydroxylation reaction, leading to the antitumoral active phosphoramid 
mustard (106). 
In the context of this thesis, evaluation of this approach was performed with plasmid 
DNA encoding for rat CYP2B1 enzyme, due to substantial evaluations and 
characterizations of prior studies (107-111). For sufficient expression levels of the 
therapeutic gene in tumor cells, CYP2B1 expression was regulated by a highly 
efficient CMV-promoter/enhancer. 
Evaluation of sensitizing tumor cells towards CPA/IFO treatment via CYP2B1 
expression was performed in standard cell culture and additionally in the agarose 
overlay system, mimicking tumor environmental characteristics. Finally this GDEPT 
approach was investigated in vivo by intratumoral CYP2B1 gene transfer followed by 
CPA treatment in a CT26 xenograft tumor model. 
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Conventional cell culture 
Evaluation of sensitizing tumor cells towards CPA/IFO treatment via CYP2B1 
expression was performed on transiently transfected cells as well as on stably 
transfected cell lines. Different from prior studies on the CYP/CPA combination, 
attention was focused to low CPA concentrations, reflecting the metronomic 
scheduled CPA treatment regimes and not high dose therapy. 
Beside assurance of expressed CYP2B1 protein in transfected cells via specific 
antibody staining, special attention was set to the evaluation of enzymatic activity. 
Enzymatic activity does not directly correlate, of necessity, on CYP protein content. 
Beneath environmental conditions (50) other factors are crucial for CYP2B1 
enzymatic activity (112-114). Therefore two different assays for detecting CYP2B1 
enzymatic activity were performed. The acrolein assay that directly reflects 
conversion of CPA/IFO was found to suffer from low signal to noise ratios, especially 
in culture systems with low CPA concentrations. Low detection rate of free acrolein in 
supernatants may be due to covalent reaction to serum proteins, present in the cell 
culture medium. To circumvent low sensitivity of the acrolein assay a modified 
resorufin assay was used for evaluation of CYP enzymatic activity. Resorufin 
recovery in serum containing biological fluids was easily detectable due to high 
sensitivity and sufficient signal to noise ratio. Therefore the resorufin assay was used 
by default to evaluate CYP2B1 enzymatic activity in the thesis. 
In following studies, wt tumor cell lines and the CYP2B1 expressing X39- and 9L-
D2B1 cells were analyzed on CYP2B1 enzymatic activity via resorufin assay. In line 
with literature, wt tumor cell lines exhibited only very low conversion capability (115); 
however, compared to CT26, 9L and Neuro2A, HUH7 cells exhibited 10-fold higher 
CYP activity in the resorufin assay (FIG 3-2). Elevated conversion capability of HUH7 
cells can be explained by their origin on human hepatocytes, whereas enzymatic 
activity of severally CYP P450 systems were detected (116). 
Stabely transfected CYP2B1 expressing cell lines X39 and 9L-D2B1 showed high 
enzymatic activity, whereas resorufin conversion capability of X39 cells was about 
twice as high in comparison to 9L-D2B1. This result was confirmed by the acrolein 
assay, indicating high relevance of the resorufin assay in terms of CPA metabolism 
(FIG 3-8 and 3-9). 
Further on, sensitivity of wt CT26 and Neuro2A tumor cells towards CPA and IFO 
treatment was investigated. Treatment with IFO resulted in enhanced antiproliferative 
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effects compared to CPA; low CYP2B1 levels in this wt cancer cell lines indicate 
higher unspecific toxicity of the IFO prodrug (FIG 3-4). This phenomena may be 
based on the non-enzymatic hydrolysation reaction of IFO that is catalyzed by 
anorganic phosphates and results in the formation of cytotoxic chlorethylamine (117-
119). No enhanced sensitivity of stable expressing CYP2B1 X39 tumor cells towards 
IFO treatment was detected (FIG 3-12). Enhanced sensitivity towards CPA treatment 
was detected when stable CYP2B1 expressing tumor cell lines X39 and 9L-D2B1 
were cultured with CPA compared to the corresponding wt tumor cells (FIG 3-10). 
This indicates in situ conversion of CPA to cytotoxic metabolites and is a proof of 
principle for this GDEPT concept. 
Even at low concentrations, relevant for the in vivo situation significantly decreased 
proliferation and survival was detected for both CYP2B1 expressing cell lines. In this 
context CYP2B1 high expressing X39 tumor cells tended to exhibit enhanced suicidal 
effects compared to 9L-D2B1 cells. However, due to predominantly apoptotic 
processes, induced by the in situ formed phosphoramid mustard (120;121), 
correlation of enzymatic activity and suicidal effects are not necessary direct. Beside 
the delivery of stably transfected, encapsulated, CYP2B1 expressing cells (31), in 
vivo approaches within the GDEPT concept includes strategies with tumor targeted 
gene transfer vehicles leading to transient expression of the therapeutic gene in 
tumor cells. Transient transfection of Neuro2A and 9L cells resulted in detectable 
enzymatic activity of the expressed CYP2B1 enzyme within 20h after the 
transfection. Maximum enzymatic activity was measured in Neuro2A tumor cells 60h 
after the transfection, whereas activity levels in transfected 9L cells were more 
constant over the observation period (FIG 3-14). 
CYP2B1 enzymatic activity levels of Neuro2A cells were about two times (at maximal 
enzymatic activity, 60h after the transfection) compared to 9L cells when total 
transfection rates (measured by EGFP reporter gene expression) were considered. In 
the case of CYP2B1 plasmid DNA delivery to CT26 tumor cells no enhanced 
enzymatic activity was detectable in the resorufin assay despite similar transfection 
rates as detected in 9L cells via EGFP reporter gene expression. 
Differences in CYP2B1 enzymatic activity after gene delivery are critically depending 
on several cellular characteristics. Beside influences on protein expression levels, 
several factors are crucial for enzymatic activity. Predominately, supply with NADH 
reduction equivalents by the P450 reducase were described for the 9L cell line (122); 
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additional effects on CYP2B1 activity might result form differences of total metabolic 
activity and characteristics of the endoplasmatic reticulum (123). 
After transient transfections with LPEI polyplexes only a part of the cell population is 
transfected successfully. Thus, bystander activity is crucial. Malfunction can 
therefore result, beneath insufficient CYP2B1 expression and activity, from dilution 
effects in conventional cell culture. This effect seem to play an important role when 
enzymatic activity is rather low (50). In transwell coculture systems of wt CT26 and 
CYP2B1 expressing tumor cells influence of proliferation and survival was detected in 
both compartments when culturing was performed in the presence of 0.5mM CPA 
(FIG 3-13). In contrast to other GDEPT-based enzyme/prodrug combinations, e.g. 
herpes simplex virus thymidine kinase/ganciclovir, 4-OH-CPA readily diffuses across 
cell membranes and is not dependent on direct cell-cell contact for bystander killing 
(50). 
However, strong cytotoxic effects were only detected for the 4-OH-CPA producing 
X39, whereas the wt CT26 acceptor cells only exhibited a moderate response in 
terms of proliferation and survival. This result indicates the importance of dilution 
effects especially in a low dose CPA GDEPT concept in vitro. In addition, 4-OH-CPA 
is very unstable and breaks down with a half-life time of only 17 min at 37ºC in serum 
containing medium (50). Efficiency of bystander effect seems to be dramatically 
linked to degrading of 4-OH-CPA and dilution effects. In vitro artifacts were 
circumvented by the development of the agarose overlay technique, mimicking 
limited diffusion effects of tumor tissue. 
 
Evaluation of the CPA GDEPT approach in the agarose overlay system 
Drug diffusion and concentration effects within the tumor tissue play an important role 
in the action of drugs such as CPA due to the short half-life of its active metabolites 
(124). Tumor cell uptake of CPA and 4-OH-CPA is facilitated by the low extracellular 
pH associated with tumors, which may increase intracellular accumulation of this 
weakly acidic drug and its metabolite by an ion trapping mechanism (125). The tumor 
microenvironment has a substantial impact on the response of tumor cells to 
cytotoxic agents (126). The diffusion of nutrients, drugs and metabolites within a solid 
tumor is limited. Moreover, most solid tumors are characterized by extended hypoxic 
regions and areas with an acidic microenvironment (127). 
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In addition to the level of CYP gene expression, the extent of CPA activation is highly 
dependent on the availability of oxygen, which is a cosubstrate for all CYP-
catalyzed monooxygenation reactions. Low oxygen pressure resulting from 
insufficient blood supply is a hallmark of solid tumors (128). Despite the limited 
oxygen supply, excellent antitumor activity was reported in mouse and rat models of 
GDEPT using CYP2B enzymes (122;129), with some indications of efficiency 
reported in initial clinical trials after local delivery of a CYP gene (130).  
Results obtained in bystander experiments of prior studies may be non-physiological 
and reflect the unnatural environment of conventional cell culture. Therefore, the 
CYP-CPA-GDEPT strategy was evaluated by using an agarose overlay technique 
to study the effect of limited diffusion and reduced oxygen supply on the bystander 
cytotoxicity of CYP activated CPA.  
Agarose has been described as a suitable material for simulation of diffusion within a 
solid tumor (131). This effect was confirmed by injecting the membrane-permeable 
DNA dye Hoechst 33258 into the agarose layer. The limited diffusion of this dye led 
to the formation of a concentration gradient and the staining of tumor cell nuclei in the 
immediate vicinity of the injection site (FIG 3-16). 
Beside bystander activity in the environment mimicking cell culture model, the impact 
of the agarose layer was evaluated in terms of cell morphology, proliferation rate and 
induction of hypoxia sensitive gene expression. 
Within 24h of agarose overlay no obvious changes in cell morphology (FIG 3-17) and 
no induction of hypoxia induced gene expression was detected (FIG 3-19). However, 
cell proliferation rate was influenced when cells were cultured under an agarose layer 
for several days (FIG 3-18). Oxygen deprivation under the agarose layer was not 
leading to hypoxia induced gene expression within 24h, measured by luciferase 
expression under control of a HRE (hypoxic responsive element) containing 
promoter. This indicates that the agarose overlay reflects areas in the tumor with 
moderate hypoxia. Despite the lack of hypoxia induced gene expression, the agarose 
overlay imposed an apparent hypoxic environment on the cells, as shown by the 
88% decrease in CYP metabolic activity of X39 tumor cells cultured under an 
agarose layer, which corresponds to the CYP activity at an ambient oxygen content 
of 2% (v/v) (FIG 3-21). 
Regardless of reduced CYP activity, however, the CYP-expressing tumor cells 
cultured with the agarose overlay exhibited an enhanced bystander cytotoxic effect.  
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The increased bystander activity was seen in experiments with cocultures of CYP-
expressing cells and CYP-deficient cells, and in experiments where the CYP gene 
was introduced by transient transfection. 
Thus, with the agarose overlay, a population of 25% CYP-expressing X39 cells killed 
80% of the overall tumor cell population compared to only 13% tumor cell killing in 
the absence of the overlay. Of note, X39 cells exerted greater bystander toxicity in 
HUH7 hepatoma cells compared to CT26 cells. The enhanced sensitivity of the 
HUH7 cells towards CPA may in part be due to the intrinsic CYP activity of HUH7 
cells, which is ~2% of that seen with the X39 clone. 
CPA induced decrease of cell survival in the agarose overlay model resulted in 
similar kinetics as in conventional cell culture when CYP2B1 expressing X39 tumor 
cells were cocultured with CT26 or Neuro2A cells. However, decrease in survival was 
more pronounced and was maximal at the third day of treatment under the agarose 
layer. The similar kinetic indicates that the mechanism of induced cytotoxicity is not 
influenced by the agarose overlay. The latency period of one to two days concede 
the case for maintaining an induction of apoptotic cell death also in the tumor 
environment mimicking cell culture model (FIG 3-23). 
Short-term treatment (5 h) with 0.5 mM CPA should mimic the in vivo situation, 
where short exposures to CPA at peak levels of <1 mM can be found in tumor tissue, 
even after a high dose bolus of CPA (132). In the transient transfection studies, 
where only a limited number of cells expressed CYP2B1 (13%, estimated based on 
CYP2B1 antibody staining and EGFP as reporter gene in a parallel experiment), a 
clear CPA-induced killing effect was only observed for cells cultured under an 
agarose layer (FIG 3-25). 
In conclusion, the present studies highlight the utility of an agarose overlay method 
that mimics moderate hypoxic areas in the tumor tissue and restricted diffusion of 
activated drug metabolites. In the case of CYP2B1-dependent CPA activation, the 
restricted diffusion of activated metabolites out from the tumor cell microenvironment 
is likely to prolong the exposure to elevated concentrations of active metabolites that 
play a crucial role in enhancing bystander cytotoxicity. Despite the fact that CYP 
activity, and therefore prodrug activation, is substantially reduced under the hypoxic 
conditions imposed by the agarose overlay, a strong bystander effect could 
nevertheless be observed as a consequence of the restricted diffusion of active 
metabolites. This bystander effect becomes even more important at low oxygen 
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concentrations and under conditions where only a limited fraction of the tumor cells 
express the CYP gene, as is likely to be the case in any in vivo gene delivery 
situation. 
 
In vivo evaluation of the CPA GDEPT approach 
For further evaluation of the CYP-CPA GDEPT strategy, CYP2B1 plasmid DNA was 
delivered to subcutaneous CT26 tumors via electroporation, followed by systemic 
CPA treatment on 2 consecutive days after gene transfer. Pronounced decrease in 
tumor growth was observed for CPA treatment regime combined with gene transfer 
(FIG 3-29). Interestingly, also transfection with an empty control plasmid increased 
antitumoral effects of treatment, which can be explained by several factors. Already 
electroporation of the tumor alone led to reduced tumor growth in certain cases (Silke 
van der Piepen, unpublished results). Moreover, local application of plasmid DNA can 
evoke enhanced immune response due to non methylated CpG sequences (133). 
Control experiments with subcutaneous CYP2B1 expressing X39 cells in SCID mice 
with a similar CPA treatment regime (without gene transfer via electroporation) did 
not result in enhanced antitumoral activity compared to wt CT26 xenografts. 
Therefore, primary resistance was supposed in the CT26 xenograft model.  
4.2 Extended GDEPT concept – antiangiogenic approach 
Antiangiogenic approaches exhibit several advantages in comparison to conventional 
strategies in tumor treatment, e.g. reduced side effects. Therefore the CYP/CPA 
GDEPT approach was extended on endothelial cells and the strategy of locally 
activated CPA was evaluated with attention to antiangiogenic effects.  
The bystander effect of in situ activated CPA via CYP2B1 expressing X39 tumor cells 
(producer) on primary endothelial cells (acceptor) was investigated in terms of critical 
key steps in the angiogenic process. Endothelial cells exhibit only low CYP activity 
and are therefore not able to contribute to CPA conversion. This results in low 
sensitivity towards CPA treatment (FIG 3-30). In prior studies, however, impact on 
proliferation and migration capability were detected when primary endothelial cells 
were cultured with 4-OH-CPA (20). Coculturing endothelial cells with CYP2B1 
expressing tumor cells resulted in increased sensitivity in terms of proliferation and 
survival towards CPA treatment. Interestingly, PEC cells exhibited pronounced 
sensitization compared to HUVEC cells (FIG 3-31 and 3-32). In the case of 
coculturing producer and acceptor cells in a transwell system, bystander activity was 
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evident on PEC but not on HUVEC cells (FIG 3-33 and 3-34). Differences in 
sensitivity in the context of proliferation and survival are supposed to be provoked by 
higher proliferation rate of PEC cells due to certain cell cycle specificity of the 
phosphoramid mustard. However, several other factors including phenotype and 
species might be involved in the difference of sensitization towards CPA and its 
metabolites. In particular, differences in cellular GSH levels are crucial in the 
detoxification of the metabolite acrolein (134); interestingly, treatment of primary PEC 
and HUVEC cells with acrolein alone resulted in similar difference in sensitivity (FIG 
3-40); in this context HUVEC cells were shown to exhibit an adaptive protection 
system (135). In addition, acrolein was shown to exhibit a more potent impact on cell 
death in the case of endothelial cells than the metabolite phosphoramid mustard 
(136). 
Further on, the impact of in situ activated CPA was evaluated in terms of 
antimigrative effects on primary endothelial cells by coculturing with CYP2B1 
expressing X39 cells. HUVEC as well as PEC cells exhibited decreased migration 
capabilities, however, antimigrative effects were less distinctive compared to 
treatment with 4-OH-CPA (20). Reasons for non significant effects on migration might 
result from different pharmacokinetics of in situ activated CPA and 4-OH-CPA 
administered directly to the cell culture medium. However, CPA conversion by 
CYP2B1 expressing X39 tumor cells is sufficient to inhibit endothelial differentiation 
processes via bystander activity (FIG 3-35). Control experiments with wt CT26 tumor 
cells indicate that disturbance of differentiation processes are specific in terms of 
CYP2B1 expression in the presence of CPA. Moreover, changes in the 
rearrangement of endothelial F-actin cytoskeleton was only detected in coculture 
systems with CYP2B1 expressing tumor cells in the presence of CPA (FIG 3-36). 
 
In the GDEPT strategy, CYP2B1 expressing tumor cells can be utilized as producer 
cells for activated CPA metabolites, inhibiting crucial key steps in the angiogenic 
process. The bystander principle can therefore be extended on endothelial acceptor 
cells in terms of an antiangiogenic treatment approach. 
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4.3 Acrolein – unwanted side product or contribution to 
  antiangiogenic properties of metronomic CPA therapy? 
Metronomically scheduled CPA has been linked to antiangiogenic effects, reduced 
tumor blood supply and decreased side effects compared to conventional high dose 
CPA therapy (19). Moreover, activated CPA was shown to inhibit endothelial cell 
proliferation and migration in vitro and endothelial cell apoptosis in experimentally in 
vivo tumors (17;20). Modulation of endogenous antiangiogenic cytokines like 
thrombospondin-1 by metronomic scheduled CPA was described and is discussed as 
a potential mediator of antiangiogenic effects of this approach (21;22;93;137). 
CPA is an anticancer prodrug that is dependent on cytochrom P450 metabolism to be 
activated to the first metabolite 4-OH-CPA. In vivo, this hydroxylation reaction is 
predominantly conducted by liver P450 cytochrom systems. The activated drug is 
released to the blood stream and distributed systemically over the body including the 
tumor site. 4-OH-CPA exists in equilibrium with aldophosphamide that releases 
spontaneously the phosphoramid mustard and acrolein. Antitumor activity was 
accredit to the phosphoramid mustard whereas acrolein was considered as a side 
product, responsible for unwanted side effects (138). However, some recent studies 
certify antitumor modulating effects, e.g. over modulation of the immunosystem, to 
acrolein, predominantly within low dose CPA therapy regimes (139-142). 
For in vivo evaluation, CT26 xenografts were treated with a metronomic low dose 
CPA therapy regime (40mg/kg on two consecutive days, followed by two days 
without treatment). CPA treatment resulted in significant decreased tumor growth 
compared to the untreated control group (FIG 3-29). Possible antiangiogenic effects 
of this treatment regime were analyzed by intravenously injection of Hoechst33258 
dye as a tracer. By performing this method only functional tumor blood vessels are 
visualized. In recent studies, tumor vessels are quantified after visualizing vessel cell 
markers by antibody staining, e.g. CD31. However, staining for vessel markers and 
quantification of anatomically present tumor blood vessels does not give evidence for 
the contribution of indicated vessels on tumor blood supply. Even in non treated 
experimental subcutaneous tumors, great discrepancy between CD31 stained tumor 
vessels and functional vessels was detected (not shown). Due to the fact that blood 
supply in tumors is very heterogeneous and experimentally subcutaneous grown 
tumors are often characterized by a necrotic central area and highly proliferating 
regions in the periphery, measurements were performed separately for three different 
areas (central, middle and peripheral area). Tumor blood supply of the peripheral 
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area of the tumors tended to be higher than in the central parts of the analyzed 
tissue, indicated by enhanced Hoechst33258 fluorescence signal. CPA treatment 
resulted in decreased tumor blood supply in all three tumor areas , whereas reduction 
was most pronounced in the peripheral areas. Tumor cell proliferation and angiogenic 
processes are most active in the peripheral areas of experimental subcutaneous 
tumors. Distinct reduction of blood supply in this proliferation zones indicated that 
the performed low dose CPA treatment regime indeed affected the forming of new 
functional blood vessels in terms of antiangiogenic therapy (FIG 3-37). For further 
investigation of a possible contribution of acrolein to antiangiogenic properties of low 
dose CPA scheduling, tumor tissue was analyzed for the presence of acrolein 
adducts by specific antibody staining against mouse CD31. Indeed, acrolein 
modified proteins were detected within the tumor tissue of CPA treated CT26 tumors. 
Moreover, colocalisation of CD31 and acrolein adduct antibody staining was evident, 
indicating a possible impact of acrolein on tumor endothelial cells (FIG 3-38). Acrolein 
adducts were also detected in prior studies far away form the site of CPA activation; 
e.g. acrolein-lysin adducts were located in aorta walls of CPA treated rats (143). 
Delivery of acrolein towards the tumor site can occur directly by 4-OH-CPA or 
aldophosphamide, respectively, due to relevant concentrations of these metabolites 
in peripheral blood (144). A second pathway of acrolein transport to the tumor tissue 
may be supported via thiol conjugates. In this context, these metabolites are 
described for transporting and releasing acrolein via ?-elimination and were identified 
for delivery of toxic side effects of acrolein to distant organs like lung and bladder 
(145;146). Notably, tumor regions with increased acrolein adduct content displayed 
reduced tumor blood supply as identified by low Hoechst33258 staining. The in vivo 
results initiated further in vitro studies to evaluate a possible role for contribution of 
acrolein to the antiangiogenic effects of metronomic CPA therapy. 
Antiangiogenic properties of acrolein on primary endothelial cells were evaluated in 
terms of classical antiangiogenic assays including proliferation, migration and 
differentiation studies. Further on, the impact of acrolein was assayed in terms of 
crucial cellular mechanisms that are linked to cell survival, migration and angiogenic 
phenotype. 
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Proliferation 
Growing tumors require flexible adaptation and expanding tumor vessel networks. A 
basic requirement for the expansion of the vessel network is therefore the entrance of 
usually resting endothelial cells into cell cycle. The switch from resting endothelial 
cells to an angiogenic active phenotype is driven by several factors like hypoxia, 
released proangiogenic factors and other tumor environmental conditions. Culturing 
of primary endothelial cells in the presence of acrolein resulted in decreased 
proliferation and survival (FIG 3-40). In prior studies it was shown that acrolein is the 
crucial metabolite affecting endothelial cells survival; the metabolite phosphoramid 
mustard was recognized in this context to exhibit a minor role (147). Moreover, 
acrolein was shown to have the potential of inhibiting cell cycle regulating proteins 
(148). 
 
Migration 
Cell motility and migration are critical aspects in tumor progression influencing the 
sprouting of new blood vessels in the angiogenic process, cancer cell invasion and 
metastasis (149). During tumor blood vessel formation angiogenic endothelial cells 
migrate towards the direction of the angiogenic stimuli (chemotaxis). During the 
migration process further proliferation of endothelial cells can occur. Prior studies 
exhibited antimigrative effects of 4-OH-CPA on primary endothelial cells (20). 
However, treatment with acrolein alone inhibited endothelial cell migration in a dose 
dependent manner (FIG 3-41). Disturbance of cell migration by acrolein was more 
pronounced than in experiments with enzymatically in situ activated CPA. This 
difference in migration capability might result from different pharmacokinetics of 
acrolein which is released by enzymatic activated CPA and acrolein which is 
administrated directly to the cell culture medium. 
 
Differentiation 
Another crucial step in the angiogenic process is the endothelium specific 
differentiation of vascular cells in order to form lumen and functional blood vessels. 
Therefore potential antiangiogenic active drugs are evaluated for disturbing this 
differentiation processes. The matrigel assay operates on the capability of primary 
endothelial cells to form tube-like structures when cultured on a supportive matrix 
(150). The differentiation processes are promoted by different protein structures in 
the gel; laminin and to a lesser extend collagen IV seem to be the key regulator 
elements which interact with cellular surface receptors. Moreover, several 
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proangiogenic factors and growth factors like bFGF and EGF are embedded in the 
matrix. Morphological differentiation is rapid and occurs within several hours (151). 
Performing the matrigel tube formation assay in the presence of indicated 
concentrations of acrolein in the medium resulted in a pronounced and dose 
dependent inhibition of tube forming (FIG 3-42 and 3-43). 
 
In summary, acrolein disturbs crucial key steps in the angiogenic process including 
proliferation, migration and differentiation 
 
Actin cytoskeleton and integrin ?v?3 receptors 
Dynamics of the actin cytoskeleton is a key element in cell migration and 
differentiation processes of endothelial cells (152). VEGF induces angiogenic 
activation of endothelial cells by assessing endothelial stress fiber assembly and F-
actin cytoskeletal rearrangements are a very early step in the angiogenic process 
(153). While cell cycle proteins and apoptosis have been under investigation for anti-
cancer drug development for several years, processes involved in controlling actin 
cytoskeleton dynamics, responsible for cell motility and cell shape, receives 
increasing attention. Actin cytoskeleton of endothelial cells and inhibitors for actin 
based endothelial cell migration are mainly investigated in the context of developing 
new antiangiogenic drugs or in mechanistic evaluation of already known 
antiangiogenic compounds. Disturbance of the endothelial F-actin cytoskeleton 
results in decreased migration and tube/capillary forming ability. 
Actin has several nucleophilic reaction sites and can be targeted for Michael 
adduction. Acrolein was shown to react with actin in cell free systems in a dose 
dependent manner, leading to structural distortions and changes in polymerization 
rates. Moreover, it was shown that acrolein leads to the breakdown of the actin 
cytoskeleton in fibroblasts (154). 
In this thesis a breakdown of the F-actin cytoskeleton was detected in primary 
endothelial cells when coculture experiments with CYP2B1 expressing X39 tumor 
cells were performed in the presence of CPA (FIG 3-36). Further, acrolein interacted 
with F-actin of HUVEC cells in a dose dependent manner and leads to the 
breakdown of the F-actin cytoskeleton (FIG 3-44), accounting for the ability of 
acrolein to inhibit cell migration and tube forming morphogenesis. 
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Endothelial cell adhesion molecules of the integrin family are critical mediators and 
regulators in the angiogenic process. Integrins are heterodimeric cell surface 
molecules consisting of two associated subunits (? and ?) providing physical 
interaction with the extracellular matrix and are linked with the F-actin cytoskeleton 
(94;155); therefore integrins exhibit a crucial role for adhesion and migration 
processes. Especially, integrin ?v?3 is one of the central surface molecules in 
capillary forming during the angiogenic process (156). Moreover, integrins interact 
with several signaling pathways via cytoplasmic domains and are necessary for 
signaling events essential for cell survival, proliferation, migration and differentiation 
of endothelial cells (157). Following adhesion, integrin receptor clustering occur 
which recruit cytoskeletal and cytoplasmatic proteins to link the new formed integrin 
complexes to the actin cytoskeleton. The integrin signaling leads to cytoskeletal 
rearrangements, entry into S-phase of the cell cycle and as well to integrin mediated 
gene transcription (94). Several studies showed that disturbance of integrin ?v?3 
clustering results in antiangiogenic effects in vitro and in vivo. 
Specific antibody staining for integrin ?v?3 receptors exhibited dramatically changes 
in cell surface distribution on cultured primary endothelial cells after treatment with 
acrolein. Notably, integrin receptor clustering, being essential for signal transduction, 
was diminished. Moreover, accumulation of integrin ?v?3 receptors at filopodia 
structures, providing adhesion in migration processes, were prevented (FIG 3-45). 
Total expression levels, analyzed by antibody staining followed by FACS analyses, 
however, were not changed during observation period. 
 
In summary, disturbance of integrin ?v?3 clustering by acrolein and the influence on 
regulation of F-acting cytoskeletal rearrangements indicate profound interference of 
acrolein with angiogenic processes. Additionally, results suggest possible 
mechanistic insights in the direct effects of acrolein on endothelial cell migration and 
differentiation. 
 
NF-?B levels 
Besides direct interference of acrolein with integrins and the F-actin cytoskeleton, 
modulation of NF-?B levels by acrolein was assayed. NF-?B signaling plays a critical 
role in cancer development, progression, angiogenesis and influences response to 
chemotherapy. In this context hypoxia (158) but also hormones (159) and growth 
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factors like EGF (160) were identified as important triggers of NF-?B activity. High 
levels of NF-?B were shown to be linked with cancer cell survival, expression of 
proteases (e.g. MPPs) and upregulation of proangiogenic cytokines (161;162). 
Several proangiogenic factors and extracellular matrix degrading enzymes are not 
only secreted by tumor cells themselves but additionally by stromal fibroblasts in the 
vicinity of tumor cells. Also in fibroblasts the expression of critical proangiogenic 
genes are regulated by NF-?B and fibroblasts NF-?B activity levels are in turn 
regulated by cytokines released from tumor cells (163). 
 
Fig.: 4-1 Network of tumor, tumor stroma and endothelial cells in the regulation of proangiogenic 
processes, leading to tumor progression and neovascularisation.  
 
This network of paracrine effects, based on NF-?B mediation, indicates NF-?B as a 
promising target in tumor therapy. Therefore contribution of acrolein on 
antiangiogenic effects regarding metronomic CPA treatment was assayed in the 
context of NF-?B regulation in CT26 tumor cells, primary fibroblasts and as well in 
primary endothelial cells (HUVECs). Downregulation of NF-?B activity levels by 
acrolein was described for human A549 lung tumor cells (164); however modulation 
of NF-?B was not evident in CT26 tumor cells (FIG 4-50). Therefore it is assumed 
that effects of acrolein on CT26 tumors are not based on NF-?B dependent 
pathways. However, influence of acrolein on other pathways in terms of the 
expression of proangiogenic cytokines, have to be evaluated. 
Analyzing primary fibroblasts in terms of modulation on NF-?B activity levels due to 
acrolein treatment resulted in a dose dependent inhibition of NF-?B activity within 6h 
(FIG 3-51A). Moreover, acrolein treatment reduced fibroblast cell survival within 24h 
(FIG 3-52B). Therefore, it is assumed that acrolein can interact with tumor supportive 
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stromal fibroblasts and may contribute to antiangiogenic effects of CPA therapy by 
reducing NF-?B regulated output of proangiogenic factors.  
NF-?B activity is crucial for regulation of angiogenic or resting phenotype in 
endothelial cells. Autocrine expression of several proangiogenic factors are 
modulated by NF-?B (165;166). On the other hand proangiogenic factors like VEGF 
(167) can in turn activate NF-?B signaling in endothelial cells. Moreover, inhibition of 
NF-?B signaling inhibits bFGF induced angiogenesis (168) and resulted in inhibition 
of tube formation in in vitro matrigel assays (169). Another potential mechanism by 
which NF-?B may promote angiogenesis is via autocrine effects inducing endothelial 
VEGF expression. (170). In addition, NF-?B was identified as an important signaling 
molecule in integrin ?v?3 mediated endothelial cell survival (171) and was linked to 
the PI3K/Akt pathway (172), influencing survival, proliferation and differention. As 
tumor derived endothelial cells show upregulation of the PI3K/Akt pathway, 
suppression of TSP-1 expression was functionally linked to an upregulated PI3K/Akt 
pathway (173). 
 
Fig.: 4-2 Interplay of important receptors, cytokines, pathways and the cytoskeleton in an angiogenic 
active endothelial cell  
 
Reduction of NF-?B activity was significant when HUVEC cells were treated with 
10µM acrolein for 24h. Decrease in NF-?B activity was even more pronounced when 
treatment was carried out with 20µM acrolein. Interestingly, culturing HUVEC cells 
with 30 µM acrolein resulted in highly increased NF-?B activity levels (FIG 3-46). This 
increase, however, seems to be not relevant in the context of angiogenesis, due to 
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the fact that treatment of HUVEC cells with 30µM or higher concentrations of acrolein 
were shown to interfere with cell survival after 3 days of treatment (unpublished 
results). 
 
Thrombospondin-1 
The hypothesis that acrolein interferes partly via NF-?B in the regulation of 
endothelial angiogenic phenotype may be assured by the expression profile of TSP-1 
in HUVEC cells. TSP-1 expression was found to be highly upregulated in HUVEC 
cells cultured with 5, 10, and 20µM acrolein for 24h (FIG 3-48). TSP-1 expression 
falls back to control levels when treatment was carried out with 30µM acrolein and 
above. However, the strongest induction in TSP-1 expression was detected at a 
concentration of 5 µM, whereby NF-?B activity levels were reduced in a dose 
dependent manner with minimal activity levels at 20.0µM acrolein. These data 
suggest participation of other pathways involved in the acrolein affected regulation of 
TSP-1 expression. Other regulatory proteins affected by acrolein might be AP-1 
(activator protein 1) (148;174), or the modulation of JNK- (175;176) and PKC 
pathways (177;178). Enhanced TSP-1 expression levels, however, seems to be 
specific, as general protein expression is downregulated, indicated by decreased 
luciferase expression levels after transfection with pCMV-LUC and acrolein treatment 
(not shown). 
 
In conclusion, acrolein was shown to inhibit several crucial steps of the angiogenic 
process. Further on, disturbance of integrin clustering and reorganization processes 
of the F-actin cytoskeleton was detected in acrolein treated primary endothelial cells. 
Modulation of endothelial NF-?B regulated gene expression by acrolein and induction 
of TSP-1 expression was evident. Due to prior studies, TSP-1 is one of the most 
important endogenous inhibitors of angiogenesis and was functionally linked to 
metronomic CPA therapy regimes. The detection of acrolein protein adducts in 
tumors and especially acrolein modified endothelial cells suggest an important 
contribution of acrolein to antiangiogenic effects of metronomic CPA treatment 
regimes. 
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4.4 Resistance towards CPA treatment 
Chemotherapy is the standard treatment in metastasized cancers. A major drawback 
of such treatment regimes, however, is resistance that either exists from the 
beginning of treatment (primary resistance) or is developed during chemotherapy 
(secondary resistance). 
4.4.1 Primary resistance 
Primary resistance is an existing obstacle in several types of cancer. Interestingly, 
drug resistant phenotypes described in several studies occur in multicellular tumor 
spheroids or in in vivo tumor models but not in monolayer cultures (179). 
As described in chapter 1, CT26 tumor cells were highly sensitized towards CPA 
treatment in monolayer cultures when CYP2B1 gene expression was evident. 
However, this sensitizing effect was diminished when CYP2B1 expressing CT26 
tumor cells (X39) were grown as subcutaneous tumors in vivo from the beginning of 
CPA treatment (FIG 3-56). Therefore, failure of sensitizing towards CPA treatment 
was classified as primary resistance. 
In order to exclude the possibility of downregulation of therapeutically expressed 
CYP2B1 protein or to recognize possible selection effects occurring under CPA 
treatment, tumor tissue was collected and analyzed for CYP2B1 expression by 
specific antibody staining at the end of treatment. CYP2B1 expression was evident in 
control as well as in CPA treated tumors, indicating that the non-response towards 
treatment is not based on changes in expression levels or selection processes (FIG 
3-57). 
For further evaluation of this effect, CYP2B1 expressing X39 tumor cells were 
cultured in a combined cell culture system including a monolayer section as well as 
three dimensional grown X39 spheroids. The compartments in the system were 
connected over a joint medium reservoir to assure the exchange of free diffusible 
metabolites occurring in CPA prodrug conversion. Reduction in cell survival and 
proliferation in the monolayer section was even more pronounced than in standard 
cell culture experiments performed in chapter 1; whereas reduction in the 
multicellular tumor spheroid compartment was not pronounced (FIG 3-52). Killing rate 
in the monolayer section indicates high total concentrations of activated CPA in the 
joint medium by contribution of multicellular tumor spheroids to CPA conversion. 
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This is contradictive to the possibility of inadequate CPA conversion within the 
agarose wrapped spheroids due to limitations of oxygen supply as an explanation for 
insufficient cytotoxic effects in the spheroid compartment. In addition, limitations in 
oxygen supply by an agarose layer were detected to exhibit only a secondary role in 
the efficiency of CPA to induce cell death. 
The possibility of insufficient diffusion of CPA prodrug to agarose wrapped X39 tumor 
cells were excluded by control experiments with prematured X39 tumor spheroids, 
exhibiting similar sensitivity towards CPA treatment as X39 cells grown as a 
monolayer (data not shown). In addition, analyses of multicellular tumor spheroids for 
CYP2B1 expression via specific antibody staining resulted in similar CYP2B1 
expression for treated X39 multicellular tumor spheroids and not treated control 
spheroids. Hoechst33258 counterstaining in agarose wrapped X39 microspheres 
resulted in the detection of fragmented cell nuclei in CPA treated tumor spheroids, 
indicating presence of active CPA metabolites and deterioration of tumor cells (FIG 3-
53). Further evaluation of resistance in the multicellular spheroid model of 
established wt CT26 tumor spheroids resulted in decreased sensitivity to 4-OOH-
CPA compared to the monolayer systems. By the use of 4-OOH-CPA, which breaks 
up into phosphoramid mustard and acrolein without enzymatic conversion, effects in 
terms of enzymatic capability in agarose wrapped tumor microspheres were 
excluded. This experimental system assures that reduction in CYP2B1 dependent 
CPA conversion was unincisive in the case of multicellular spheroids, assuring 
resistance mediated effects via three dimensional conditions in the agarose wrapped 
microspheres (FIG 3-54). 
 
In conclusion, these results demonstrate that resistance of CT26/X39 cells in vivo is 
manifested in cell culture only under three dimensional conditions in the case of 
multicellular tumor spheroids. Since CT26 or X39 cells were not resistant against 
CPA or 4-OH-CPA treatment, when grown as two dimensional monolayer cultures, 
(uni)cellular resistance is implausible. In several prior studies phenomena of 
spontaneous drug resistance in three dimensional conditions were described e.g. for 
vinca alkaloids and antimetabolites (180;181). Moreover, resistance towards CPA 
treatment, mediated by three dimensional culture conditions was described for 
murine mammary tumor cells (182). When treatment is performed with high 
molecular drugs, resistance phenomena can be explained by limited drug diffusion. 
Discussion   145
However, in the case of CPA, which is a low molecular weight drug (271 g/mol), this 
is unlikely to be predominant. This observation suggests that tumor tissue may be 
able to increase its relative resistance towards cytotoxic CPA metabolites by 
alterations in tissue architecture resulting in a “group protection” of the individual 
tumor cell. This point of view is assisted by the loss of resistance when treatment is 
performed on premature spheroid cultures. However, limited diffusion of drugs into 
the microspheroids seems not to be crucial, indicating other mechanisms of 
resistance. Usually proliferation rate is reduced in multicellular spheroids, which leads 
to decreased numbers of cells in the S phase of cell cycle; however, reduction in cell 
proliferation may play a major role in conventional spheroid culture technology and 
not in agarose wrapped microspheres due to constant growing over several days 
(183). Other mechanisms that may be involved are changes in DNA conformation or 
altered expression of intracellular proteins, surface proteins and cytokines. Changes 
in the expression of proteins mediating cell-cell or cell-ECM (extracellular matrix) 
contacts have to be considered. Integrins were shown to essentially modulate 
apoptotic signaling (184) and preventing CPA induced cell death in endothelial and 
epithelial cells (185). This might be a mechanism in epithelial CT26/X39 tumors, as 
alterations in cell surface integrin ?v receptors of in vitro monolayers compared to 
subcutaneously grown tumors were observed: integrin ?v cell surface receptors were 
only detected in CT26 tumor tissues (FIG 3-58A), whereas on CT26 tumor cells, 
cultured as two dimensional monolayers, a very low expression of integrin ?v 
receptors (CD51) was observed (FIG 3-58B). Primary resistance in the context of 
CT26 and X39 multicellular tumor spheroids is a supposable explanation for GDEPT 
treatment failure in vivo. 
In summary, agarose wrapped tumor microspheres seem to be a suitable model 
system for multicellular mediated drug resistance. Moreover, in contrast to 
establishing multicellular spheroids e.g. by the liquid overlay technique (186;187), 
tumor cells maintain proliferating phenotype and form spheroids via cell division over 
several days, which is a more natural way of generating tumor spheroids (188). 
Different from other techniques, agarose wrapped spheroids implies the forming of a 
natural extracellular matrix (189-191). 
4.4.2 Secondary resistance 
In contrast to primary resistance, secondary resistance is characterized by its 
development under ongoing therapy of tumors being sensitive prior to treatment. This 
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type of resistance occurred within the metronomically scheduled CPA treatment 
regimes of subcutaneous grown PC3 and HUH7. Interestingly, therapy failure 
became evident around day 50 to day 70 in all both tumor models. 
Despite the proposal of avoiding acquired drug resistance by metronomic CPA 
therapy (192;193), recent studies indicate resistance mechanisms also occurring in 
this treatment regimes. However, previous reimplantation studies of reisolated tumor 
cells presented sensitivity towards treatment again, indicating the involvement of 
other resistance mechanism than conventional acquired multidrug resistance (MDR), 
which is predominantly based on alterations of tumor cells, e.g. upregulation of DNA 
repair, modulation of apoptotic pathways or expression of transporter systems 
(20;194;195). 
 
PC3 xenograft model 
Subcutaneous human PC3 tumors in SCID mice were treated with a higher dose of 
CPA (120mg/kg, compared to treatment of HUH7 (75mg/kg) and Neuro2A (75mg/kg) 
tumor bearing mice. Tumor volume remained constant up to day 50 after tumor cell 
implantation, thereafter tumor volume increased despite ongoing CPA therapy. Due 
to initial sensitivity towards the treatment, resistance was classified as secondary 
resistance. 
Histological analyses of collected tumor tissue, comparing relapsing CPA treated 
tumors and untreated control tumors resulted in similar tissue structure; however, 
treated tumors exhibited larger areas of condensed and fragmented cell nuclei, which 
probably resulted from direct cytotoxic effects of CPA or may be induced by hypoxic 
effects due to the antiangiogenic scheduling. 
Angiogenesis was demonstrated to be associated with the aggressiveness of tumors 
(196). Recent studies indicate that also non-angiogenesis based mechanisms may 
exist in certain tumors and are predominately promoted by tumor cell plasticity (197). 
To give consideration to possible resistance mechanism resulting from metronomic 
scheduled CPA treatment, which targets predominately tumor vessel cells, 
immunohistochemical analysis of collected tumor tissues was performed with 
attention on alterations in vascular markers. Analysis of laminin, which is a main 
compound of the basal lamina of blood vessels, and staining for CD31 positive 
endothelial cells showed colocalisation in treated as well as in untreated tumors (FIG 
4-62). Moreover, the appearance of vascular mimicry in treated PC3 tumors was not 
evident. Reduction in blood supply, indicated by decreased Hoechst33258 staining 
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levels contribute to the suggestion that regrowth of tumors are not due to malfunction 
of antiangiogenic scheduled CPA. 
Further on, laminin and CD13, a marker expressed on angiogenic active endothelial 
cells, only colocalized in untreated control tumors, but not in treated tumors. Tumor 
angiogenesis is predominately promoted by sprouting form the existing blood vessel 
network which exhibits laminin as well as CD31 markers (198); therefore, 
organization and colocalisation of CD13 with vessel markers of already established 
blood vessels can be interpreted as angiogenesis. Analysis of laminin and CD13 
staining indicate that ongoing metronomic CPA therapy is effective regarding 
antiangiogenic effects; thus the observed resistance likely results from alterations of 
the tumor cells themselves. 
Reisolated tumor cells were characterized and identified in the context of cell 
morphology and receptor status; no differences in cell morphology or EGF- or 
transferrin receptor expression were detected by comparing reisolated tumor cells 
with PC3 cells from the parental cell line, indicating identity of reisolated cells (FIG 4-
64). Due to the involvement of NF-?B on mediating resistance towards cytotoxic CPA 
treatment by modulating apoptotic pathways, the detected upregulation of NF-?B 
mediated gene expression can contribute to the resistant phenotype (199). 
Reisolated tumor cells did not manifest their drug resistant phenotype in two-
dimensional monolayer, when treatment was performed with 4-OOH-CPA (FIG 4-
67). However, drug resistant phenotype of reisolated tumor cells (PC3ID3 and 
PC3ID4) was manifested after reimplantation into mice (FIG 4-68). 
Immunohistochemical analysis of vascular markers laminin and CD31 in the 
reimplanted tumors resulted in a similar distribution and colocalisation of laminin and 
CD31 compared to tumors of parental PC3 cells (FIG 3-68).  
Multicellular spheroids were established from PC3ID3 and PC3ID4 reisolated 
sublines and subjected to 4-OOH-CPA treatment. Interestingly, multicellular 
spheroids were found to show resistance as detected by MTT assay (MTT, blue 
staining; FIG 4-3) when 4-OOH-CPA treatment was performed in concentrations that 
decreased metabolic activity levels in monolayer cultures to 15% of control values in 
both sublines (FIG 3-66). Comparison with parental PC3 cells failed due to it was not 
possible to establish agarose wrapped microspheroids of the parental PC3 cell line.  
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Fig.: 4-3 Metabolic activity (MTT) in established PC3ID3 (A) and PC3ID4 (B) agarose wrapped 
multicellular spheroids after 3 days of incubation with 50.0µM 4-OH-CPA. Spheroids were incubated 
with MTT reagent and metabolic activity was analyzed via transmitted light microscopy after 2h of 
incubation. Dark or blue staining of spheroids indicates metabolic activity and cell survival. 
  
Despite lacking comparableness to parental PC3 cells, occurring resistance in 
agarose wrapped spheroids indicate again possible mechanisms resulting from three 
dimensional growth conditions. For further clarifying possible mechanism involved in 
the resistant PC3 phenotype, follow up studies have to be performed.  
  
HUH7 xenograft model 
Subcutaneous human HUH7 tumors in SCID mice were treated with a low dose 
metronomic scheduled CPA treatment regime (75mg/kg). Tumor volume was kept 
constant up to day 70 after tumor cell implantation before tumor volume began to 
increase despite ongoing CPA therapy. Due to primary sensitivity towards the 
treatment, occurring resistance was likewise classified as secondary resistance. 
Tumor tissue of relapsed CPA treated tumors appeared obviously different compared 
to untreated control tumors. Whereas, control tumors exhibited a macroscopical 
homogenous and compact tissue structure, relapsed tumors were characterized by 
an inhomogeneous and spongy structure and the incorporation of several blood lakes 
(FIG 3-70). 
Further histological analysis via H/E stain assured the differences in tissue 
structure found by macroscopical analyze (FIG 3-72). Interestingly, in contrast to the 
increase of areas with condensed and fragmented cell nuclei in the relapsed PC3 
tumors, no obvious changes in histological indicators for tumor cell death were 
evident in treated HUH7 tumors. Preevaluation a possible contribution of integrated 
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blood lakes to tumor blood supply by Hoechst33258 as a tracer, resulted in fractional 
staining of blood lakes, indicating connection to systemic blood circulation (FIG 3-72). 
The incidence of tumor cell lined blood vessels (vascular mimicry) (200) and 
mosaic vessels (tumor cells located in blood vessel wall) (201) was predominately 
described for aggressive melanomas. In the case of vascular mimicry, tumor cells 
acquire trans-endothelial functions and are able to participate in forming channels in 
order to contribute to blood supply (202). By this mechanism, tumors are less 
dependent on functional angiogenic processes, indicating that the appearance of 
vascular mimicry and mosaic vessels might be a reasonable resistance mechanism 
in antiangiogenic treatment strategies (203). 
Again, to give consideration to possible resistance mechanism resulting from 
metronomic CPA treatment which targets predominately tumor vessel cells, 
immunohistochemical analysis of collected tumor tissues was performed with 
attention on alterations in vascular markers. 
Analysis of laminin and simultaneous staining for CD31 positive endothelial cells 
resulted in colocalisation in treated as well as in untreated control tumors. However, a 
decreased rate of anatomical present tumor vessels was detected in treated tumors, 
likely resulting from antiangiogenic effects of metronomic CPA treatment. Moreover, 
tendency of functional blood flow in treated tumor was found to be reduced, indicated 
by decreased Hoechst33258 staining. 
However, in contrast to control tumors, vessels were not continuously lined with 
CD31 positive endothelial cells in relapsed tumors. Hoechst33258 staining indicated 
that these channels within the tumor tissue are contributing to tumor blood supply 
and therefore provide oxygen and nutrients. By detailed fluorescence microscopical 
analysis of these functional channels, the presence of mosaic- as well as tumor-cell 
lined vessels was evident (FIG 3-73). The appearance of vascular mimicry 
phenomena in treated HUH7 tumors suggest a possible resistance mechanism 
towards antiangiogenic scheduled CPA therapy, due to the relative autonomy of 
tumors in the context of angiogenic processes. Analysis of laminin and CD13, 
resulted in colocalisation in untreated control tumors, but not in treated tumors. 
Moreover, organization of CD13 positive cells appeared disordered in such a 
manner, that sprouting of new blood vessels from existent ones was completely 
inhibited. Therefore, malfunction of metronomic CPA treatment regarding 
antiangiogenic effects was not evident, indicating sufficient conversion of CPA 
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prodrug and still antiangiogenic effective concentrations of active metabolites in 
blood stream. However, relapsing tumors achieved independence from angiogenesis 
and therefore were able to revoke antiangiogenic scheduled CPA treatment. 
Reisolated tumor cells were characterized and identified in the context of cell 
morphology and receptor status; no differences in cell morphology or EGF-
receptor cell surface expression were detected by comparing reisolated tumor cells 
with HUH7 cells from the parental cell line, indicating the identity of reisolated cells 
(FIG 3-74 and 3-75). Changes in endogenous CPA conversion capability may 
contribute to the resistant phenotype in HUH7 tumor cells due endogenous CYP 
activity. Indeed, endogenous CYP activity was significantly reduced, comparing 
reisolated and parental HUH7 cells (FIG 3-77). This finding suggests that decreased 
conversion of CPA to cytotoxic metabolites may further assist to treatment 
malfunction. 
Involvement of NF-?B in resistance against cytotoxic treatment was reported in 
several studies. In this context, significant upregulation of NF-?B induced gene 
expression was detected in reisolated HUH7 cells, indicating a role in mediating CPA 
resistant phenotype (FIG 3-78). In addition to the modulating effects of NF-?B in 
apoptotic processes (161), increased NF-?B induced gene expression may also 
contribute to differentiation processes (204). Therefore, NF-?B might play an 
essential role in the case of mediating drug resistance in the HUH7 xenograft model, 
due to a possible involvement in structuring tumor tissue and in vascular mimicry 
phenomena. 
Similar to PC3ID3 and PC3ID4 sublines, reisolated tumor cells did not manifest their 
drug resistant phenotype in a two dimensional monolayer, when CPA treatment was 
performed in a coculture system with CYP2B1 expressing X39 tumor cells (FIG 3-
80). However, reisolated tumor cells manifested their drug resistant phenotype when 
reimplantation in vivo was performed. Interestingly, resistance was not absolute in 
this case. Reimplanted HUH7 xenografts exhibited decreased sensitivity towards 
CPA treatment in comparison to parental HUH7 tumors; the lag phase in tumor 
growth up to day 70 after cell implantation was not evident. On the other hand, tumor 
growth was influenced by the CPA treatment, whereby reduction in tumor growth was 
not significant at any time point of measurement (FIG 3-80). 
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Interestingly, tissue structure of reimplanted control tumors was again characterized 
by regions with a spongy, heterogeneous structure similar to relapsed CPA treated 
tumors (FIG 3-81). 
Simultaneous analysis of vessel markers, laminin and CD13, resulted partly in 
colocalisation in reimplanted HUH7 tumors (FIG 3-81A). Interestingly, colocalisation 
was not evident in all tumor regions (FIG 3-81 B). Simultaneous staining of laminin 
and CD31 resulted in unobtrusive colocalisation of both vascular markers. However, 
several tumor cell lined channels were detected to be functional for tumor blood 
supply (FIG 3-81A and 3-81B), indicated by Hoechst33258 staining. This reaches to 
the conclusion that reimplanted HUH7 tumors again manifest vascular mimicry 
phenomena in vivo and revoke tumors, at least, partly from metronomic CPA 
treatment. 
The ability of forming angiogenesis independent channels for tumor blood supply is 
therefore suggested to be “stored” in resistant HUH7 tumors and affect HUH7 
phenotype in vivo even in the absence of CPA treatment. 
Vascular mimicry phenomena are predominately described for aggressive melanoma 
tumors (205-210). However, there is growing evidence for the existence of similar 
phenomena in breast carcinoma (211-213), prostatic carcinoma (214;215), ovarian 
carcinoma (216), different sarcomas (217) and is recently detected in hepatocellular 
tumors (218;219). Forming angiogenesis independent channels for tumor blood 
supply in melanoma was linked to upregulation of the PI3K pathway and expression 
of several downstream controlled proteins (220;221). The “stored” significantly 
increased activity levels of NF-?B in reisolated HUH7 tumor cells (FIG 3-78) indicate 
possible modulation of the PI3K pathway and may be therefore involved in a HUH7 
phenotype which forms a tumor cell lined channel network for blood supply. 
The possibility of NF-?B/PI3K involvement in the context of the phenotype of 
reimplanted HUH7 tumors is further supported by differences in the regulation of NF-
?B activity levels by CPA metabolites. Acrolein resulted in significantly increased NF-
?B induced gene expression in reisolated HUH7 tumor cells but not on, in parental 
HUH7 tumors (FIG 4-4). In the cases of resistant PC3 tumors, which were 
unremarkable for vascular mimicry, regulation of NF-?B induced gene expression by 
acrolein was not evident (data not shown). 
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Fig.: 4-4 Induction of NF-?B induced gene expression by the metabolite acrolein in reisolated HUH7 
tumor cells. Parental and reisolated HUH7 tumor cells were transfected transiently with LPEI 
polyplexes (N/P 6; HBS) containing luciferase encoding plasmid DNA with a NF-?B sensitive 
promoter/enhancer region (pNF-?B-LUC). Control experiments were performed with pTAL-LUC. 24h 
after the transfection cells were subjected acrolein treatment for further 24h. Luciferase measurements 
were performed as described in materials and methods. Values represent NF-?B activity levels in 
HUH7 cells. Values ±SE are means of four values.  
 
However, a possible connection of NF-?B activity levels and phenotype of reisolated 
HUH7 tumor cells has to be evaluated in further studies, particularly due to the 
lacking knowledge about possible PI3K mediation on vascular mimicry phenomena in 
human hepatoma tumors.  
 
In summary, resistance towards metronomic CPA treatment in HUH7 tumors is 
suggested to be based predominately on the ability of forming angiogenesis 
independent channels for blood supply, potentially resulting from differences in NF-
?B/PIK3 modulated pathways. The spongy tissue structure, easing metabolic 
requirements due to lower cell count and advanced diffusion of oxygen and nutrients 
might contribute to this effect. Reduced endogenous CPA conversion capability of 
resistant tumor cells might be an additional reason for resistant HUH7 tumors in 
revoking CPA treatment. 
 
4.4.3 Resistance in the syngeneic Neuro2A tumor model 
Subcutaneous Neuro2A tumors were treated with a low dose metronomic scheduled 
CPA treatment regime (75mg/kg) in combination with CYP2B1 gene transfer via 
electroporation. Tumor volume was kept constant up to day 60 after tumor cell 
implantation before tumor volume began to increase despite ongoing treatment (FIG 
3-82). Reisolated Neuro2A tumor cells from refractory tumors were characterized and 
identified via cell morphology and cell surface receptor status. Interestingly, 
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reisolated tumor cells exhibited slightly increased CD71 expression levels (FIG 3-84). 
Further studies, including evaluation of proliferation rate, endogenous CYP activity 
and NF-?B activity, showed no significant difference compared to parental Neuro2A 
cells.  
Similar to PC3ID3, PC3ID4 and HUH7 REISO cells, reisolated Neuro2A tumor cells 
did not manifest their drug resistant phenotype in a two dimensional monolayer, 
when treatment was performed with 4-OOH-CPA (FIG 3-87). However, in contrast to 
reimplanted PC3 and HUH7 tumors, reimplantated Neuro2A tumors resulted in high 
sensitivity towards metronomic CPA treatment, indicating that reimplanted Neuro2A 
tumor cells are not able to manifest their drug resistant phenotype in vivo again (FIG 
3-88). This suggests that in reisolated Neuro2A tumor cells the drug resistant 
phenotype is not a typical secondary resistance; resistance is not “stored” as in the 
cases of PC3 and HUH7 drug resistant tumors. This observation is conform to prior 
studies with experimentally PC3 and Lewis Lung carcinoma (20;222;223). 
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5 Summary 
The development of more specific and effective anti cancer strategies is crucial in 
overcoming current obstacles in tumor therapy. Especially antiangiogenic 
approaches and gene therapy might be suitable instruments in the treatment of 
already metastasized cancers. Further on, the development of relevant cellular model 
systems, mimicking tumor environment or permitting three dimensional culture 
conditions, are crucial for improved assessment of therapeutic approaches. 
 
Gene transfer with vectors coding for CYP2B1 was shown in several studies to 
enhance sensitivity of tumor cells towards CPA treatment. However, investigation of 
this concept was performed so far predominately with high dose CPA regimes. In this 
work, the concept was further evaluated with special attention to low dose CPA 
treatment regimes and in the context of tumor environmental characteristics. To 
provide an in vitro model system that recapitulates limited diffusion and hypoxia, an 
agarose overlay model was established. Evaluation of CYP2B1 enzymatic activity 
levels and bystander activity, which are the “supporting pillars” in the CYP/CPA 
concept, demonstrated great influence of the agarose overlay in terms of conversion 
capability and induced cytotoxicity. Restricted diffusion of activated drug metabolites 
was found to play a crucial role in enhancing bystander cytotoxicity.  
Further on, the classical CYP/CPA GDEPT concept was extended and evaluated in 
terms of antiangiogenic properties. In this context, CYP2B1 expressing tumor cells 
were found to exert antiangiogenic bystander effects on endothelial cells in the near 
vicinity. 
 
In the context of evaluation antiangiogenic properties of CYP/CPA GDEPT concept 
and low dose metronomic CPA treatment regimes, the 4-OH-CPA released 
metabolite acrolein was investigated for antiangiogenic properties. Interestingly, 
acrolein was detected to disturbe several crucial key steps in the angiogenic process 
including proliferation, migration and differentiation processes. Further on, 
upregulation of TSP-1, which was identified as a crucial endogenous inhibitor of 
angiogenesis and recently associated with metronomic scheduled CPA treatment 
regimes, by acrolein in primary endothelial cells, was detected. In addition, NF-?B 
activity levels, which were shown to exhibit important proangiogenic properties in 
primary endothelial cells, were reduced by acrolein treatment. Detection of acrolein-
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protein adducts in CPA treated subcutaneous tumors and high levels of 4-OH-CPA 
(360µM) suggest a contribution of acrolein in vivo in the context of the antiangiogenic 
properties of metronomic CPA treatment. 
 
Resistance towards chemotherapy is a major reason for failure of conventional 
chemotherapy and occurs also in metronomically scheduled treatment regimes as 
investigated in this thesis. Resistance can either occur as primary resistance, as 
detected for CT26/X39 subcutaneous tumors or secondary, acquired drug resistance 
occurred in experimentally PC3, HUH7 and Neuro2A tumors in a similar time period 
of treatment. Primary resistance phenomena result in most cases from protection of 
the individual tumor cell by three dimensional conditions and established cell-cell-
contacts. This protection effects are supposed to play the crucial role in 
subcutaneous CT/X39 tumors or in established three dimensional microsphere 
model. In this context agarose wrapped tumor microspheres seem to be a suitable 
model system for multicellular mediated drug resistance. 
 
Despite drug resistance in experimental PC3, HUH7 and Neuro2A tumor models at a 
similar period of CPA treatment, mechanisms resulting in drug resistance were 
apparently varied. While drug resistance in the experimentally PC3 xenograft model 
predominantly seems to be based on the protection of the individual cancer cell in a 
multicellular network, resistance of HUH7 xenografts was found to be a result from 
plasticity of tumor tissue and the ability to form angiogenesis independent structures. 
In contrast to reimplanted PC3 and HUH7 tumors, Neuro2A did not manifest the drug 
resistant phenotype in vivo again. 
 
In summary, CPA is an anticancer drug that can be applied in conventional tumor 
therapy, in combination with gene transfer and in antiangiogenic approaches with low 
dose metronomically scheduled regimes. In the context of metronomic CPA therapy, 
acrolein was shown to exhibit antiangiogenic effects and therapeutic contribution has 
to be reconsidered. Despite improved treatment regimes, drug resistance will be still 
an obstacle in chemotherapeutic regimes due to different escape mechanisms; 
progress in the development of new strategies might be achieved by suitable in vitro 
models such as the agarose overlay system or agarose wrapped microspheroids. 
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6 Appendix 
6.1 Abbreviations 
4-OOH-CPA 4-hydroperoxy-cyclophosphamide 
AP-1IL activator protein 1Interleukin 
ATP adenosine triphosphate 
bFGF basic fibroblast growth factor 
BPEI branched PEI of 25 kDa 
BSA bovine serum albumine 
CMV cytomegalovirus 
CPA cyclophosphamide 
CYP cytochrom P450 
DMEM Dulbecco´s Modified Eagle´s Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
ELISA enzyme-linked immunosorbent assay 
EPR enhanced permeability and retention effect 
FCS fetal calf serum 
FITC fluorescein 
FLU relative fluorescence units 
g relative centrifugal force 
GDEPT gene directed enzyme prodrug therapy 
GSH glutathione 
HBG HEPES-buffered glucose 
HBS HEPES buffered saline 
HEPES N-(2-hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid) 
HRE hypoxia response element 
huEGF human endothelial growth factorHuman EGF 
huTF human transferrin 
IFO ifosphamide 
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IL interleukin 
LPEI linear PEI of 22 kDa 
LPEI polyplexes LPEI/DNA, N/P 6 
LUC luciferase 
MCR multicellular resistance 
MDR multidrug resistance 
MMP metalloprotease 
mTF murine transferrin 
MTT methylthiazol tetrazolium salt 
N/P ratio molar ratio of PEI nitrogen to DNA phosphate 
NA numerical aperture 
NF-?B nuclear factor ?B 
PBS phosphate buffered saline 
PE phycoerythrin 
PEG polyethylene glycol 
PEI polyethylenimine 
PFA paraformaldehyde 
PI propidiumiodide 
PKC protein kinase C 
RLU relative light units 
RT room temperature 
SCID severe combined immunodeficiency syndrome 
SD standard deviation 
SE standard error 
SDS sodium dodecyl sulphate 
TSP-1 thrombospondin-1 
V volume 
VEGF vascular endothelial growth factor 
wW weight 
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Gunther M, Wagner E, Ogris M. 
Acrolein – unwanted side product or contribution to antiangiogenic properties of 
metronomic scheduled CPA therapy. In preparation. 
 
Fahrmeir J, Gunther M, Wagner E, Ogris M. 
An electroporetic method for purification of DNA polyplexes. In preparation. 
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Annex 4
1 Introduction 
1.1 Targeting strategies within the GDEPT concept 
Tumor cells as well as tumor endothelial cells are possible targets for gene delivery 
within the GDEPT (gene directed enzyme prodrug therapy) concept (compare FIG 1-
5 of the thesis). Therefore, development of highly specific and efficient gene delivery 
systems for in vivo application is necessary to achieve sufficient levels of therapeutic 
enzyme expression. 
1.1.1 Gene delivery strategies 
Current gene therapy vectors can be divided into two major groups: viral vectors 
which are derived form natural viruses, and nonviral, synthetic vectors (1).  
Viral vectors have developed natural pathways to transfer their genetic information 
into cells, and offer an efficient system for introducing foreign DNA sequences into 
mammalian cells. Viral vectors are highly efficient in cellular uptake, intracellular 
delivery and therefore results in high gene transfer efficiency. Therefore viral systems 
were one of the first vectors used in gene delivery systems (2). Genetically 
engineered retroviral vectors were the first gene delivery systems used in gene 
therapy studies being utilized for efficient transduction of mammalian cells ex vivo 
and already led to therapeutic success (3;4). Good progress has been achieved in 
terms of modifying viral vectors in terms of removing viral genes associated with 
pathogenic function and in altering their natural tropism (5). In spite of recent 
improvements, concerns about their safety are still a strong aspect in their usage as 
these vectors bear the risk of random integration into the host genome followed by a 
possible activation of oncogenes (3;6). Moreover, inflammatory effects and host 
immune response are further obstacles in the application of viral vectors for gene 
therapy, particularly when the therapeutic concept demands multiple applications (7). 
Nonviral vectors are usually based on chemically defined cationic lipids (lipoplexes) 
or cationic polymers (polyplexes) which condense DNA to protect it from enzymatic 
digestion (8-11). Polycationic carriers for gene delivery include natural DNA binding 
molecules like histones and protamines or chemically synthesized polycationic 
polymers like polylysine or polyethylenimine (PEI), which was shown to be a highly 
efficient carrier for the delivery of genetic information (8;12). Lipoplexes and 
polyplexes were already used for gene delivery in vitro and in vivo. Non viral vectors 
have only low immunogenicity since immunogenic proteins can be avoided in vector 
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design (13). This allows repeated applications of the gene delivery system. Moreover, 
non viral vectors offer high flexibility regarding size of the genetic material that should 
be delivered and exhibit a wide spectrum in surface modifications that allows a more 
universal usage than viral gene delivery systems. The major obstacle of non viral 
systems is that they are still less efficient compared to viral systems (14). For in vivo 
application it is necessary that the vector is small and does not exhibit unspecific 
interactions with biological fluids and non-target cells (15). 
1.1.1.1 Targeting to tumor cells 
Tumors can be targeted passively by their capacity to accumulate macromolecular 
components and particles due to an effect called “enhanced retention and 
permeability” (EPR effect) (16;17). This effect results from an abnormal leaky 
architecture of tumor vasculature (hyperpermeability) and inadequate lymphatic 
drainage. As blood flow is decelerated in tumor vessels, diffusion into the tissue is 
increased and accumulation of blood delivered compounds can reach 10 fold higher 
ranges compared to healthy tissue (18;19). 
Both, tumor cells and the tumor vasculature offer specific molecular targets, which 
can be utilized for even more specific delivery of therapeutic genes. Various cell 
surface markers have been identified that are highly expressed on proliferating tumor 
cells. Incorporation of binding ligands against these specific surface structures into 
gene transfer systems has the potential to further increase selectivity and efficiency 
of tumor targeted vectors (20;21). 
1.1.1.2 Targeting towards tumor vasculature 
Due to the fact that tumor cells critically depend on a functional blood vessel network, 
tumor vessels seem to be an attractive target for gene therapy. Moreover drug 
resistance of tumors often is the reason for negative outcome of chemotherapy. 
Endothelial cells have a functional apoptosis system, are genetically stable and in 
close contact to the blood stream witch make them easily accessible for systemically 
applied drugs (22). The efficient, save and selective delivery of gene transfer 
complexes to the tumor vasculature is therefore a major goal for therapeutic 
approaches. 
Especially the GDEPT concept seems to be useful for therapies focused to tumor 
vasculature and has several advantages compared to the “classical” antiangiogenic 
tumor therapy with low molecular drugs (1). 
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Tumor vasculature is characterized by mitotic activity of endothelial cells and several 
surface markers are highly expressed that are not present in resting blood vessels of 
healthy tissue. Many of these surface proteins are involved in promoting tumor 
angiogenesis (23;24) 
 
 
Fig.: 1-1 Tumor vessel ligands: Gene delivery vectors (top left) can be targeted to certain markers of 
the tumor vascular system with the help of corresponding ligands. In this work, vectors based on PEI 
were targeted with RGD- and NGR- peptides to achieve selectivity in gene transfer. 
 
Targeting these specific receptors by incorporating targeting ligands into the gene 
delivery systems, therapeutic genes can be delivered in a selective way to tumor 
endothelial cells (25). 
Integrins are heterodimeric cell surface receptors consisting of an ?- and a ?-subunit. 
Their function is to mediate adhesion processes, to provide for traction during cell 
migration and to forward mechanical and chemical signals from the surrounding 
matrix. Many integrin receptors are involved in cell cycle regulation, differentiation, 
survival and apoptosis of endothelial cells (26). Endothelial cells in angiogenic active 
vessels exhibit an integrin expression pattern that is different from endothelial cells in 
resting blood vessels. Especially the integrins ?v?5 and ?v?3 are upregulated in 
endothelium undergoing angiogenesis (27). Integrin antagonists are shown to induce 
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apoptosis and inhibit proliferation of endothelial cells, hence receptor function of ?v?3 
integrins are essential for survival and maturation of newly formed blood vessels. The 
overexpression of these integrins in tumor vessels and integrin supported 
internalization of payloads (28),bound to integrin recognition sequences, makes them 
an attractive target for gene transfer systems. 
Utilizing phage display technique, a short peptide sequence, arginine-glycine-aspartic 
acid (RGD) was found to be highly selective for tumor vasculature (29;30). The 
integrins ?v?5 and ?v?3 have been identified to be the corresponding receptors for 
the RGD peptide sequence. Modification of the sequence into a bicyclic version of 
the RGD motif showed increased binding affinity for ?v?5 and ?v?3 and decreased 
binding to other integrins (31). 
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Fig.: 1-2 Targeting Peptides: A) bicyclic RGD containing peptide binding to integrins B) Cyclic NGR 
containing peptide binding to aminopeptidase N 
 
Aminopeptidases are ubiquitously expressed in a wide subset of cells and have been 
recently identified to play an important role in angiogenesis. Aminopeptidase N (APN, 
also termed CD13) was shown to be expressed exclusively on newly formed blood 
vessels and is absent on normal vasculature (32;33). A short peptide sequence NGR 
has been identified to be a highly selective ligand to APN by in vivo screening of 
peptide libraries. Cyclic as well as linear peptides containing the NGR peptide 
sequence home to tumor vessels in vivo (34). Stabilizing the binding peptide through 
a disulfide bond (sequence CNGRC) led to conformational changes and increased 
targeting efficiency (35). Both, RGD and NGR-ligands were already used in tumor 
targeted gene delivery systems based on PEI; different efficiency in tumor targeting 
capability was observed (36-38). 
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2 Additional materials and methods 
2.1 Melittin derivate (CMA-3) 
The melittin analog CMA-3 was obtained from the Genzentrum (group of G.J. Arnold, 
Munich, Germany), or IRIS Biotech (Marktredwitz, Germany). The peptide was 
synthesized with a purity of > 95% and was used as acetate salt after lyophilization in 
4% acetic acid. C-mel-analog (CMA-3) had the following sequence: 
CMA-3: GIGA VLKV LTTG LPAL ISWI KRKR EEC 
The CMA-PEI conjugate are synthesized according to (39). The molar ratio CMA-
3/PEI was 9/1. 
2.2 Targeting ligands and conjugates 
Integrin binding sequence ACDCRGDCFC and CD13 binding sequence CNGRC 
were purchased from Jerini Peptide Technology. 
RGD-PEG-PEI25 and NGR-PEG-PEI25 conjugates linked with a heterobifunctional 
3.5kDa PEG derivate were synthesized as described in (40). The molar ratio of 
PEG/PEI in the resulting conjugates was approximately 0.8/1. 
2.3 PEG-PEI conjugate 
NHS-PEG 5kD was coupled to BPEI as described in (41). The molar ratio of 
PEG/PEI25 was 23/1. 
2.4 Additional antibodies 
Primary antibodies 
Rat-anti-mouse CD13 antibody and mouse-anti-human CD13 antibody, were 
obtained from Dako, Copenhagen, Denmark. 
 
Secondary antibodies 
Goat-anti-mouse IgG Horseradish Peroxidase conjugate antibody was part of the 
Amplex Red ELISA KIT and was obtained from Invitrogen, UK. 
2.5 Polyplex formulation 
2.5.1 Polyplex formation for RGD/NGR targeting experiments 
Plasmid DNA encoding luciferase was condensed with LPEI or peptide-PEI 
conjugates at an N/P ratio (PEI nitrogen to DNA phosphate ratio) of 6. DNA/PEI 
polyplexes were prepared at a final DNA concentration of 200µg/ml as described in 
Kircheis et al. 1997. Briefly, indicated amounts of plasmid DNA and PEI or peptide-
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PEI conjugates were each diluted in HEPES-buffered glucose (HBG, 5% (w/w) 
glucose, 20mM HEPES, pH 7.1) and rapidly mixed by pipetting up and down 10-20 
times. Targeted and non-targeted polyplexes were allowed to stand for at least 20min 
at room temperature (RT) before use. 
2.5.2 Polyplex formation for in vitro transfection 
  (GDEPT experiments) 
In general, polyplexes were generated by condensing plasmid DNA encoding 
luciferase, EGFP-N1 or pCMV-CYP2B1 with LPEI at a molar ratio of PEI nitrogen to 
DNA phosphate (N/P) of 6. For this reason, plasmid DNA and PEI or PEI conjugates 
were each diluted in HBS (HEPES buffered saline and rapidly mixed by pipetting up 
and down 10 to 20 times. DNA/PEI polyplexes were prepared at a final DNA 
concentration of 20µg/ml. Polyplexes were allowed to stand for at least 20min at 
room temperature before use. 
2.5.3 Measurement of particle size and zeta potential 
Particle size of polyplexes was measured by laser-light scattering using a Malvern 
Zetasizer 3000HS (Malver Instruments, Worcestershire, UK). Polyplexes for RGD- 
and NGR-targeting experiments were generated in HBG at DNA concentrations of 
200µg/ml and subsequently diluted in Optimem to 10µg/ml prior to size 
measurement. For estimation of the surface charge, polyplexes were diluted in 10mM 
NaCl to give a final DNA concentration of 2µg/ml and zeta potential was measured as 
previously described (42). 
2.6 Transfection of HUVEC cells by electroporation 
HUVEC cells were grown prior to the transfection up to 90% confluency in collagen G 
coated tissue flasks (TPP, Switzerland). Cells were harvested by treatment with 
Trypsin/EDTA and washed with prewarmed PBS. 106 cells were diluted in 100µl 
Nucleofector solution, followed by the administration of 1µg plasmid DNA. 
Afterwards, the cell suspension was transferred in the Amaxa certified cuevette and 
transfection was carried out according to manufactures protocol. 
2.7 Covalent labelling of plasmid DNA 
Plasmid pCMV-LUC was covalently labelled with the fluorophores Cy3 or Cy5 using 
the Label IT kits (MIRUS, Madison, WI) according to the manufacture’s instructions. 
20µg of DNA were diluted with 1xBuffer A to a final volume of 195µl. After addition of 
5µl reconstituted Label IT reagent, the reaction mixture was incubated for 3h at 37°C. 
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To precipitate labelled DNA, 550µl of ice-cold 100% ethanol and 22µl of 3M sodium 
acetate were added. The solution was then mixed and placed at -20°C overnight. 
Subsequent centrifugation at 16000g for 60min (4C) allowed removal of unreacted 
label in the supernatant. The pellet was gently washed with ice-cold 70% ethanol, 
centrifuged again and all traces of ethanol were removed. Labelled DNA was allowed 
to dry for 5min and finally resuspended in sterile HBG. 
Cy3 (?550nm=150,00lxmol-1xcm-1) and CY5 (?650nm=250,00lxmol-1xcm-1) content 
was measured by absorption at 550nm and 650nm, respectively. DNA was quantified 
by measuring the absorbance at 260nm with the ratio of 260nm/280nm serving as an 
index for DNA purity (?1.8 ?1.9). On average, one dye molecule was bound per 50bp 
to 100bp, approximately. 
2.8 Hypoxia induced regulation of integrin  
  and aminopeptidase N expression 
Cells were seeded in collagen G (Biochrome AG, Germany) coated 24 well plates 
(TPP, Switzerland) at a density of 15000 cells per well. About 20h after the seeding, 
standard medium M199 containing 10% FBS and 20ng/ml bFGF was replaced by a 
M199 medium, containing 2% FBS and 20ng/ml bFGF. Cells were cultured for further 
24h at 37ºC in humified atmosphere containing either air (20.9% oxygen; normoxia) 
or air sufficient to give 1% oxygen. 5% CO2 was used in all normoxic and hypoxic 
incubators, with the balance being nitrogen in the hypoxic incubation. Oxygen partial 
pressure was measured with a digital oxymeter (GMH 3690, Greisinger Electronic, 
Germany). The treatment was followed by a washing step with prewarmed PBS and 
fixing the cells with paraformaldehyde (4% in PBS) for 5min. 
After removing surplus fixing solution, cells were washed repeatedly with MACS 
buffer (PBS containing 2.5% FBS). For receptor status detection, cells were exposed 
to the mouse-anti-human CD51/CD61 (Dako) antibody and the mouse-anti-human 
CD13 antibody (Dako) for 2h at room temperature. Both antibodies were dissolved in 
MACS buffer (PBS containing 2.5% FBS) at a dilution of 1:200. Background staining 
was determined by exposing the cells to the mouse IgG control antibody (Dako), 
likewise. The incubation was followed by a repeatedly washing procedure with MACS 
buffer (PBS containing 2.5% FBS) whereas the last washing step was performed with 
PBS containing 0.05% Tween 20. Afterwards cells were exposed to the goat-anti-
mouse IgG Horseradish Peroxidase Conjugate (Invitrogen) for 1h at room 
temperature. The secondary antibody was used at a dilution of 1:500 in MACS buffer 
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(PBS containing 2.5% FBS).The incubation was again followed by a repeated 
washing procedure with MACS buffer (PBS containing 2.5% FBS) to remove 
unbound secondary antibody, whereas the last washing step was performed with 
PBS. Following HRP detection was performed according to manufactures protocol, 
using the Amplex® Red ELISA KIT #1 (Invitrogen). 
Fluorescence signal of in situ converted resorufin was measured using a Cary 
Eclipse fluorimeter (Cary, Mulgrave, Australia) with excitation and emission 
wavelengths set to 562 and 585 nm, respectively. Measurements were performed in 
triplicate and receptor status was expressed as relative fluorescence units (RFU) 
after normalizing on DNA content via the Hoechst33258 based DNA content assay. 
2.9 Flow cytometric analysis of integrin receptor and 
  aminopeptidase N on MDA-435 and CT26 tumor cells 
MDA-MB435 and CT26 tumor cells were seeded in collagen G (Biochrome AG, 
Germany) coated 24 well plates (TPP, Switzerland) at a density of 30000 cells per 
well, 24h prior receptor status detection. Cells were washed with prewarmed PBS 
and harvested by treatment with collagenase (Biochrome AG) (625 U/ml). The 
obtained cell suspensions were pooled and adjusted to 106 cells/ml with MACS buffer 
(PBS containing 2.5% FBS) after centrifugation for 5min at 150g (Haereus, Megafuge 
1.0 R). The cell suspension was divided up and exposed separately to the following 
antibodies at 4°C for 1h; mouse-anti-human CD51/61 antibody (Dako), mouse-anti-
human aminopeptidase N (CD13) (Dako), rat-anti-mouse CD51 (Dako) and rat-anti-
mouse CD13 (Biolegend). All antibodies were applied at a total dilution of 1:200. 
Afterwards, cells were washed repeatedly with prewarmed MACS buffer (PBS 
containing 2.5% FBS) to remove unbound antibody. Secondary antibody staining 
was performed by exposing the cell suspension to ALEXA488 labelled anti-mouse- or 
anti-rat-antibody (Invitrogen), respectively for 1h at 4°C. The secondary antibody was 
applied at a total dilution of 1:400. 
Samples were kept on ice until analysis. Receptor status was assayed by flow 
cytometry using a CyanTM MLE flow cytometer (Dako). The fluorophore was excited 
at 488nm and emission was detected by using a 530/40nm bandpass filter. To 
discriminate between viable and dead cells and to exclude doublets, cells were 
appropriately gated by forward/side scatter and pulse width. Antibody staining was 
evaluated via electronically analysis by using the WINMDI software.  
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2.10 Flow cytometric analysis of cellular polyplex 
  association after inhibition with antibody and free 
  peptide ligands 
Cells were seeded in a collagen G (Biochrome AG, Germany) coated 24 well plate 
(TPP, Switzerland) at a density of 30000 cells per well 24h prior the inhibition 
experiment. About 30min prior to administration of indicated polyplexes, containing 
Cy5-labelled DNA (20% Cy5 DNA), anti-human CD51/61 antibody (1:100) (Dako), 
free peptide ligands RGD or NGR (1000-fold excess, compared to polyplex 
incorporated ligands), respectively were added to the cells in 300µl of serum free 
Optimem I medium at 4°C. Indicated polyplexes were added (350ng/well, N/P 6, 
HBG) and cells were further incubated for 30min at 4°C. After total incubation time of 
1h, supernatant was removed and cells were washed with cold PBS to remove 
unbound polyplexes. Cells were harvested by treatment with collagenase (625 U/ml) 
(Biochrome) and kept on ice until analysis. Cell association of polyplexes was 
assayed by flow cytometry using a CyanTM MLE flow cytometer (Dako). The 
fluorophore Cy5 was excited at 635nm and emission was detected at 665/20nm. To 
discriminate between viable and dead cells and to exclude doublets, cells were 
appropriately gated by forward/side scatter and pulse width. Polyplex association was 
evaluated via electronically analysis by using the WINMDI software.  
2.11 In vivo application of polyplexes 
For the intravenous application of polyplex formulations mice were fixed in a modified 
50 ml Falcon tube, whereas supply of air was enabled by a hole in the bottom of the 
tube. Another hole near the closure head of the tube provided accession to the tail of 
the mice. Shortly before the injection, the tail was heated with warm water (about 38-
39ºC) in order to reach a dilatation of the tail veins. Polyplex formulations were 
administered into the tail vein (applied volume was about 250µl) with an insulin 
needle (30 G needle, U40, Becton Dickinson) within about 20 seconds. 
2.12 In vivo application of Cy3-labeled polyplexes 
At a tumor volume of approximately 400mm3, NGR- peptide ligand containing 
polyplexes (LPEI-NGR30) and control polyplexes containing BPEI instead of NGR-
PEG-conjugate were injected into the tail vein of CT26 tumor bearing mice at a dose 
of 50µg DNA/20g body weight 2h before mice were sacrified. 
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2.13 In vivo application of FITC-dextran 
For systemic application of FITC-dextran (42kDa) (10mg/ml in PBS, 200µl), as a 
marker for vessel leakiness, procedure of injection was similar to the application of 
the polyplex formulations described above. After the injection mice were removed 
from the tube. At 0.5h after the application of the FITC-dextran mice were sacrified. 
2.14 Luciferase reporter gene expression,  
  in vivo experiments 
Animals were sacrified 48h after the application of polyplex formulations with CO2. 
Before organs were removed the vein to the liver was cut in order to reduce rest 
blood. Removed organs were immediately frozen in liquid nitrogen and kept at -80C. 
For luciferase assay, organs were thawed on ice followed by lyses with 1ml of 
250mM TRIS buffer pH 7.5. For homogenisation of tissue samples an IKA-tissue 
homogenizer (IKA, Staufen) was used. The homogenisation process was performed 
on ice to avoid heating of the samples. Homogenisized samples were centrifuged for 
10min at 4C and 2800g (Haereus, Megafuge 1.0 R). For measurement of luciferase 
activity 25µl of the clear supernatant was submitted to luciferase measurement in a 
luminometer (Berthold, Bad Wildbad, Austria) as described previously (42). 
Background signal (about 200RLU) was substracted; reporter gene expression was 
calculated in RLU for each organ. 
2.15 GFP reporter gene expression, in vivo experiments 
Animals were sacrified 48h after the application of polyplex formulations with CO2. 
Before organs were removed the vein to the liver was cut in order to reduce rest 
blood. Collected organs were fixed with 4% PFA in PBS for 24h before embedding in 
OTC and freezing. Analysis was performed by fluorescence microscopy. 
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3 Results 
3.1 Evaluation of endothelial cells as producer cells 
   in the antiangiogenic GDEPT concept 
In situ activated CPA influences primary endothelial cells in terms of proliferation, 
migration and differentiation processes. CPA activation in the context of the 
CYP/CPA GDEPT concept can be mediated either by CYP2B1 expressing tumor 
cells via bystander activity or directly by CYP2B1 expression in tumor endothelial 
cells. In following studies the suitability of primary endothelial cells to act as producer 
cells was investigated. 
3.1.1 Transient transfection of HUVEC cells with polyplexes 
  based on PEI 
3.1.1.1 Evaluation of optimized transfection conditions for 
  HUVEC cells with PEI22lin polyplexes 
For evaluation of optimal in vitro transfection conditions, HUVEC cells were 
transfected with increasing amounts of LPEI polyplexes, containing plasmid DNA 
encoding luciferase as a reporter gene. Transfection efficiency was investigated by 
determination of luciferase activity 24h after the transfection as described in materials 
and methods. 
In a parallel performed experiment, transfected cells were analyzed for their viability. 
Therefore the MTT assay was performed 24h after the transfection with the LPEI 
polyplexes. 
Up to 300ng of plasmid DNA per 15000 cells, HUVEC cells did not show significant 
reduction in metabolic activity determined by the MTT assay. When the transfection 
was performed with 400ng of plasmid DNA or more, decrease in metabolic activity 
was more distinctive (FIG 3-1). 
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Fig.: 3-1 Luciferase expression and metabolic activity of transfected HUVEC cells. HUVEC cells were 
transfected with LPEI (N/P=6, HBS) polyplexes and indicated amounts of transfection complexes. 
Luciferase and metabolic activity was determined 24h after the transfection as described in materials 
and methods. Values are means ± SE of triplicates. 
 
In summary, transfection efficiency and cell viability LPEI polyplexes at a dose of 
300ng of plasmid DNA was chosen for further experiments. 
3.1.1.2 Evaluation of CYP expression of transient  
  transfected HUVEC cells 
3.1.1.2.1 Detection of CYP2B1 expression in HUVEC cells 
HUVEC cells were transfected with LPEI (N/P=6, HBS) polyplexes containing pCMV-
CYP2B1 plasmid DNA and 48h after transfection antibody-staining against rat 
CYP2B1 protein was performed as described in materials and methods. Control-
experiments were performed with plasmid DNA encoding for luciferase and 
additionally, staining was performed with the negative control antibody (Dako).  
Expressed CYP2B1 protein was detected in several HUVEC cells. 
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Fig.: 3-2 Antibody-staining of expressed 
rat CYP2B1 protein in HUVEC cells. Expression 
of CYP2B1 protein was detectable in HUVEC 
cells 48h after the transfection with pCMV-CYP 
containing LPEI polyplexes. Samples were 
visualized by epifluorescence microscopy. Blue: 
Hoechst 33258 stained nuclei. Red: antibody 
stained CYP2B1 protein. 
 
3.1.1.2.2 Transfection efficiency with pCMV-CYP2B1 
HUVEC cells were transfected under optimized conditions (300ng plasmid DNA, 
LPEI N/P=6, HBS) with pCMV-CYP2B1 plasmid DNA containing polyplexes. 48h 
after the transfection antibody-staining against ratCYP2B1 protein was performed 
and transfection efficiency was quantified by epifluorescence microscopy. The 
detected rate of ratCYP2B1 expressing HUVEC cells was 6.7%. 
3.1.1.2.3 Detection of CYP2B1 enzymatic activity by the resorufin assay 
HUVEC cells were transfected under optimized transfection conditions (300ng 
plasmid DNA, LPEI N/P=6, HBS) with pCMV-CYP2B1 plasmid DNA containing 
polyplexes. Control experiment was performed with LPEI polyplexes containing 
plasmid DNA encoding for luciferase. Forty eight hours after transfection CYP2B1 
enzymatic activity was evaluated by performing the resorufin assay. Fluorescence 
levels of the CYP2B1 transfected cells were at the same level of pCMV-LUC 
transfected cells. Specific CYP2B1 enzymatic activity was not detectable by the 
resorufin assay (data not shown). 
This might be due to rather low transfection efficiency of LPEI polyplexes on HUVEC 
cells and/or insufficient enzymatic activity of expressed ratCYP2B1 in HUVEC cells.  
3.1.1.3 Evaluation of biological activity of transient 
  CYP2B1 expression 
3.1.1.3.1 Proliferation 
HUVEC cells were transfected under optimized conditions with pCMV-CYP2B1 and 
pCMV-LUC as a control (300ng plasmid DNA, LPEI N/P=6, HBS). Thirty six hours 
after the transfection cells were incubated with different concentrations of CPA (0mM, 
0.05mM, 0.5mM and 1mM) in the medium. After culturing the transfected cells for 3 
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days in the absence or in the presence of CPA, respectively, proliferation rate was 
determined by Hoechst DNA content assay. Additionally metabolic activity of the cells 
was measured by MTT assay. Proliferation rate of HUVEC cells transfected with 
pCMV-CYP and with pCMV-LUC was decreased in the same manner when cells 
were cultivated with 1.0mM CPA, indicating the occurrence of unspecific toxicity (data 
not shown). When transfected cells were cultured for 3 days with 0.05 and 0.5mM 
CPA in the medium no anti-proliferative effects of CPA treatment were detectable 
(data not shown). Additionally performed MTT assay resulted in similar decrease in 
metabolic activity of CYP2B1 transfected HUVECs and reporter gene transfected 
HUVEC cells when incubation was performed for 3 days with 1.0 mM CPA in the 
medium (data not shown). Similar to the result of the DNA content assay, CPA 
concentrations of 0.05mM and 0.5mM CPA did not influence metabolic activity of the 
cells (data not shown). 
3.1.1.3.2 Migration 
HUVEC cells were transfected under optimized conditions with pCMV-CYP2B1 and 
pCMV-LUC as a control (300ng plasmid DNA, LPEI N/P=6, HBS). 24h after the 
transfection the medium was removed and cells were washed 2 times with warm 
(37°C) PBS. Cells were harvested with trypsin/EDTA (Promega) and seeded on 
collagen coated glass dishes. When the cell layer was confluent after 12h the scratch 
wound assay was performed in the absence or in the presence of 0.5mM or 1.0mM 
CPA. Migration was visualized by transmitted light microscopy and quantification was 
performed by picture analysis using Axio Vision LE. 
No antimigrative effects in CYP2B1 transfected cells were detectable in comparison 
to the reporter gene transfected HUVEC cells (data not shown). 
 
3.1.1.3.3 Tube forming 
HUVEC cells were transfected under optimized conditions with pCMV-CYP2B1 and 
pCMV-LUC as a control (300ng plasmid DNA, LPEI N/P=6, HBS). 36h after the 
transfection the medium was removed and cells were washed 2 times with warm 
(37°C) PBS. Cells were harvested with trypsin/EDTA (Promega) and the matrigel 
tube forming assay was performed in the absence or in the presence of 0.5mM or 
1.0mM CPA. Tube forming was visualized by transmitted light microscopy. 
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There was no difference detectable in the ability of the cells in forming tube like 
structures between pCMV-CYP and pCMV-LUC transfected cells (data not shown). 
3.1.1.4 Transient transfection of HUVEC cells by electroporation  
3.1.1.4.1 Transfection efficiency and detection of the CYP2B1 
   protein by antibody staining 
HUVEC cells were transfected with pCMV-CYP by electroporation as described in 
materials and methods (Amaxa). Transfection efficiency was quantified 48h after the 
transfection by antibody staining against rat CYP2B1 protein. Control experiment was 
performed with luciferase encoding plasmid (pCMV-LUC). Following the antibody 
staining, cell nuclei were counter stained with Hoechst 33258 and quantification was 
performed by epifluorescence microscopy. The detected rate of ratCYP2B1 
expressing cells was 38%. 
3.1.1.4.2 Detection of CYP2B1 enzymatic activity by the resorufin assay 
HUVEC cells were transfected with pCMV-CYP by electroporation as described in 
materials and methods (Amaxa). Enzymatic activity of expressed CYP2B1 protein 
was measured by resorufin-assay 48h after the transfection. Control experiments 
were performed with Luciferase encoding plasmid (pCMV-LUC). 
Enzymatic activity of expressed CYP2B1 was detectable in HUVEC cells transfected 
with CYP2B1 encoding plasmid. Fluorescence levels in control plasmid (pCMV-LUC) 
transfected cells were not clearly distinguishable from signal to noise ratio. 
Yet detected fluorescence signal in pCMV-CYP transfected HUVEC cells was low 
compared to X39 cells. 
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Fig.: 3-3 Enzymatic activity of transiently CYP2B1 expressing HUVEC cells. HUVEC cells were 
transfected by electroporation (Amaxa, standard protocol for HUVEC cells) with either pCMV-LUC or 
pCMV-CYP2B1 plasmid DNA. CYP2B1 enzymatic activity was measured 48h after the transfection by 
resorufin-assay. Values are means ±SE of triplicates. *p<0.05 compared to control plasmid DNA 
(Mann-Whitney U-test). 
 
3.1.1.5 Evaluation of biological activity of transient 
  CYP2B1 expression 
3.1.1.5.1 Antiproliferative effects 
HUVEC cells were transfected with pCMV-CYP2B1 by electroporation as described 
in materials and methods (Amaxa). Control transfections were performed with 
Luciferase encoding plasmid (pCMV-LUC). Thirty six hours after transfection HUVEC 
cells were cultured for 3 days in the absence or in the presence of indicated 
concentrations of CPA, followed by determination of cell proliferation by Hoechst 
DNA content assay. Additionally metabolic activity of treated cells was measured by 
MTT assay.  
The proliferation rate of transfected HUVEC cells was not decreased in pCMV-
CYP2B1 and in control plasmid (pCMV-LUC) transfected cells when cultivation was 
performed in the presence of up to 0.5 mM CPA. Culturing CYP2B1 transfected 
HUVEC cells in the presence of 1.0mM CPA resulted in a reduction in proliferation 
rate by 50%, whereas control plasmid expressing cells did not exhibit a significant 
decrease in proliferation rate.  
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Fig.: 3-4 Proliferation of pCMV-CYP transfected HUVEC cells (by electroporation) treated with different 
concentrations of CPA.HUVEC cells were transfected by electroporation as described in materials and 
methods (Amaxa) with either pCMV-LUC or pCMV-CYP2B1 plasmid DNA. 36h after the transfection 
cells were treated for 3 days with different concentrations of CPA (0mM, 0.05mM, 0.5mM and 1.0mM). 
Cell proliferation was determined by the Hoechst DNA content assay. Measurements were normalized 
on DNA content of CPA untreated cells. Values are means ±SE of triplicates. *p<0.05 compared to 
control plasmid DNA (Mann-Whitney U-test). 
 
Similar to DNA content, metabolic activity of CYP transfected HUVEC cells was not 
significantly decreased in pCMV-CYP and in control plasmid (pCMV-LUC) 
transfected cells when culture was performed up to 0.5 mM CPA. However, treatment 
of pCMV-CYP transfected cells with 1.0 mM CPA resulted in a reduction of metabolic 
activity by 53%, whereas control plasmid expressing HUVEC cells did not exhibit 
significant decrease in metabolic activity (data not shown). 
3.1.1.5.2 Antimigrative effects of transient expressed CYP2B1 in HUVEC cells 
HUVEC cells were transiently transfected with pCMV-CYP or pCMV-LUC plasmid 
DNA by electroporation as described in materials and methods. 24h after the 
transfection cells were seeded on collagen coated glass dishes and cultivated in the 
absence of CPA for further 12h, followed by the scratch wound assay in the presence 
of indicated concentrations of CPA. 
Migration capability of HUVEC cells transfected with the pCMV-CYP was decreased 
in the presence of CPA. However also control cells transfected with pCMV-LUC 
exhibited reduced migration rate when the scratch wound assay was performed in 
the presence of CPA. Inhibition of migration was not significantly different comparing 
pCMV-CYP and pCMV-LUC when the scratch wound assay was performed in the 
presence of 0.5mM CPA. A more pronounced decrease in migration rate occurred 
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when pCMV-CYP transfected HUVEC cells were incubated with 1mM CPA whereas 
migration rate of pCMV-LUC transfected cells was not further decreased.  
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Fig.: 3-5 Inhibition of migration after transient transfection of HUVECs with pCMV-CYP in the presence 
of CPA. HUVEC cells were transfected by electroporation (Amaxa) with either pCMV-LUC or pCMV-
CYP plasmid DNA. Scratch wound assay was performed 36h after transient transfection for 12h at 
CPA concentrations 0.0mM, 0.5mM and 1.0mM. Measurements were normalized on migration 
capability of untreated cells. Values are means ±SE of four measurements. *p<0.05 compared to 
control plasmid DNA (Mann-Whitney U-test). 
3.1.1.5.3 Transient expressed CYP2B1 inhibits tube forming in the presence of CPA 
HUVEC cells were transiently transfected with pCMV-CYP or pCMV-LUC by 
electroporation (Amaxa). 24h after the transfection a matrigel tube forming assay was 
performed in the presence of indicated concentrations of CPA. After an incubation 
time of 4h, tube forming was analyzed by transmitted light microscopy. 
Forming of tube like structures was similar in pCMV-CYP and pCMV-LUC transfected 
HUVEC cells. The count rate of tube like structures was reduced in the presence of 
CPA in pCMV-CYP and pCMV-LUC transfected cells in a similar manner, indicating 
unspecific toxic effects of the prodrug CPA (data not shown). 
 
3.2 Tumor and tumor vasculature targeting 
Gene therapy is a promising strategy to treat tumors due to the potential of higher 
specificity and lower side effects in comparison to established therapies with 
cytotoxic chemotherapeutics. In the in vitro evaluated GDEPT concept it was shown 
that tumor cells as well as endothelial cells can act as producer cells for in situ 
activated cyclophosphamide. CYP2B1 metabolic activity in the tumor/tumor vessels 
would cause higher, therapeutic relevant concentrations of activated 
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cyclophosphamide in the tumor area leading to more effective treatment and lower 
side effects. 
Insufficient transfection efficiency of target cells in vivo is one main obstacle in 
current gene therapy approaches with polyplexes based on PEI. Therefore it is 
necessary to improve gene delivery vectors to enhance their specificity and 
transfection efficiency. Tumor cells and tumor vasculature can both act as promising 
targets for the delivery of therapeutic genes. Microenvironmental conditions in the 
tumor (hypoxia) can be utilized for further increasing transfection specificity of vectors 
by choosing ligands, targeted to receptors, upregulated by hypoxia. As hypoxia 
sensitive targeting ligands the RGD-peptide and the NGR-peptide were chosen. The 
receptors for these ligands are present on tumor and/or tumor vessel cells and are 
upregulated on endothelial cells in hypoxic environment (43-45). 
3.2.1 Biophysical Characterisation of Targeted PEI Polyplexes 
3.2.1.1 Size and stability in salt containing media 
Different polyplex formulations for tumor and tumor vasculature targeting with defined 
amounts of PEG-PEI and Peptide ligand (Tab 3-1) were analyzed in terms of particle 
size and stability in salt containing medium (Optimem I). 
Polyplex LPEI BPEI-
PEG 
BPEI BPEI-PEG-ligand 
Plain LPEI 100%    
LPEI-BPEI-PEG50 50% 50%   
LPEI-BPEI-PEG20-BPEI30 50% 30% 20%  
LPEI-RGD50 50%   50% RGD- 
LPEI-RGD45 50% 5%  45% RGD- 
LPEI-RGD40 50% 10%  40% RGD- 
LPEI-RGD35 50% 15%  35% RGD- 
LPEI-RGD30 50% 20%  30% RGD- 
LPEI-RGD25 50% 25%  25% RGD- 
LPEI-RGD20 50% 30%  20% RGD- 
LPEI-RGD15 50% 35%  15% RGD- 
LPEI-RGD10 50% 40%  10% RGD- 
LPEI-NGR50 50%   50% NGR- 
LPEI-NGR45 50% 5%  45% NGR- 
LPEI-NGR40 50% 10%  40% NGR- 
LPEI-NGR35 50% 15%  35% NGR- 
LPEI-NGR30 50% 20%  30% NGR- 
LPEI-NGR25 50% 25%  25% NGR- 
LPEI-NGR20 50% 30%  20% NGR- 
LPEI-NGR15 50% 35%  15% NGR- 
LPEI-NGR10 50% 40%  10% NGR- 
LPEI-NGR5 50% 45%  5% NGR- 
Tab 3-1: Polyplex formulations for control and targeted PEI-Polyplexes 
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Incorporation of at least 15 to 20% of the PEG-PEI25br compound leads to the 
formation of polyplexes that did not aggregate in salt containing medium. PEG-
containing polyplexes (LPEI-RGD30 to LPEI-RGD5 and LPEI-NGR30 to LPEI-
NGR30 to LPEI-NGR5, LPE-BPEI-PEG50 and LPEI-BPEI-PEG20-BPEI30) had a 
size around 250nm. 
Above mentioned polyplex formulations remained stable for 16h, whereas unshielded 
or insufficient shielded polyplexes formed aggregates. 
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Fig.: 3-6 Evaluation of stability of A) RGD-targeted polyplex formulations and B) NGR targeted 
polyplex formulations over the time in a salt containing medium. 
 
Additionally, stability of size over the time was confirmed by fluorescence 
microscopy. Therefore, the different polyplex formulations used for the transfection 
experiments were labelled with sytox green. Polyplex formulations were analyzed 
after 30min of polyplex formation time in HBG and again after 16h incubation in 
Optimem. Particles LPEI-RGD20 and LPEI-NGR30 as well as LPEI-BPEI-PEG50 
and LPEI-BPEI-PEG20-BPEI30 did not form aggregates whereas unshielded LPEI 
particles formed large aggregates (data not shown). 
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3.2.1.2 Zetapotential measurements of polyplexes 
Measurements for Zeta potential was performed as described in materials and 
methods. Shielded polyplexes without peptide ligand incorporation exhibited a Zeta 
potential of 4.0±0.2 mV for LPEI-BPEI-PEG50 and 3.0±0.9mV for LPEI-BPEI-PEG20-
BPEI30. Unshielded PEI polyplexes (plain LPEI22) had a Zetapotential of 
21.0±1.6mV. The replacement of BPEI-PEG by BPEI-PEG-Ligand of up to 30% of 
peptide ligand in the polyplex did not change the zeta potential of the PEG-shielded 
polyplexes. 
Polyplex Particle Size [nm] Zeta Potential [mV] 
Plain LPEI >1000 (aggregates) 21.0 ± 1.6 
LPE-BPEI-PEG50 170 ±   22 4.0 ± 0.2 
LPEI-BPEI-PEG20-BPEI30 141±     4 3.0 ± 0.9 
LPEI-RGD20 199±   15 3.8 ± 0.5 
LPEI-NGR30 176 ±   18 4.1 ± 0.4 
Table 3-2: Particle size and Zeta potential of Targeted PEI-Polyplexes 
3.2.1.3 Freeze/Thaw stability 
Storage capability of ligand-containing polyplex formulations in the context of particle 
size was evaluated. Therefore particle size of freshly prepared polyplex formulations 
was determined. Afterwards polyplexes were subjected a freeze/thaw cycle followed 
by particle size measurements at 3 different time points. 
The unshielded PEI-polyplexes (plain LPEI) initially of a medium size (400nm) formed 
aggregates within 30min after thawing. PEG-shielded polyplexes (LPE-BPEI-PEG50 
and LPEI-BPEI-PEG20-BPEI30) initially of a medium size (150nm) were stable in 
size during the freeze/thaw cycle and maintained their particle size for at least 60min 
after thawing. The incorporation of 20% or 30% peptide ligand, respectively, did not 
decrease freeze/thaw stability. LPEI-RGD20 and LPEI-NGR30 did not form 
aggregates for at least 60min after thawing (data not shown). 
3.2.2 Biological activity/Targeting 
3.2.2.1 Receptor status 
Receptor status for integrin ?v?3 (CD51/61) and aminopeptidase N (CD13) was 
determined on the human tumor cell line MDA-MB435 and the mouse tumor cell line 
CT26 by antibody-staining followed by FACS analysis. For detection of the receptor-
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status for integrin ?v?3 and aminopeptidase N on primary endothelial cells, antibody 
staining was performed on HUVEC cells and analyzed also by FACS. 
Cellular binding of MDA-MB-435 cells with a CD51/61 mouse-anti-human antibody 
clearly increased fluorescence, whereas preparations with control antibody against 
murine CD51/61 and with the unspecific IgG1 isotype control did not. 
Antibody-staining of MDA-MB-435 cells for aminopeptidase N did not increase the 
fluorescence signal compared to isotype control or rat-anti-mouse CD13 antibody. 
Incubation of CT26 cells with a CD13 anti-mouse antibody resulted in significantly 
increased fluorescence compared to the preparations with mouse-anti-human CD13 
and unspecific IgG control antibody. Quantitative evaluation of the FACS data 
demonstrated that about 58% of the CT26 showed positive reaction for 
aminopeptidase N on the cell surface. 
Staining of CT26 cells for integrin ?v receptor did not increase fluorescence signal 
compared to the isotype control or anti-human integrin ?v?3 control antibody. 
Incubating HUVEC cells with a CD51/61 mouse-anti-human antibody resulted in 
clearly increased fluorescence signal compared to the preparations with control 
antibody against murine CD51 and compared to the unspecific IgG isotype control. 
Also antibody-staining for the aminopeptidase N on HUVEC cells significantly 
increased the fluorescence signal compared to isotype control or rat-anti-mouse 
CD13 antibody. 
Cell line Integrin ?v aminopeptidase N 
MDA-MB435 100% - 
CT26 - 58% 
HUVEC 100%  100% 
TAB.: 3-3. Receptor status of MDA-MB435, CT26 and HUVEC cells in terms of integrin ?v?3 and 
aminopeptidase N. Antibody-staining was performed as described in materials and methods, followed 
by FACS analysis. Measurements represent % positively stained cells.  
3.2.2.2 Cell association 
In order to evaluate differences in cell association of RGD-targeted polyplex 
formulations (LPEI-RGD20) versus not targeted control formulations (plain LPEI and 
LPE-BPEI-PEG50), integrin ?v?3 expressing MDA-MB435 cells were incubated with 
Cy5-labelled, indicated polyplex formulations for 1h at 4°C. Afterwards, cell 
association was analyzed by FACS as described in materials and methods. 
Association of polyplexes occurred within 1h in all cases. Unshielded plain LPEI were 
detected to exhibit a broad distribution in cell association, whereas shielded 
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polyplexes LPEI-BPEI-PEG50 and LPEI-RGD20 resulted in narrower distributions. 
Association of targeted LPEI-RGD20 polyplexes resulted in increased fluorescence 
signal compared to the shielded control polyplex LPE50-BPEI-PEG50, despite similar 
biophysical properties (compare TAB 3-2). 
 
 
 
 
 
Fig.: 3-7 Total cellular association after 
transfection with polyplexes at 4°C. MDA-
MB435 cells were transfected with plain LPEI 
(black), shielded LPE50-BPEI-PEG50 (green) 
and RGD-targeted LPEI-RGD20 (blue) 
polyplexes. (HBG, N/P 6) containing Cy5-
labeled plasmid DNA. Total cellular association 
was determined by flow cytometry after 1h.  
 
3.2.2.3 Inhibition of cell association by competition 
In order to further evaluate specific binding of the peptide ligand containing 
polyplexes to the target cells, competition experiments with an excess of free peptide 
or antibody were performed on the integrin ?v?3 positive MDA-MB435 cell line. 
Competition of RGD-containing polyplexes (LPEI-RGD20) with the antibody against 
integrin ?v?3 did not show an inhibition of cell association indicating a different 
binding location than the RGD binding site. Competition of LPEI-RGD20 with free 
RGD peptide (1000-fold molar excess) decreased clearly cell association. 
Interestingly, competition of K7 with free NGR peptide (1000-fold molar excess) 
resulted also in a similar decrease of cell association (FIG 3-8B). 
The preincubation of the MDA-MB435 cells with antibody, free RGD- and free NGR-
peptide (1000-fold molar excess) did not influence cell association of control 
polyplexes LPE50-BPEI-PEG50 (FIG 3-8A). 
However, preincubation of MDA-MB435 cells with antibody resulted in decreased 
cellular association of plain LPEI polyplexes, whereas preincubation with free RGD- 
and NGR- peptide exhibited no influence on total cell association (FIG 3-8C and D). 
Interestingly, no decreased fluorescence signal was detected when NGR-targeted 
polyplexes LPEI-NGR30 were inhibited by an excess of free NGR-peptide, whereas 
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an excess of free RGD-peptide influenced total association of LPEI-NGR30 
polyplexes (FIG 3-8D). 
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Fig.: 3-8 Total cellular association of indicated polyplexes formulations after preincubation of MDA-
MB435 tumor cells with anti-human CD51/61 antibody or an excess of free RGD- or NGR-peptide. 
Cells were transfected with (A) LPE50-BPEI-PEG50 polyplexes, (B) LPEI-RGD20 polyplexes, (C) plain 
LPEI polyplexes and (D) plain LPEI or LPEI-NGR30 polyplexes, containing Cy5 labelled plasmid DNA. 
Total cellular association was analyzed by flow cytometry. 
3.2.2.4 Increase in transfection efficiency by stepwise 
  increasing ligand in shielded polyplexes on HUVECs 
Reporter gene expression (luciferase activity) was evaluated on primary endothelial 
cells (HUVECs). HUVEC cells were transfected with pegylated polyplexes containing 
increasing amounts of incorporated peptide ligand. Control transfection was 
performed with the unshielded LPEI polyplexes. 
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The luciferase expression was significantly increased by incorporating peptide ligand 
in the PEG-shielded polyplexes. Incorporation of RGD-PEG-PEI and NGR-PEG-PEI 
resulted in an increase in luciferase activity in a targeting-peptide rate dependent 
manner.  
PEG-shielded, peptide ligand containing polyplexes reached a similar luciferase 
expression level as the unshielded plain LPEI22 control when the transfection was 
performed in the presence of serum. 
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Fig.: 3-9 Increase in luciferase expression levels by equipping shielded polyplex formulations with 
increasing amounts of RGD- or NGR- peptide ligands. HUVEC cells were transfected with polyplex 
formulations incorporated indicated amounts of targeting ligand in the polyplexes. Control transfection 
was performed with plain LPEI polyplexes. Luciferase activity was measured 24h after the transfection 
as described in materials and methods. Values are means ± SE of triplicates. 
 
3.2.2.5 In vitro transfection efficiency of  
  LPEI-RGD20 and LPEI-NGR30 
Reporter gene expression (luciferase activity) was evaluated in the tumor cell lines 
MDA-MB435 and CT26 and in primary endothelial cells (HUVECs). Cells were 
transfected with different polyplex formulations and luciferase assay was carried out 
24h after the transfection as described in materials and methods. For the transfection 
experiments all polyplexes were generated at an N/P ratio of 6 in HBG. 
Polyplex formulations included the biophysically characterized polyplexes with RGD- 
and NGR-peptides (LPEI-RGD20 and LPEI-NGR30). Cells were also transfected with 
plain LPEI polyplexes as a control for unshielded polyplexes; LPEI-BPEI-PEG50 and 
LPEI-BPEI-PEG20-BPEI30 were used as a control for ligand free shielded polyplexes 
in the transfection experiments. 
Annex 29
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
plain LPEI LPEI-BPEI-
PEG20-BPEI30
LPEI-BPEI-
PEG50
LPEI-RGD20 LPEI-NGR30
R
L
U
 /
 7
5
0
0
 c
e
lls
R
L
U
 /
 7
5
0
0
 c
e
lls
 
A 
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
plain LPEI LPEI-BPEI-
PEG20-
BPE30
LPEI-BPEI-
PEG50
LPEI-RGD20 LPEI-NGR30
R
L
U
/ 
7
5
0
0
 c
e
ll
s
R
L
U
/ 
7
5
0
0
 c
e
ll
s
 
B 
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
plain LPEI LPEI-BPEI-
PEG20-BPEI30
LPEI-BPEI-
PEG50
LPEI-RGD20 LPEI-NGR30
R
L
U
 /
 1
5
0
0
0
 c
e
lls
R
L
U
 /
 1
5
0
0
0
 c
e
lls
 
C 
Fig.: 3-10 Transfection efficiency of RGD- and NGR-peptide ligands containing polyplexes. (A) MDA-
MB435, (B) CT26 and (C) HUVEC cells were transfected with plain LPEI22, LPEI-BPEI-PEG20-
BPEI30, LPEI-BPEI-PEG50 or targeted polyplexes LPEI-RGD20 and LPEINGR30. Polyplexes were 
prepared in HBG at N/P 6. Luciferase assay was performed 24h after transfection as described in 
materials and methods. Mean values ± SE of triplicates are shown. 
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3.3 Hypoxia increases selectivity of RGD-   
  and NGR- peptide ligands containing polyplexes 
Hypoxia is a common phenomenon in solid tumors. Hypoxia triggers several 
adjustment processes as well in tumor cells and in tumor stroma cells. Endothelial 
cells are able to adjust to hypoxic environment, among other mechanism, by 
increasing several types of receptors on the cell surface. 
3.3.1 Receptor regulation in primary endothelial cells 
  by hypoxia in terms of integrin ?v?3 and aminopeptidase N 
Primary endothelial cells (HUVECs) were grown in normoxic and hypoxic 
environment for 24h (21% Oxygen or 1% Oxygen). To evaluate regulations in integrin 
?v?3 and aminopeptidase expression on the cell surface antibody staining was 
performed followed by the Amplex® red assay. Simultaneous cell number was 
evaluated by Hoechst 33258 based DNA content assay as described in materials 
and methods. HUVEC cells showed upregulation of the integrin ?v?3 and the 
aminopeptidase receptor indicated by higher enzymatic activity when cells were 
grown for 24h in the hypoxic environment. Fluorescence signal was normalized on 
cell count in order to avoid falsification by unequal proliferation rate in different 
environments. 
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Fig.: 3-11 Receptor status CD13 and CD51/61 of HUVEC cells; normoxic versus hypoxic conditions. 
HUVEC cells were cultured for 24h either in a normoxic (21% O2) or in hypoxic atmosphere (1%) in 
the presence of 2% serum. Receptor status was determined by incubating the pretreated cells with 
antibodies against integrin avb3 or aminopeptidase followed by incubation with a second antibody with 
enzymatic activity. Conversion of a non-fluorescent compound to resorufin by the enzymatic activity of 
the second antibody is therefore representative for the amount of receptors on the cell surface. 
Receptor signal was normalized on DNA content measured by Hoechst 33258 based DNA content 
assay. Mean values ± SE of triplicates are shown. *p<0.05, compared to normoxic receptor expression 
levels (Mann-Whitney U-test). 
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3.3.1.1 Enhancement of transfection efficiency by hypoxic  
  pre-treatment 
Primary endothelial cells (HUVECs) were grown in normoxic and hypoxic 
environment for 24h before transfection with peptide ligand containing polyplexes. In 
order to investigate a targeting specific enhancement of receptor regulation HUVEC 
cells were parallel transfected with the unshielded plain LPEI22 and the pegylated 
LPEI-BPEI-PEG50 polyplex. Transfection efficiency of the untargeted polyplexes 
remained at a similar level when cells were pretreated in a hypoxic environment. In 
contrast, targeted polyplexes reached higher levels of transfection efficiency when 
cells were pretreated in hypoxic environment before the transfection.  
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Fig.: 3-12 Transfection efficiency of targeted polyplexes on HUVEC cells after hypoxic pre-treatment. 
HUVEC cells were cultured for 24 in a normoxic (21% oxygen) or hypoxic (1% oxygen) containing 
atmosphere with 2% serum. Afterwards transfection was performed as described in materials and 
methods with indicated polyplex formulations in a normoxic atmosphere and in the presence of 10% 
serum. Luciferase expression levels were determined 24h after the transfection. Values were 
normalized on expression levels of cells grown under normoxic conditions. Values are means ± SE of 
four measurements. *p<0.05, compared to reporter gene expression levels at normoxic conditions 
(Mann-Whitney U-test). 
 
3.3.2 Enhancement of transfection efficiency by  
  incorporation of the endosomolytic compound CMA-3 
Endosomal release of internalized polyplexes is an important step in achieving 
efficient gene expression with non viral gene vectors. Coupling an analog of the 
membrane active peptide melittin (CMA-3) to PEI25 and incorporation into the 
targeted polyplex should improve endosomal release and therefore enhance gene 
expression of the targeted polyplexes (39;46). To evaluate effects on transfection 
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efficiency in terms of improved endosomal release of the targeted polyplexes CMA-3-
PEI25br was incorporated instead of LPEI into the polyplexes. MDA-MB435 cells 
were transfected with different targeted and non targeted, plain and pegylated 
polyplexes. CMA-3 could enhance luciferase expression to the level of the 
unshielded plain LPEI control polyplex for shielded RGD-targeted polyplex. 
Incorporation of CMA-3-PEI25br instead of LPEI resulted in a 120- to 320-fold 
increase in luciferase activity. 
The incorporation of CMA-3 into the untargeted pegylated control polyplexes LPEI-
BPEI-PEG50 did not enhance transfection efficiency significantly. 
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Fig.: 3-13 Effect of the melittin analog CMA-3 on transfection efficiency of targeted PEI polyplexes. 
7500 cells were seeded in 48-well plates 24h prior to transfection. Cells were transfected with either 
plain LPEI22, LPEI-BPEI-PEG50, LPEI-RGD20 or LPEI-NGR30 and compared to cells transfected 
with CMA-3 containing formulations of these polyplexes (-CMA3) (formulations see Tab. 4-4). 
Polyplexes were prepared in HBG at N/P 6. Polyplexes in a total volume of 300µl with serum 
containing medium were kept on cells for 4h, thereafter the solution was replaced by fresh medium. 
Luciferase assay was performed 24h after transfection. Mean values + SD from n=3 are shown. 
 
In order to verify that increased transfection efficiency is not based on altered 
biophysical properties of the polyplexes, particle size and zeta potential 
measurements were performed (TAB 3-5). 
The size of the polyplexes was not altered significantly when PEI22 was exchanged 
by CMA3-PEI25br; polyplexes maintained their small size of <250nm for at least 
60min. Furthermore incorporation of CMA-3 into the polyplexes did not result in 
changes in the surface charge of the indicated polyplexes. 
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Tab.: 4-4: CMA-3 containing polyplex formulations 
Tab.: 3-4: CMA-3 containing polyplex formulations 
 
 
Polyplex Particle size Zeta potential 
LPEI-PEG50-CMA3 192 ± 15 4.0 ± 1.2 
LPEI-RGD20-CMA3 213 ±   8 7.1 ± 2.6 
LPEI-NGR30-CMA-3 210 ± 15 4.2 ± 0.3 
Tab.: 3-5: Particle size and Zeta potential of CMA-3 containing Polyplexes 
 
 
3.4 In vivo evaluation 
In order to evaluate characteristics of RGD- and NGR- peptide containing polyplexes 
in vivo, experiments were performed with subcutaneous CT26 tumor bearing SCID 
mice. Prior to polyplex administration morphology, blood supply and properties of 
tumor vesselas were analyzed.  
3.4.1 Morphology of subcutaneous CT26 tumors in SCID mice 
Morphology of subcutaneous CT26 tumors was evaluated by Haematoxilin/Eosin 
stain and is described in the thesis, chapter 1. 
3.4.2 Blood supply, distribution of endothelial cells 
  and aminopeptidase N expression 
Areas of high level of CD31 staining (rat anti mouse antibody, which can specifically 
identify endothelial cells) correlates well with Hoechst stain, indicating sufficient blood 
supply in these parts of the tumor. The well vascularized regions were detected in 
most cases in the peripheral of the subcutaneous tumors. Regions in the core 
showed less CD31 staining and also less Hoechst stained nuclei. 
Polyplex CMA-3-
PEI25 
PEG-PEI25 Ligand-PEG-PEI25 
LPEI-PEG50-CMA-3 50% 50%  
LPEI-RGD20-CMA-3 50% 30% 20% RGD- 
LPEI-NGR30-CMA-3 50% 20% 30% NGR- 
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Fig.: 3-14 Distribution of endothelial cells 
(CD31+ cells) and functional blood vessels in 
subcutaneous CT26 Xenografts in SCID mice. 
Cryo-sections (5µm) were fixed with 4% 
paraformaldehyde and stained with the specific 
antibody rat-anti-mouse CD31 (red). The 
second antibody was labelled with Alexa 488. 
The intravenously injected Hoechst 33258 
stain was visualized as well (blue). Analysis 
was performed with 20x 0.4 Zeiss objective 
with a Zeiss Axiovert 200 fluorescence 
microscope equipped with a Zeiss Axiocam. 
 
Cryosections were further investigated for CD13 staining. In contrast to the CD31 
staining, positive immunoreactions was detected for CD13 all over the tumor tissue. 
This indicates an expression of aminopeptidase N on the CT26 tumor cells 
themselves. Control staining was performed with the unspecific control IgG. 
A B 
Fig.: 3-15 Cryo sections (5µm) were fixed with 4% paraformaldehyde and stained with specific 
antibodies for A,B rat-anti-mouse CD13 (yellow). Secondary antibodies were labelled with Alexa 488. 
The intravenously injected Hoechst 33258 stain was visualized as well (blue). Analysis was performed 
either with 63x1.4 Zeiss oil immersion objective with a Zeiss Axiovert 200 fluorescence microscope, 
equipped with a Zeiss Axiocam. 
3.4.2.1 Blood supply and vessel leakiness in the CT26 tumor model 
Gene vector systems depend highly on vascular escape to achieve efficient delivery; 
leakiness of tumor vessels enhances uptake of polyplex formulations within the tumor 
tissue and increases transfection efficiency. Therefore, to investigate the tumor 
vessels in the subcutaneous CT26 tumor model in terms of leakiness, experiments 
with high molecular fluorescent marked dextrane (FITC-dextrane, 42 kDa) were 
performed. 200 µl of FITC-dextran, solved in PBS (10mg/ml) were administered 
intravenously to CT26 bearing SCID mice. One h after the FITC-dextran application, 
mice were subjected to a second intravenous injection with Hoechst33258 in PBS 
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(2.5mg/ml). The Hoechst 33258 staining was detected in all organs and the tumor 
(blue staining). The staining of the FITC-dextran was located all over the tumor tissue 
(green staining) (FIG 3-16), whereas FITC-dextran was distributed in healthy tissue 
only in a small degree (data not shown). In brain tissue FITC-dextran staining was 
only detectable in the cavity of blood vessels (data not shown). The localisation of 
FITC staining within the tumor tissue indicates leakiness of vessels.  
 
 
 
 
Fig.: 3-16 Cryo sections (8µm) were 
visualised unfixed immediately after preparation. 
Distribution of FITC-dextran in the tissue was 
visualized by fluorescence microscopy. The 
intravenously injected Hoechst 33258 stain was 
visualized as well (blue).Analysis was performed 
with 20x 0.4 Zeiss objective with a Zeiss Axiovert 
200 fluorescence microscope equipped with a 
Zeiss Axiocam. 
 
 
3.4.2.2 Distribution of polyplexes 
Evaluation of polyplex distribution of the untargeted polyplex LPEI-BPEI-PEG50 and 
NGR- peptide containing polyplex LPEI-NGR30 was performed by fluorescence 
microscopy. Therefore Cy3 labelled DNA was incorporated into the polyplexes and 
the polyplexes were administered intravenously. At 2h after the application mice were 
sacrified and organs were collected. Both polyplex formulations were found in the 
tumor tissue. No obvious difference in tissue distribution could be found by 
fluorescence microscopic analysis. 2h after application, polyplexes were not 
distributed within the tumor tissue but associated to vessel like structures in the tumor 
tissue.  
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A        B 
Fig.: 3-17 Cryo sections (8µm) were fixed with 4% paraformaldehyde and visualized with Zeiss 64x1.4 
immersion oil objective and a Zeiss Axiovert 200 fluorescence microscope equipped with a Zeiss 
Axiocam. Localisation of polyplex formulations in the tumor tissue is indicated by the fluorescence 
signal of the incorporated Cy3 labelled plasmid DNA (red) A) control polyplexes and B) NGR targeted 
polyplexes.  
3.4.2.3 In vivo transfection efficiency 
In order to investigate targeting effects in subcutaneous CT26 bearing mice, polyplex 
formulations LPEI-BPEI-PEG20-BPEI30 and LPEI-NGR30 with incorporated CMV-
LUC plasmid DNA were administered intravenously. Mice were sacrified 48h after the 
application; tumor and organs were collected and analyzed for luciferase activity. No 
significant difference in the luciferase expression in the tumors could be found. Only 
a slight enhancement in luciferase activity was found in tumors when LPEI-NGR30 
was administered compared to the control polyplex LPEI-BPEI-PEG20-BPEI30. 
Transgene expression levels were low in control tumors and as well in tumors 
targeted with LPEI-NGR20. Yet, administration of NGR- peptide containing 
polyplexes tended to result in decreased transfection rate of non targeted organs. 
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NGR-Targeting (K15) not targeted control
Fig.: 3-18 Reporter gene expression 
(luciferase) 48h after systemic 
application of polyplex formulations 
LPEI-BPEI-PEG20-BPEI30 (untargeted 
control polyplex) and LPEI-NGR30 
(NGR-targeted polyplex) in HBG, N/P 6 
in CT26 tumor bearing SCID mice. 250 
µl of the polyplex formulations (total 
amount of plasmid DNA: 50µg) were 
injected into the tail vene of the mice. 
Luciferase activity was determined by 
performing the luciferase assay as 
described in materials and methods. 
Luciferase activity is visualized as total 
luciferase activity per organ. Values are 
means ± SE of four animals per groups. 
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3.4.2.4 Transfection GFP 
Localisation of transfected cells in the tumor tissue after the administration of the 
NGR- peptide containing polyplex LPEI-NGR30 was performed by fluorescence 
microscopy. Therefore p-CMV-EGFP containing LPEI-NGR30 polyplexes were 
administered intravenously. 48h after the administration mice were sacrified and 
tumor tissue was fixed with 4% PFA in PBS before embedding in OTC and freezing. 
Clusters of GFP fluorescent cells were detectable in the tumor tissue. Also GFP 
positive endothelial cells were detected by fluorescent microscopy in the tumor 
tissue. 
 
A B 
Fig.: 3-19 Cryo sections (8µm) were fixed with 4% paraformaldehyde and analyzed for GFP positive 
cells by fluorescence microscopy. The intravenously injected Hoechst 33258 stain was visualized as 
well (blue). Slide A shows clustered GFP positive cells in distant to areas with blood supply (blue 
stain). In slide B GFP fluorescence is located directly in an area of blood supply (blue stain), indicating 
endothelial cells of a tumor blood vessel. Analysis was performed with 20x 0.4 Zeiss objective with a 
Zeiss Axiovert 200 fluorescence microscope equipped with a Zeiss Axiocam. 
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4 Discussion 
4.1 Evaluation of endothelial cells as producer cells  
  in the antiangiogenic GDEPT approach 
In the following, the suitability of primary endothelial cells as producer cells is 
discussed in terms of an antiangiogenic CYP-CPA-GDEPT approach. Therefore, 
HUVEC cells were transiently transfected with the therapeutic plasmid, followed by 
CPA treatment. Gene transfer was performed with LPEI polyplexes (N/P 6; HBS) 
containing pCMV-CYP2B1 plasmid DNA or by in vitro electroporation (Amaxa). 
Both transfection methods resulted in ratCYP2B1 gene expression in HUVEC cells; 
protein expression was detected by specific antibody staining, indicating that in 
principle HUVEC cells are suitable for therapeutic CYP2B1 gene expression. 
However, CYP2B1 enzymatic activity was only detectable when gene transfer was 
performed via electroporation. This difference in conversion capability in the resorufin 
assay is probably due to the difference in transfection efficiency: ratCYP2B1 protein 
was detected in only 6.7% of HUVEC cells after LPEI transfection versus 38% in the 
case of gene transfer via electroporation. Compared to enzymatic activity of 
transiently expressed CYP2B1 in tumor cells, HUVEC cells exhibited only moderate 
conversion capability. This might be provoked by an unincisive endoplasmatic 
reticulum, low activity of P450 reductase or the low total metabolic activity of this cells 
type. However, HUVEC cells are an artificial model and do not reflect specific 
characteristic of tumor derived endothelial cells; discrepancies can occur in several 
aspects e.g. expansion of the endoplasmatic reticulum (47). 
Due to the insufficient CYP2B1 enzymatic activity in LPEI transfected HUVEC cells, 
specific effects in terms of preventing proliferation, migration and differentiation were 
not detected. 
In the case of gene transfer via electroporation, specific effects of the transgene 
were detected in the context of proliferation and survival (FIG 3-4). 
Inhibition of migration capability after gene transfer via electroporation and following 
CPA treatment was measured at concentrations of 1.0mM. Decrease in migration 
capability of endothelial cells was not pronounced and resulting partly from unspecific 
toxic effects of the treatment (FIG 3-5). Unspecific effects were even more distinctive 
in the matrigel tube forming assay, resulting a non detectable specific effect of the 
therapeutic gene. 
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In summary, CYP2B1 expression in primary endothelial cells is a possible concept in 
an antiangiogenic GDEPT approach. However, gene transfer via plain LPEI 
polyplexes to primary endothelial cells suffer from low transfection efficiency. 
Moreover, endothelial cells exhibit only low conversion capability, when transfection 
is performed with pCMV-CYP2B1 plasmid DNA via electroporation. These limitations 
seem to be due to characteristic properties of primary endothelial cells, at least in the 
HUVEC model system, and resulted only in weak specific antiangiogenic effects. 
Tumor derived endothelial cells might be therefore a better model in evaluation of 
CYP2B1 based antiangiogenic strategies and indicates that improvement of the gene 
delivery system is necessary. 
 
4.2 Targeted gene transfer to tumor cells 
   and tumor vasculature 
Gene therapy is a promising approach in tumor therapy due to the potential of higher 
specificity in comparison to established cytotoxic treatment wit low molecular drugs.  
In the in vitro evaluated GDEPT concept it was found that tumor as well as 
endothelial cells might be in principal adequate target cells for expressing therapeutic 
genes in the context of GDEPT. Polyethylenimine (PEI) is one of the most efficient 
nonviral gene delivery systems in vitro and in vivo. However, to achieve specificity in 
transfer of therapeutic genes, several modifications of PEI are necessary. 
Unmodified, plain PEI polyplexes bind, due to their positive surface charge, to any 
cell membrane via unspecific electrostatic interactions. Therefore, systemic 
administration of plain PEI polyplexes is associated with high lung gene expression 
(48) and pronounced toxicity (49). Moreover, positively charged polyplexes were 
detected to be not suitable for tumor targeted gene transfer in vivo due to interactions 
with erythrocytes, resulting again in toxic effects and fast clearing from the blood 
stream. Incorporation of the hydrophilic 5kDa PEG-PEI25 conjugates were resulted in 
low surface charge (41). On the other hand, pegylation of polyplexes resulted in 
strong decrease of gene transfer efficiency also in target cells. Gene transfer 
efficiency was restored partly by incorporation of RGD- and NGR- peptide ligands 
into the vector system. 
 
 
Biophysical Characterization of targeted PEI-polyplexes 
Due to the fact that biophysical characteristics of polyplexes (Zeta Potential and 
particle size) play a crucial role for transfection efficiency (50) and their applicability 
for systemic administration, polyplexes were analyzed for these parameters. 
Annex 40
Measurements showed that a minimum amount (at least 15-20% (w/w)) of pegylated 
conjugate is necessarily incorporated into the PEI polyplexes to generate small sized 
and stable vector systems. Incorporation of lower ratios of pegylated compounds 
resulted in aggregation of polyplexes in the presence of salt containing medium, 
indicating insufficient shielding (FIG 3-6). Small polyplexes have been shown to 
internalize more efficiently by receptor-mediated uptake than larger polyplexes (51). 
In addition, extravasation into tumor tissue as well as tissue diffusion is proposed to 
be dependent on a small particle size. This turns up the achieved particle size of 
about 150 to 250nm to be optimal for in vivo application and receptor-mediated 
uptake and tissue diffusion. 
Another aspect in developing polyplexes for in vivo applications is their storage 
capability. Therefore polyplexes were analyzed for their stability in terms of particle 
size during a freeze/thaw cycle. Previous experiments demonstrated that pegylation 
effectively stabilizes PEI-polyplexes during a freeze/thaw cycle (41). This could be 
confirmed for peptide targeted polyplex formulations LPEI-RGD20 and LPEI-NGR30, 
which were further analyzed in transfection and targeting experiments. 
 
 
Targeting to tumor- and endothelial cells 
Main part of this section was the analysis of targeting capabilities and specificity of 
RGD- and NGR-peptide containing polyplexes in vitro. Therefore, cell association 
and transfection efficiency has been investigated on MDA-MB-435 and CT26 tumor 
cells as well as primary endothelial (HUVECs) cells. It was described previously 
that human MDA-MB-435 breast carcinoma cells highly express integrins on their cell 
surface (52). Antibody staining followed by cell flow cytometric analysis could confirm 
integrin ?v?3 expression on MDA-MB-435 cells, whereas expression of 
aminopeptidase N on the cell surface was not detected. 
Antibody staining followed by cell flow cytometric analysis resulted in the detection of 
aminopeptidase N expression on approx. 58% of CT26 tumor cells, whereas 
expression of ?v integrins was not evident. 
In contrast to above mentioned tumor cells, which express either integrin receptors of 
?v family or aminopeptidase N, both receptors were detected on HUVEC cells. 
In order to evaluate for targeting specificity of peptide ligand modified vector systems, 
inhibition studies with polyplex formulations were performed by incorporation of 
fluorescence labeled plasmid DNA and an excess of free peptide ligand or an specific 
antibody, respectively. Attention was directed towards RDG-peptide ligand containing 
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polyplexes, due to pronounced targeting effects in terms of transfection efficiency, 
compared to NGR (FIG 3-10). Increased targeting effects may be based on an effect 
called “integrin supported internalization”, which increases the uptake of payloads 
bound to integrin recognition sequences (53). Inhibition studies were therefore 
performed on the MDA-MB-435 cell line, due to expression of integrin ?v?3 
receptors, but not aminopeptidase N. Cell association of plain LPEI polyplexes as 
well as shielded, untargeted LPEI-BPEI-PEG50 polyplexes was, as expected, not 
inhibited by an excess of free RGD- and NGR-peptides. Interestingly, cell association 
was disturbed when binding of plain LPEI polyplexes was inhibited with the integrin 
specific antibody; presumably, antibody and plain LPEI polyplexes form complexes. 
This effect might be triggered by high positive surface charge of plain LPEI 
polyplexes and therefore resulting in adhesiveness. Thus, this effect was not evident 
in the inhibition studies with the shielded control polyplex formulation LPEI-BPEI-
PEG50, whereas cell association was not altered due to administration of the integrin 
specific antibody (FIG 3-8A and B). Further on, cell association was not altered when 
inhibition studies were performed with the specific anti-integrin antibody and the PEI-
RGD20 polyplex formulation. This indicates that antibody binding location and RGD 
recognition region are different; further on, in contrast to plain LPEI polyplexes which 
associate assumedly with the integrin antibody, PEI-RGD20 polyplexes exhibit 
sufficient shielding to avoid interaction. However, cell association was diminished 
when binding of the PEI-RGD-20 polyplex formulation was inhibited with an excess of 
free RGD peptide, indicating targeting specificity. Interestingly, cell association was 
reduced in the same degree when inhibition was performed with an excess of free 
NGR-peptide even though MDA-MB-435 tumor cells were negative for 
aminopeptidase N on the cell surface (FIG 3-8B). This finding, however, is consistent 
with previously performed studies, where cross reactivity between RGD- and NGR- 
recognition sequences were already described. The NGR binding motif resembles 
RGD, consequently NGR peptides can bind to integrin receptors; however binding 
affinity of the NGR peptides is lower (54). Consequently, cell association with integrin 
expressing MDA-MB-435 tumor cells was not altered when the NGR-peptide ligand 
containing polyplex formulation (PEI-NGR30) competed with an excess of free NGR-
peptide for recognition sequences, though an excess of free RGD peptide leaded to 
reduced cell association of PEI-NGR30 (FIG 3-8D). 
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In summary, the LPEI-RGD20 polyplex formulation exhibited high specificity in cell 
association. The described cross reactivity is a plausible explanation for the 
increased transfection efficiency by NGR-peptide containing polyplexes on 
aminopeptidase N negative MDA-MB435 cells and of RGD-peptide containing 
peptides on integrin ?v negative CT26 tumor cells. The developed polyplex 
formulations PEI-RGD20 and PEI-NGR30 exhibited similar binding attitudes as 
phages, displaying the conformable binding sequence (34). 
In the context of developing gene delivery systems specific for tumor cells and, to a 
greater extent, for angiogenic active endothelial cells, polyplex formulations were 
optimized in terms of transfection efficiency on primary endothelial cells. 
Therefore, reporter gene expression was evaluated on integrin ?v?3 and 
aminopeptidase N expressing HUVEC cells with different peptide targeted polyplex 
formulations delivering plasmid DNA encoding for luciferase. Control transfection 
experiments were performed with plain LPEI polyplexes and the shielded untargeted 
polyplex formulation LPEI-BPEI-PEG50. Luciferase expression levels were 
significantly increased by incorporating peptide ligand into PEG-shielded polyplexes; 
increase in transfection efficiency was dependent on the ratio of RGD-PEG-PEI or 
NGR-PEG-PEI, respectively. The influence of incorporating peptide ligands into the 
shielded polyplex formulations in terms of transfection efficiency was further 
evaluated on integrin ?v?3 expressing MDA-MB-435 and aminopeptidase N positive 
CT26 tumor cells. The incorporation of targeting ligands into the shielded polyplex 
formulations resulted in increased transfection efficiency of MDA-MB-435 and CT26 
tumor cells, compared to both untargeted, shielded polyplex formulations. 
Transfection efficiency was significantly increased for the NGR-targeted polyplex 
formulation LPEI-NGR30 on aminopeptidase N negative MDA-MB435 cells; 
transfection with LPEI-RGD20 resulted on CT26 tumor cells in similar expression 
levels as with the NGR-peptide containing formulation, even though integrin ?v- 
receptors were not detected on the cell surface. This finding, however, can be 
explained by a cross reactivity of RGD- and NGR- recognition sequences. 
Comparing targeting capability in the context of transfection efficiency, higher 
reporter gene expression levels were detected for the LPEI-RGD20 polyplexes 
compared to the LPEI-NGR20 polyplex formulation on MDA-MB435 tumor cells and 
on primary endothelial cells. The increased transfection efficiency is probably based 
on “integrin supported internalization”, which increases the uptake of payloads bound 
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to integrin recognition sequences (55). Transfection of integrin ?v negative CT26 
tumor cells with RGD-targeted polyplex formulations is presumably driven by binding 
to aminopeptidase N receptors due to cross reactivity, which exhibit, in contrast to 
integrin receptors, no supported internalization. Alternatively, internalization of RGD-
peptide ligand containing polyplexes may be supported by integrin receptors of other 
families, which exhibit as well RGD-recognition sequences. 
 
 
Receptor regulation by hypoxia influences targeting properties 
Hypoxia is a common phenomenon in solid tumors. Hypoxia triggers several 
processes in tumor cells as well as in tumor stroma cells. Endothelial cells adapt to 
hypoxic environment by, amongst other mechanisms, increasing several cell surface 
molecules relevant for angiogenic processes. Among these angiogenesis promoting 
receptors, integrin ?v?3 and aminopeptidase N were found to be upregulated by 
hypoxic stimuli in prior studies (32;56). Modulation of integrin ?v?3 and 
aminopeptidase N cell surface expression by hypoxia was further on confirmed by 
specific antibody staining followed by quantification with the Amplex-Red kit within 
this work (FIG 3-11). In order to evaluate if hypoxia therefore enhances transfection 
efficiency by upregulation of hypoxia responsible integrin ?v?3 and aminopeptidase 
N receptors on the cell surface of primary endothelial cells transfection experiments 
were performed after preincubation of HUVEC cells in a hypoxic environment. 
Indeed, transfection efficiency was increased when the transfection was carried out 
with the targeted polyplex formulations LPEI-RGD20 and LPEI-NGR30, whereas 
transfection efficiency with plain LPEI polyplexes remained unchanged. This 
supposes increased transfection efficiency due to upregulation of cell surface 
receptors by the hypoxic treatment (FIG 3-12). Increase in transfection efficiency of 
LPEI-RGD20 was even more pronounced compared to the LPEI-NGR-30 polyplex 
formulation, though, integrin ?v?3 receptor was lower than aminopeptidase N 
upregulation (FIG 3-11). This effect might be triggered by “integrin supported  
internalization”, which increases the uptake of payloads bound to integrin recognition 
sequences (57) and indicates integrin ?v?3 receptor mediated gene transfer with 
RGD-peptide containing polyplexes as highly effective to primary endothelial cells, 
especially in hypoxic environments. 
 
Incorporation of endosomolytic escape domains in targeted polyplexes 
After cellular association of polyplexes, particles are internalized by receptor-
mediated endocytosis, macropinocytosis, phagocytosis or related processes (58-60). 
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Internalized particles are captured in intracellular vesicles such as endosomes. For 
efficient transgene expression, polyplexes need to escape from the endosomes by 
endosomal release. Incorporation of the melittin analog CMA-3 into the polyplex 
formulations indicated an effective approach towards enhanced transfection 
efficiency of targeted polyplexes. The membrane active peptide melittin was able to 
enhance endosomal release of internalized polyplexes. However, effective cellular 
uptake is necessary and can be accomplished by receptor mediated internalization. 
Therefore, transfection efficiency of RGD-peptide containing polyplexes can be 
enhanced up to levels of plain LPEI polyplexes. Targeted polyplexes profit from 
effective endocytosis via integrins, whereas the incorporated CMA-3 enhances 
intracellular endosomal release of the polyplexes. Importantly, transfection efficiency 
of shielded, but untargeted control polyplex formulation LPEI-BPEI-PEG50 was not 
enhanced by the incorporation of CMA-3, indicating that internalization of polyplexes 
play a crucial role for their intracellular trafficking. The internalization of LPEI-BPEI-
PEG50 is less efficient on MDA-MB-435 cells and/or may be accomplished by a 
pathway leading directly to degradation of the polyplexes. Targeted polyplexes with 
NGR-peptide were shown to exhibit lower total transfection efficiency compared to 
RGD-peptide containing polyplexes, however, enhancement in transfection efficiency 
by the incorporation of the endosomolytic compound CMA-3 was similar. 
 
In vivo evaluation of targeted polyplex formulations 
Receptor expression strongly depends on cellular microenvironment. Moreover in 
vivo transfection efficiency is influenced by several tissue specific parameters as e.g. 
total tumor blood supply, vessel diameter and vessel leakiness. Further on 
distribution of polyplex formulations in vivo depend on diffusion capability in the 
indicated tissue. CT26 tumors are well vascularized especially in the peripheral 
regions, whereas less blood supply was detected in the central areas (FIG 3-14). 
However, reasoning view of a therapeutic approach, gene delivery to the angiogenic 
active peripheral regions is supposed to be sufficient. Antibody staining of CD31 
positive endothelial cells in combination with systemically Hoechst33258 staining 
indicated that functional blood supply and the existence of endothelial cell lined blood 
vessels correlated in this tumor model. Antibody staining against mouse 
aminopeptidase N (CD13) indicated that aminopeptidase N is distributed over the 
whole tumor tissue, including vessel like structures (FIG 3-15A and B). Subcutaneous 
CT26 were evaluated for vessel leakiness by systemic administration of FITC-dextran 
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(42kDa) in combination with likewise systemically applied Hoechst33258 dye. 
Accumulation of FITC-dextran was evident within the tumor tissue (FIG 3-16), 
whereas FITC-dextran was distributed in healthy control tissue only in a small 
degree. Despite the difference in molecular weight of the FITC-dextran used as a 
marker in comparison to the indicated polyplex formulations, its accumulation in the 
tumor tissue indicates enhanced vessel leakiness compared to healthy tissue. 
Leakiness of vessels has great impact on passive tumor targeting effects (EPR 
effect), allows escape of gene vector systems from the blood stream and is therefore 
crucial for uptake within the tumor tissue. 
For evaluation of delivery and subsequent distribution of polyplexes in the tumor 
tissue, targeted LPEI-NGR30 and control polyplexes LPEI-BPEI-PEG20-BPEI30, 
containing Cy3-labeled plasmid DNA, were administered into the tail vain of CT26 
bearing SCID mice. Both, targeted as well as shielded, untargeted control polyplexes 
were detected in the tumor indicating that both polyplex formulations reach the tumor 
via blood stream (FIG 3-17). Nevertheless, 2h after polyplex administration, labeled 
polyplexes were still found in close vicinity to vessel like structures. This indicates 
limited diffusion within the tumor tissue and may result from the compact structure of 
subcutaneous CT26 tumors (compare thesis, chapter 1). Differences in the 
distribution of targeted and untargeted control polyplexes were not detectable by 
microscopic analysis. However, in order to investigate if the incorporation of peptide 
ligands enhances transfection efficiency, the polyplex formulation LPEI-NGR30 
and shielded control polyplexes LPEI-BPEI-PEG20-BPEI30 were utilized for systemic 
delivery of plasmid DNA encoding for luciferase in the subcutaneous CT26 tumor 
model. In contrast to in vitro experiments, enhanced tumor transfection efficiency by 
incorporation of NGR-peptide into the polyplex formulation for was not significant. 
Notably, transgene expression in not targeted organs, however, tended to result in 
lower levels, when the application was performed with the LPEI-NGR30 polyplex in 
comparison to the shielded, untargeted control (FIG 3-18). Indistinctive enhancement 
in tumor transfection efficiency by the incorporation of the NGR-peptide may be on 
one hand explained by rather low transfection rates in total. On the other hand, low 
tumor transfection efficiency might result form insufficient diffusion processes within 
the tumor tissue. Incorporation of the endosomolytic compound CMA-3 can be 
utilized in further experiments to overcome these limitations and may lead to more 
distinctive targeting characteristics of NGR-peptide containing polyplex formulations, 
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due to the enhancement of transfection efficiency only for receptor mediated uptake 
(FIG 3-13). 
Aminopeptidase N, which is the receptor targeted by LPEI-NGR30 polyplexes is 
expressed on CT26 tumor as well as on tumor vessel endothelial cells. For 
evaluation of transfected cell type in vivo, delivery of plasmid DNA encoding for 
EGFP was performed by systemic application of LPEI-NGR30 polyplex formulation. 
Prior to sacrifying, Tumor tissue was collected and analyzed via fluorescence 
microscopy for EGFP positive cells, resulting in the detection of EGFP expressing 
tumor as well as endothelial cells in the direct vicinity of functional blood flow (FIG 3-
19). Recently, transfection of tumor vessel endothelial cells with NGR-targeted PEI 
polyplex formulations was described (37). 
 
In summary, pegylated LPEI polyplexes containing RGD- and NGR-peptide ligands 
are small and stable particles (<200nm). RGD- and NGR- ligands are able to 
enhance transfection efficiency significantly on target cells, moreover, tumor specific 
environmental properties, like hypoxia further enhance selectivity. Transfection 
efficiency of peptide ligand containing polyplex formulations on target cells can be 
further enhanced by the incorporation of endosomolytic compounds. 
Reasons for indistinctive enhancement of tumor transfection efficiency in vivo have to 
be further investigated by establishment of in vitro spheroid tumor models and further 
transfection experiments. 
Incorporation of CMA-3, as a compound enhancing endosomal release, might be 
performed in further in vivo studies to overcome limitations and may further adjust 
tumor selectivity and transgene expression levels. 
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